NZ619241B2 - Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer - Google Patents
Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer Download PDFInfo
- Publication number
- NZ619241B2 NZ619241B2 NZ619241A NZ61924112A NZ619241B2 NZ 619241 B2 NZ619241 B2 NZ 619241B2 NZ 619241 A NZ619241 A NZ 619241A NZ 61924112 A NZ61924112 A NZ 61924112A NZ 619241 B2 NZ619241 B2 NZ 619241B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- hif
- stabilizer
- cancer
- disclosed
- tumor
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title claims abstract description 111
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 150000001875 compounds Chemical class 0.000 title claims description 70
- 101700027987 EPAS1 Proteins 0.000 title abstract description 194
- 102100016168 EPAS1 Human genes 0.000 title abstract description 194
- 230000000087 stabilizing Effects 0.000 title description 8
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 93
- 238000004519 manufacturing process Methods 0.000 claims description 53
- 239000011780 sodium chloride Substances 0.000 claims description 33
- 108020004454 Phosphoglycerate kinases Proteins 0.000 claims description 30
- 102000011755 Phosphoglycerate kinases Human genes 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 30
- 201000001441 melanoma Diseases 0.000 claims description 28
- 206010025650 Malignant melanoma Diseases 0.000 claims description 27
- 230000001965 increased Effects 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 22
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 230000002222 downregulating Effects 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 4
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 claims 2
- 239000000651 prodrug Substances 0.000 abstract description 54
- 229940002612 prodrugs Drugs 0.000 abstract description 54
- PXWOWORYDKAEJO-UHFFFAOYSA-N 2-[[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid Chemical compound C1=C(O)C(C(=O)NCC(=O)O)=NC=C1C1=CC=CC(F)=C1 PXWOWORYDKAEJO-UHFFFAOYSA-N 0.000 abstract description 48
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract description 5
- 239000003381 stabilizer Substances 0.000 description 191
- 206010028980 Neoplasm Diseases 0.000 description 130
- 210000004027 cells Anatomy 0.000 description 106
- 102100006400 CSF2 Human genes 0.000 description 91
- 102100015249 VEGFA Human genes 0.000 description 83
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 83
- 206010021143 Hypoxia Diseases 0.000 description 46
- 230000001146 hypoxic Effects 0.000 description 46
- 230000002401 inhibitory effect Effects 0.000 description 43
- 230000004614 tumor growth Effects 0.000 description 42
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 37
- 210000002540 Macrophages Anatomy 0.000 description 36
- 230000033115 angiogenesis Effects 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 36
- 210000001616 Monocytes Anatomy 0.000 description 34
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 description 31
- 239000002246 antineoplastic agent Substances 0.000 description 30
- 230000001603 reducing Effects 0.000 description 30
- 108020004999 Messenger RNA Proteins 0.000 description 29
- 229920002106 messenger RNA Polymers 0.000 description 29
- 229910052757 nitrogen Inorganic materials 0.000 description 27
- 239000003112 inhibitor Substances 0.000 description 26
- 206010027476 Metastasis Diseases 0.000 description 25
- 210000002950 fibroblast Anatomy 0.000 description 25
- 229910052760 oxygen Inorganic materials 0.000 description 25
- 230000002829 reduced Effects 0.000 description 23
- -1 for example Chemical class 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- 210000004881 tumor cells Anatomy 0.000 description 22
- 230000003247 decreasing Effects 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 239000003153 chemical reaction reagent Substances 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 201000010099 disease Diseases 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- 102000002177 Hypoxia-inducible factor-1 alpha Human genes 0.000 description 15
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 230000001419 dependent Effects 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000011105 stabilization Methods 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 11
- 210000004072 Lung Anatomy 0.000 description 11
- 150000001768 cations Chemical class 0.000 description 11
- 238000003753 real-time PCR Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 238000004809 thin layer chromatography Methods 0.000 description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 9
- 229960001592 Paclitaxel Drugs 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- 101700071021 SETD2 Proteins 0.000 description 9
- 102100000940 SETD2 Human genes 0.000 description 9
- 230000000259 anti-tumor Effects 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229930003347 taxol Natural products 0.000 description 9
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 8
- NPZTUJOABDZTLV-UHFFFAOYSA-N 1,2-dihydrobenzotriazol-4-one Chemical compound O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 8
- 102100006565 FLT1 Human genes 0.000 description 8
- 101700035121 PMEL Proteins 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 108090001123 antibodies Proteins 0.000 description 8
- 102000004965 antibodies Human genes 0.000 description 8
- 230000002708 enhancing Effects 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 8
- 229940034982 ANTINEOPLASTIC AGENTS Drugs 0.000 description 7
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 102100006820 PMEL Human genes 0.000 description 7
- 230000000973 chemotherapeutic Effects 0.000 description 7
- 239000002254 cytotoxic agent Substances 0.000 description 7
- YPFZZHJUUCAMRI-UHFFFAOYSA-N ethyl 2-[[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate Chemical compound C1=C(O)C(C(=O)NCC(=O)OCC)=NC=C1C1=CC=CC(F)=C1 YPFZZHJUUCAMRI-UHFFFAOYSA-N 0.000 description 7
- 229960005277 gemcitabine Drugs 0.000 description 7
- 239000008079 hexane Substances 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 229920002676 Complementary DNA Polymers 0.000 description 6
- 229920002307 Dextran Polymers 0.000 description 6
- 206010018338 Glioma Diseases 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 206010024324 Leukaemias Diseases 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- 206010025310 Other lymphomas Diseases 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000003183 carcinogenic agent Substances 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 229940093499 ethyl acetate Drugs 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000034659 glycolysis Effects 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 230000000051 modifying Effects 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 238000010926 purge Methods 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 6
- 108010005144 Bevacizumab Proteins 0.000 description 5
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 5
- 210000003169 Central Nervous System Anatomy 0.000 description 5
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 5
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 5
- 229940115080 Doxil Drugs 0.000 description 5
- 102100019027 EGLN1 Human genes 0.000 description 5
- 101700036086 EGLN1 Proteins 0.000 description 5
- 210000002889 Endothelial Cells Anatomy 0.000 description 5
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 5
- 229960001433 Erlotinib Drugs 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 5
- 101700003847 MSN1 Proteins 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 108091007928 VEGF receptors Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000001154 acute Effects 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000001772 anti-angiogenic Effects 0.000 description 5
- 229960000397 bevacizumab Drugs 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 150000001767 cationic compounds Chemical class 0.000 description 5
- 230000001684 chronic Effects 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 229960003668 docetaxel Drugs 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 125000005842 heteroatoms Chemical group 0.000 description 5
- 229910001411 inorganic cation Inorganic materials 0.000 description 5
- 230000000670 limiting Effects 0.000 description 5
- OVYNEWMISOMTOX-UHFFFAOYSA-N methyl 2-[[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate Chemical compound C1=C(O)C(C(=O)NCC(=O)OC)=NC=C1C1=CC=CC(F)=C1 OVYNEWMISOMTOX-UHFFFAOYSA-N 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 150000002829 nitrogen Chemical group 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- WNCMCANAKFDBQR-UHFFFAOYSA-N 3-chloro-5-(3-fluorophenyl)pyridine-2-carbonitrile Chemical compound FC1=CC=CC(C=2C=C(Cl)C(C#N)=NC=2)=C1 WNCMCANAKFDBQR-UHFFFAOYSA-N 0.000 description 4
- FBWHJIGMSQFREH-UHFFFAOYSA-N 5-(3-fluorophenyl)-3-hydroxypyridine-2-carboxylic acid Chemical compound C1=C(O)C(C(=O)O)=NC=C1C1=CC=CC(F)=C1 FBWHJIGMSQFREH-UHFFFAOYSA-N 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- 229960001220 Amsacrine Drugs 0.000 description 4
- XCPGHVQEEXUHNC-UHFFFAOYSA-N Amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- KKFSCRXMCSDTQB-UHFFFAOYSA-M C1=C(O)C([N-]CC(=O)NC)=NC=C1C1=CC=CC(F)=C1 Chemical compound C1=C(O)C([N-]CC(=O)NC)=NC=C1C1=CC=CC(F)=C1 KKFSCRXMCSDTQB-UHFFFAOYSA-M 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229960002949 Fluorouracil Drugs 0.000 description 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 4
- 102100013180 KDR Human genes 0.000 description 4
- 210000002752 Melanocytes Anatomy 0.000 description 4
- 206010027458 Metastases to lung Diseases 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 229920000272 Oligonucleotide Polymers 0.000 description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
- 239000007759 RPMI Media 1640 Substances 0.000 description 4
- 210000002536 Stromal Cells Anatomy 0.000 description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 description 4
- 230000003042 antagnostic Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 125000004432 carbon atoms Chemical group C* 0.000 description 4
- 229960003901 dacarbazine Drugs 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 4
- BXKMBLNJDHKTHO-UHFFFAOYSA-N ethyl 2-[(3,5-dihydroxypyridine-2-carbonyl)amino]acetate Chemical compound CCOC(=O)CNC(=O)C1=NC=C(O)C=C1O BXKMBLNJDHKTHO-UHFFFAOYSA-N 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000000640 hydroxylating Effects 0.000 description 4
- 238000005805 hydroxylation reaction Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000002601 intratumoral Effects 0.000 description 4
- 238000003760 magnetic stirring Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000006011 modification reaction Methods 0.000 description 4
- 230000003472 neutralizing Effects 0.000 description 4
- 150000002892 organic cations Chemical class 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 230000002062 proliferating Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000004083 survival Effects 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 210000001519 tissues Anatomy 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 3
- 206010059512 Apoptosis Diseases 0.000 description 3
- 229960002756 Azacitidine Drugs 0.000 description 3
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
- JUHORIMYRDESRB-UHFFFAOYSA-N Benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 3
- 229960004630 Chlorambucil Drugs 0.000 description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 229960004397 Cyclophosphamide Drugs 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- 229960000640 Dactinomycin Drugs 0.000 description 3
- 229960004679 Doxorubicin Drugs 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 229960005420 Etoposide Drugs 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 229960001101 Ifosfamide Drugs 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 229960004338 Leuprorelin Drugs 0.000 description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 210000004293 Mammary Glands, Human Anatomy 0.000 description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 3
- 206010061289 Metastatic neoplasm Diseases 0.000 description 3
- 210000003470 Mitochondria Anatomy 0.000 description 3
- 229960004857 Mitomycin Drugs 0.000 description 3
- 229960001156 Mitoxantrone Drugs 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 206010028549 Myeloid leukaemia Diseases 0.000 description 3
- 108010061543 Neutralizing Antibodies Proteins 0.000 description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 3
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 229960003171 Plicamycin Drugs 0.000 description 3
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 3
- 229950006050 Spiromustine Drugs 0.000 description 3
- 229960001278 Teniposide Drugs 0.000 description 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 3
- IDPUKCWIGUEADI-UHFFFAOYSA-N Uramustine Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 3
- 229960004355 Vindesine Drugs 0.000 description 3
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 3
- 210000000239 Visual Pathways Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229960002092 busulfan Drugs 0.000 description 3
- 235000012970 cakes Nutrition 0.000 description 3
- 201000009030 carcinoma Diseases 0.000 description 3
- 229960005243 carmustine Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- VPOCYEOOFRNHNL-RQDPQJJXSA-J dexormaplatin Chemical compound Cl[Pt](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N VPOCYEOOFRNHNL-RQDPQJJXSA-J 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 230000002496 gastric Effects 0.000 description 3
- 230000002414 glycolytic Effects 0.000 description 3
- 150000002337 glycosamines Chemical class 0.000 description 3
- 230000002267 hypothalamic Effects 0.000 description 3
- 230000001771 impaired Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229960002247 lomustine Drugs 0.000 description 3
- 229960001924 melphalan Drugs 0.000 description 3
- 230000001394 metastastic Effects 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000019371 penicillin G benzathine Nutrition 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000006884 regulation of angiogenesis Effects 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 3
- 229960001055 uracil mustard Drugs 0.000 description 3
- 230000004400 visual pathway Effects 0.000 description 3
- VPAWVRUHMJVRHU-VGDKGRGNSA-N (2R,4R)-N,N-bis(2-chloroethyl)-4-hydroperoxy-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine Chemical compound OO[C@@H]1CCO[P@@](=O)(N(CCCl)CCCl)N1 VPAWVRUHMJVRHU-VGDKGRGNSA-N 0.000 description 2
- KNXQDJCZSVHEIW-UHFFFAOYSA-N (3-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(F)=C1 KNXQDJCZSVHEIW-UHFFFAOYSA-N 0.000 description 2
- SWXOGPJRIDTIRL-HFQRKYADSA-N (4R,7S,10S,13S,16S,19R)-10-(4-aminobutyl)-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-HFQRKYADSA-N 0.000 description 2
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8S)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3H-pyrrolo[3,2-e]indole-6-carbonyl]-1H-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- NKUWPVYXJNSCQL-UHFFFAOYSA-L 2,2-bis(aminomethyl)propane-1,3-diol;cyclobutane-1,1-dicarboxylate;platinum(2+) Chemical compound [Pt+2].NCC(CN)(CO)CO.[O-]C(=O)C1(C([O-])=O)CCC1 NKUWPVYXJNSCQL-UHFFFAOYSA-L 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- PCZUSAVLHNFWAD-UHFFFAOYSA-N 2-sulfanylidene-1,3,2$l^{5}-diazaphosphinan-2-amine Chemical compound NP1(=S)NCCCN1 PCZUSAVLHNFWAD-UHFFFAOYSA-N 0.000 description 2
- ATUOLSDAAPMVJJ-UHFFFAOYSA-N 3,5-dichloropyridine-2-carbonitrile Chemical compound ClC1=CN=C(C#N)C(Cl)=C1 ATUOLSDAAPMVJJ-UHFFFAOYSA-N 0.000 description 2
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 2
- QNKJFXARIMSDBR-UHFFFAOYSA-N 3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CCN(CCCl)CCCl)C(=O)NC11CCCCC1 QNKJFXARIMSDBR-UHFFFAOYSA-N 0.000 description 2
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 2
- NMUSYJAQQFHJEW-ARQDHWQXSA-N 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-ARQDHWQXSA-N 0.000 description 2
- MOCVYVBNJQIVOV-TVQRCGJNSA-N 5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]-2-methylchromen-4-one Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C)=CC2=O MOCVYVBNJQIVOV-TVQRCGJNSA-N 0.000 description 2
- 101700033661 ACTB Proteins 0.000 description 2
- 102100011550 ACTB Human genes 0.000 description 2
- 101710032514 ACTI Proteins 0.000 description 2
- 229950004955 ADOZELESIN Drugs 0.000 description 2
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 2
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 2
- 102100004323 ASPG Human genes 0.000 description 2
- 229960004176 Aclarubicin Drugs 0.000 description 2
- BYRVKDUQDLJUBX-UHFFFAOYSA-N Adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3CC4CC44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-UHFFFAOYSA-N 0.000 description 2
- 208000007128 Adrenocortical Carcinoma Diseases 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 206010060971 Astrocytoma malignant Diseases 0.000 description 2
- 229950006844 BIZELESIN Drugs 0.000 description 2
- XFILPEOLDIKJHX-QYZOEREBSA-N Batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 2
- 229950001858 Batimastat Drugs 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 229960001561 Bleomycin Drugs 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 210000004204 Blood Vessels Anatomy 0.000 description 2
- 206010006143 Brain stem glioma Diseases 0.000 description 2
- CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 2
- 229950009494 Bropirimine Drugs 0.000 description 2
- PXWXSVUZTJSPIB-UHFFFAOYSA-M C1=C(O)C([N-]CC(=O)N)=NC=C1C1=CC=CC(F)=C1 Chemical compound C1=C(O)C([N-]CC(=O)N)=NC=C1C1=CC=CC(F)=C1 PXWXSVUZTJSPIB-UHFFFAOYSA-M 0.000 description 2
- BBZDXMBRAFTCAA-AREMUKBSSA-N CARZELESIN Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 2
- FVLVBPDQNARYJU-KYZUINATSA-N CHEMBL1967746 Chemical compound C[C@H]1CC[C@H](NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-KYZUINATSA-N 0.000 description 2
- 102100006435 CSF3 Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000002458 Carcinoid Tumor Diseases 0.000 description 2
- 206010007275 Carcinoid tumour Diseases 0.000 description 2
- 229950007509 Carzelesin Drugs 0.000 description 2
- 210000002421 Cell Wall Anatomy 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 208000009798 Craniopharyngioma Diseases 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229960000975 Daunorubicin Drugs 0.000 description 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N Dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 2
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 2
- 229950004203 Droloxifene Drugs 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N Etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 2
- 229950006566 Etanidazole Drugs 0.000 description 2
- 229950011548 FADROZOLE Drugs 0.000 description 2
- 229950005096 FAZARABINE Drugs 0.000 description 2
- SJBFEIQGKLAQHF-UHFFFAOYSA-M FC=1C=C(C=CC=1)C1=C(C(=NC=C1)[N-]CC(=O)N)O Chemical compound FC=1C=C(C=CC=1)C1=C(C(=NC=C1)[N-]CC(=O)N)O SJBFEIQGKLAQHF-UHFFFAOYSA-M 0.000 description 2
- 101710030892 FLT1 Proteins 0.000 description 2
- CLPFFLWZZBQMAO-UHFFFAOYSA-N Fadrozole Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N Gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006822 Human Serum Albumin Proteins 0.000 description 2
- BTXNYTINYBABQR-UHFFFAOYSA-N Hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 2
- 229950006905 ILMOFOSINE Drugs 0.000 description 2
- 229940047124 Interferons Drugs 0.000 description 2
- 206010061252 Intraocular melanoma Diseases 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 210000000265 Leukocytes Anatomy 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 229950002676 MENOGARIL Drugs 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N Maitansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 210000002264 Mammary Glands, Animal Anatomy 0.000 description 2
- 229960003951 Masoprocol Drugs 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N Masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 229960004961 Mechlorethamine Drugs 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- LWYJUZBXGAFFLP-OCNCTQISSA-N Menogaril Chemical compound O1[C@@]2(C)[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H]1OC1=C3C(=O)C(C=C4C[C@@](C)(O)C[C@H](C4=C4O)OC)=C4C(=O)C3=C(O)C=C12 LWYJUZBXGAFFLP-OCNCTQISSA-N 0.000 description 2
- HRHKSTOGXBBQCB-VFWICMBZSA-N Methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 2
- 206010028576 Myeloproliferative disease Diseases 0.000 description 2
- NJSMWLQOCQIOPE-OCHFTUDZSA-N N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 2
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 2
- 229960005343 Ondansetron Drugs 0.000 description 2
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 2
- 229950008017 Ormaplatin Drugs 0.000 description 2
- 101710043771 PDCL Proteins 0.000 description 2
- 102100018954 PECAM1 Human genes 0.000 description 2
- 101710027269 PECAM1 Proteins 0.000 description 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229950009351 Perfosfamide Drugs 0.000 description 2
- 206010050487 Pinealoblastoma Diseases 0.000 description 2
- 208000007641 Pinealoma Diseases 0.000 description 2
- 206010035228 Plasma cell neoplasms Diseases 0.000 description 2
- 108010093965 Polymyxin B Proteins 0.000 description 2
- 229960004293 Porfimer Sodium Drugs 0.000 description 2
- 229950004406 Porfiromycin Drugs 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 2
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- BBNQQADTFFCFGB-UHFFFAOYSA-N Purpurin Natural products C1=CC=C2C(=O)C3=C(O)C(O)=CC(O)=C3C(=O)C2=C1 BBNQQADTFFCFGB-UHFFFAOYSA-N 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- QXKJWHWUDVQATH-UHFFFAOYSA-N Rogletimide Chemical compound C=1C=NC=CC=1C1(CC)CCC(=O)NC1=O QXKJWHWUDVQATH-UHFFFAOYSA-N 0.000 description 2
- 229950005230 Rogletimide Drugs 0.000 description 2
- 229950008902 SAFINGOL Drugs 0.000 description 2
- OTKJDMGTUTTYMP-ROUUACIJSA-N Safingol Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ROUUACIJSA-N 0.000 description 2
- 210000002784 Stomach Anatomy 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- 102000036902 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- QVMPZNRFXAKISM-UHFFFAOYSA-N Tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 2
- 229950002376 Tirapazamine Drugs 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N Toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
- 229960001727 Tretinoin Drugs 0.000 description 2
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 2
- 229960001099 Trimetrexate Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229960004824 Triptorelin Drugs 0.000 description 2
- 208000006786 Trophoblastic Neoplasm Diseases 0.000 description 2
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N Verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 2
- 229960003895 Verteporfin Drugs 0.000 description 2
- 229960003048 Vinblastine Drugs 0.000 description 2
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 241000863480 Vinca Species 0.000 description 2
- 229960004528 Vincristine Drugs 0.000 description 2
- XLMPPFTZALNBFS-INIZCTEOSA-N Vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 2
- 206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 description 2
- 229950003017 Zeniplatin Drugs 0.000 description 2
- ODEDPKNSRBCSDO-UHFFFAOYSA-N [2-(hexadecylsulfanylmethyl)-3-methoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCSCC(COC)COP([O-])(=O)OCC[N+](C)(C)C ODEDPKNSRBCSDO-UHFFFAOYSA-N 0.000 description 2
- LIQODXNTTZAGID-OCBXBXKTSA-N [4-[(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenyl] dihydrogen phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 2
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 2
- 230000000996 additive Effects 0.000 description 2
- 230000001058 adult Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229960005310 aldesleukin Drugs 0.000 description 2
- 229930013930 alkaloids Natural products 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229940045985 antineoplastic drugs Platinum compounds Drugs 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 201000008271 atypical teratoid rhabdoid tumor Diseases 0.000 description 2
- 229910052788 barium Inorganic materials 0.000 description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium(0) Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
- 229960000626 benzylpenicillin Drugs 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000012455 biphasic mixture Substances 0.000 description 2
- 229950008548 bisantrene Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 201000007335 cerebellar astrocytoma Diseases 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 229960003603 decitabine Drugs 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229950002389 diaziquone Drugs 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- WVYXNIXAMZOZFK-UHFFFAOYSA-N ethyl N-[2,5-bis(aziridin-1-yl)-4-(ethoxycarbonylamino)-3,6-dioxocyclohexa-1,4-dien-1-yl]carbamate Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 2
- 229960000752 etoposide phosphate Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229950003662 fenretinide Drugs 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- 238000005734 heterodimerization reaction Methods 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 230000002757 inflammatory Effects 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- 201000002529 islet cell tumor Diseases 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 201000000564 macroglobulinemia Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 201000011614 malignant glioma Diseases 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 230000002503 metabolic Effects 0.000 description 2
- 230000000394 mitotic Effects 0.000 description 2
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 2
- 201000009251 multiple myeloma Diseases 0.000 description 2
- 201000005962 mycosis fungoide Diseases 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 201000002575 ocular melanoma Diseases 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- 201000005443 oral cavity cancer Diseases 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000010627 oxidative phosphorylation Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960001744 pegaspargase Drugs 0.000 description 2
- 108010001564 pegaspargase Proteins 0.000 description 2
- 201000003113 pineoblastoma Diseases 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 150000003058 platinum compounds Chemical class 0.000 description 2
- 229960005266 polymyxin B Drugs 0.000 description 2
- 229920000024 polymyxin B Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000001023 pro-angiogenic Effects 0.000 description 2
- 229960000624 procarbazine Drugs 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001737 promoting Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003881 protein kinase c inhibitor Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000000268 renotropic Effects 0.000 description 2
- 230000035812 respiration Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000000717 retained Effects 0.000 description 2
- 201000000582 retinoblastoma Diseases 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 229960003440 semustine Drugs 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- XEADCOHJERWFOI-UHFFFAOYSA-M sodium;2-[[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetate Chemical compound [Na+].N1=C(C(=O)NCC([O-])=O)C(O)=CC(C=2C=C(F)C=CC=2)=C1 XEADCOHJERWFOI-UHFFFAOYSA-M 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229960001674 tegafur Drugs 0.000 description 2
- 229960002197 temoporfin Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- NOYPYLRCIDNJJB-UHFFFAOYSA-O trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=[NH+]C(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-O 0.000 description 2
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 2
- 229960002730 vapreotide Drugs 0.000 description 2
- 239000002525 vasculotropin inhibitor Substances 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- 229960001771 vorozole Drugs 0.000 description 2
- 230000003442 weekly Effects 0.000 description 2
- NDTYTMIUWGWIMO-SNVBAGLBSA-N (-)-isocarveol Chemical compound CC(=C)[C@H]1CCC(CO)=CC1 NDTYTMIUWGWIMO-SNVBAGLBSA-N 0.000 description 1
- 229930007631 (-)-perillyl alcohol Natural products 0.000 description 1
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-β-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 1
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 1
- BLOFGONIVNXZME-YDMGZANHSA-N (1R,2R,3R,4S,5R)-4-amino-5-methylsulfanylcyclopentane-1,2,3-triol Chemical compound CS[C@@H]1[C@@H](N)[C@@H](O)[C@@H](O)[C@H]1O BLOFGONIVNXZME-YDMGZANHSA-N 0.000 description 1
- YADVRLOQIWILGX-MIWLTHJTSA-N (1S,2Z,4E,8E,12E)-5,9,13-trimethyl-2-propan-2-ylcyclotetradeca-2,4,8,12-tetraen-1-ol Chemical compound CC(C)C/1=C/C=C(C)/CC\C=C(C)\CC\C=C(C)\C[C@@H]\1O YADVRLOQIWILGX-MIWLTHJTSA-N 0.000 description 1
- GCPUVEMWOWMALU-HZMBPMFUSA-N (1S,3S)-1-hydroxy-8-methoxy-3-methyl-1,2,3,4-tetrahydrobenzo[a]anthracene-7,12-dione Chemical compound C1[C@H](C)C[C@H](O)C2=C1C=CC1=C2C(=O)C(C=CC=C2OC)=C2C1=O GCPUVEMWOWMALU-HZMBPMFUSA-N 0.000 description 1
- FXPSZLHFJDHOMI-DHZHZOJOSA-N (2E)-4-methoxy-3-methylsulfanyl-2-(nitrosomethylidene)-6-pyridin-2-yl-1H-pyridine Chemical compound COC1=C(SC)\C(=C/N=O)NC(C=2N=CC=CC=2)=C1 FXPSZLHFJDHOMI-DHZHZOJOSA-N 0.000 description 1
- BUSGWUFLNHIBPT-XYBORKQMSA-N (2E,4E,6E)-7-[(1R,5R,6S)-3-[[(2E,4E)-5-cyclohexylpenta-2,4-dienoyl]amino]-5-hydroxy-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-5-yl]hepta-2,4,6-trienoic acid Chemical compound C([C@]([C@H]1O[C@H]1C1=O)(O)/C=C/C=C/C=C/C(=O)O)=C1NC(=O)\C=C\C=C\C1CCCCC1 BUSGWUFLNHIBPT-XYBORKQMSA-N 0.000 description 1
- LCADVYTXPLBAGB-AUQKUMLUSA-N (2E,4E,6Z,8E,10E,14E)-13-hydroxy-N-(1-hydroxypropan-2-yl)-2,10,12,14,16-pentamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenamide Chemical compound OCC(C)NC(=O)C(\C)=C\C=C\C=C/C=C/C(/C)=C/C(C)C(O)C(\C)=C\C(C)CCC1=CC=CC=C1 LCADVYTXPLBAGB-AUQKUMLUSA-N 0.000 description 1
- NOENHWMKHNSHGX-FAZSUBJTSA-N (2R)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@H](CCC1)C(=O)NC(C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-FAZSUBJTSA-N 0.000 description 1
- FKHUGQZRBPETJR-RXSRXONKSA-N (2R)-2-[[(4R)-4-[[(2S)-2-[[(2R)-2-[(3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-(octadecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@H](C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O FKHUGQZRBPETJR-RXSRXONKSA-N 0.000 description 1
- RXWNCPJZOCPEPQ-FNQTVZJVSA-N (2R)-2-amino-N-[(2S,3S,4R,5R)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide Chemical compound C1=CC(OC)=CC=C1C[C@@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-FNQTVZJVSA-N 0.000 description 1
- SWTGJCNCBUCXSS-ISUZDFFFSA-N (2R)-3,4-dihydroxy-2-[(4S)-2-phenyl-1,3-dioxolan-4-yl]-2H-furan-5-one Chemical compound OC1=C(O)C(=O)O[C@@H]1[C@H]1OC(C=2C=CC=CC=2)OC1 SWTGJCNCBUCXSS-ISUZDFFFSA-N 0.000 description 1
- RCGXNDQKCXNWLO-YUHQQKLOSA-N (2R)-N-[(2S)-5-amino-1-[[(2R,3S)-1-[[(3S,6Z,9S,12R,15R,18R,19R)-9-benzyl-15-[(2S)-butan-2-yl]-6-ethylidene-19-methyl-2,5,8,11,14,17-hexaoxo-3,12-di(propan-2-yl)-1-oxa-4,7,10,13,16-pentazacyclononadec-18-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopent Chemical compound N([C@@H](CCCN)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]1C(N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NC(/C(=O)N[C@H](C(=O)O[C@@H]1C)C(C)C)=C\C)C(C)C)[C@@H](C)CC)=O)C(=O)[C@H]1CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CCCC(C)C)C(C)C)[C@@H](C)O)C(C)C)C(C)C RCGXNDQKCXNWLO-YUHQQKLOSA-N 0.000 description 1
- PAYBYKKERMGTSS-MNCSTQPFSA-N (2R,3R,3aS,9aR)-7-fluoro-2-(hydroxymethyl)-6-imino-2,3,3a,9a-tetrahydrofuro[1,2][1,3]oxazolo[3,4-a]pyrimidin-3-ol Chemical compound N=C1C(F)=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 PAYBYKKERMGTSS-MNCSTQPFSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2R,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N (2R,3S,4R,5S)-1,6-dibromohexane-2,3,4,5-tetrol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- GJNXBNATEDXMAK-PFLSVRRQSA-N (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 description 1
- ZZKNRXZVGOYGJT-VKHMYHEASA-N (2S)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 description 1
- XDZGQQRZJDKPTG-HBNQUELISA-N (2S)-2-[(3S,6S)-6-[2-[(1R,2R,4aS,8aS)-1-hydroxy-2,4a,5,5,8a-pentamethyl-2,3,4,6,7,8-hexahydronaphthalen-1-yl]ethyl]-6-methyldioxan-3-yl]propanoic acid Chemical compound O1O[C@H]([C@H](C)C(O)=O)CC[C@@]1(C)CC[C@]1(O)[C@@]2(C)CCCC(C)(C)[C@]2(C)CC[C@H]1C XDZGQQRZJDKPTG-HBNQUELISA-N 0.000 description 1
- XVOCEQLNJQGCQG-ACRSGXKRSA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl- Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C=CC=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 XVOCEQLNJQGCQG-ACRSGXKRSA-N 0.000 description 1
- CUCSSYAUKKIDJV-FAXBSAIASA-N (2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]-methylamino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-4-methylpent Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)N(C)C(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CUCSSYAUKKIDJV-FAXBSAIASA-N 0.000 description 1
- MJINRRBEMOLJAK-DCAQKATOSA-N (2S)-2-[[(2S)-6-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N MJINRRBEMOLJAK-DCAQKATOSA-N 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N (2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)butan-2-yl]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- ZUQBAQVRAURMCL-DOMZBBRYSA-N (2S)-2-[[4-[2-[(6R)-2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid Chemical compound C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZUQBAQVRAURMCL-DOMZBBRYSA-N 0.000 description 1
- JRBXPUUAYKCCLQ-QMMMGPOBSA-N (2S)-2-amino-2-[3-hydroxy-4-(hydroxymethyl)phenyl]acetic acid Chemical compound OC(=O)[C@@H](N)C1=CC=C(CO)C(O)=C1 JRBXPUUAYKCCLQ-QMMMGPOBSA-N 0.000 description 1
- YOZSEGPJAXTSFZ-ZETCQYMHSA-N (2S)-2-amino-3-(5-hydroxypyridin-2-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=N1 YOZSEGPJAXTSFZ-ZETCQYMHSA-N 0.000 description 1
- RPEPXOHTYVXVMA-CIUDSAMLSA-N (2S)-2-amino-5-[[(2S)-1-[[(1S)-1-carboxy-4-(3H-diazirin-3-yl)-4-oxobutyl]amino]-5-(3H-diazirin-3-yl)-1,5-dioxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound C([C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](CCC(=O)C1N=N1)C(O)=O)CC(=O)C1N=N1 RPEPXOHTYVXVMA-CIUDSAMLSA-N 0.000 description 1
- UUSZLLQJYRSZIS-GHRWIAHFSA-N (2S)-N-[(2R)-1-[[(3S,6R,8S,12S,13R,16R,17S,23S)-13-[(2S)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl)methyl]-6,17,21-trimethyl-3-(2-methylpropyl)-2,5,7,10,15,19,22-heptaoxo-8-propan-2-yl-9,18-dioxa-1,4,14,21-tetrazabicyclo[21.3.0]hexacosan-16-yl]amino]-4- Chemical compound CN([C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)C(CC=2C=CC(OC)=CC=2)C(=O)O[C@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-GHRWIAHFSA-N 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-( Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
- BEHHCQFBLOARIX-APTPAJQOSA-N (2S,3S)-2-aminooctadecane-1,3-diol;hydrochloride Chemical compound Cl.CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO BEHHCQFBLOARIX-APTPAJQOSA-N 0.000 description 1
- HWMMBHOXHRVLCU-QOUANJGESA-N (2S,4S,5S)-4-[(1E,3E,5E)-7-[(2R,6R)-6-[(2R,3S,4aR,12bS)-2,3,4a,8,12b-pentahydroxy-3-methyl-1,7,12-trioxo-2,4-dihydrobenzo[a]anthracen-9-yl]-2-methyloxan-3-yl]oxy-7-oxohepta-1,3,5-trienyl]-2,5-dimethyl-1,3-dioxolane-2-carboxylic acid Chemical compound C[C@@H]1O[C@](C)(C(O)=O)O[C@H]1\C=C\C=C\C=C\C(=O)OC1[C@@H](C)O[C@@H](C=2C(=C3C(=O)C4=C([C@]5(C(=O)[C@H](O)[C@@](C)(O)C[C@@]5(O)C=C4)O)C(=O)C3=CC=2)O)CC1 HWMMBHOXHRVLCU-QOUANJGESA-N 0.000 description 1
- FXPSZLHFJDHOMI-FLIBITNWSA-N (2Z)-4-methoxy-3-methylsulfanyl-2-(nitrosomethylidene)-6-pyridin-2-yl-1H-pyridine Chemical compound COC1=C(SC)\C(=C\N=O)NC(C=2N=CC=CC=2)=C1 FXPSZLHFJDHOMI-FLIBITNWSA-N 0.000 description 1
- JSUANXYBLFQZGI-HDFWGNLJSA-N (2Z,4S,5R)-N-[4-[(2,3-dihydroxybenzoyl)amino]butyl]-N-[3-[(2,3-dihydroxybenzoyl)amino]propyl]-5-methyl-2-(6-oxocyclohexa-2,4-dien-1-ylidene)-1,3-oxazolidine-4-carboxamide Chemical compound O=C([C@H]1NC(/O[C@@H]1C)=C\1C(C=CC=C/1)=O)N(CCCNC(=O)C=1C(=C(O)C=CC=1)O)CCCCNC(=O)C1=CC=CC(O)=C1O JSUANXYBLFQZGI-HDFWGNLJSA-N 0.000 description 1
- UYRMXZIBPZVBNO-QPJJXVBHSA-N (4E)-4-[amino-(hydroxyamino)methylidene]-2-hydroxycyclohexa-2,5-dien-1-one Chemical compound ONC(/N)=C1\C=CC(=O)C(O)=C1 UYRMXZIBPZVBNO-QPJJXVBHSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- DRCNRVYVCHHIJP-AQBORDMYSA-N (4S)-4-[[(2S)-6-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DRCNRVYVCHHIJP-AQBORDMYSA-N 0.000 description 1
- DLWOTOMWYCRPLK-UVTDQMKNSA-N (4Z)-5-amino-6-(7-amino-6-methoxy-5,8-dioxoquinolin-2-yl)-4-(4,5-dimethoxy-6-oxocyclohexa-2,4-dien-1-ylidene)-3-methyl-1H-pyridine-2-carboxylic acid Chemical compound C1=CC(OC)=C(OC)C(=O)\C1=C\1C(N)=C(C=2N=C3C(=O)C(N)=C(OC)C(=O)C3=CC=2)NC(C(O)=O)=C/1C DLWOTOMWYCRPLK-UVTDQMKNSA-N 0.000 description 1
- GTEXXGIEZVKSLH-YPMHNXCESA-N (4aS,12bR)-8,10-dihydroxy-2,5,5,9-tetramethyl-3,4,4a,12b-tetrahydronaphtho[2,3-c]isochromene-7,12-dione Chemical compound O=C1C2=CC(O)=C(C)C(O)=C2C(=O)C2=C1[C@@H]1C=C(C)CC[C@@H]1C(C)(C)O2 GTEXXGIEZVKSLH-YPMHNXCESA-N 0.000 description 1
- HLAKJNQXUARACO-ZDUSSCGKSA-N (5'R)-5'-hydroxy-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one Chemical compound O=C([C@@]1(O)C)C2=CC(C)=CC2=C(C)C21CC2 HLAKJNQXUARACO-ZDUSSCGKSA-N 0.000 description 1
- CPTIBDHUFVHUJK-NZYDNVMFSA-N (5R,6R,7R,8R)-N'-ethyl-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carbohydrazide Chemical compound C1([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(=O)NNCC)=CC(OC)=C(OC)C(OC)=C1 CPTIBDHUFVHUJK-NZYDNVMFSA-N 0.000 description 1
- WTSKMKRYHATLLL-UHFFFAOYSA-N (6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate Chemical compound O=C1N(COCC)C=C(F)C(=O)N1C(=O)C1=CC=CC(C(=O)OC=2C(=CC=C(OC(=O)C=3C=CC=CC=3)N=2)C#N)=C1 WTSKMKRYHATLLL-UHFFFAOYSA-N 0.000 description 1
- LKBBOPGQDRPCDS-YAOXHJNESA-N (7S,9R,10R)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-9-ethyl-4,6,9,10,11-pentahydroxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1C[C@]([C@@H](C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)O)(O)CC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 LKBBOPGQDRPCDS-YAOXHJNESA-N 0.000 description 1
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
- PTBPQBZWBIRISO-IAGVQPJWSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(E)-N-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-C-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 PTBPQBZWBIRISO-IAGVQPJWSA-N 0.000 description 1
- KMSKQZKKOZQFFG-YXRRJAAWSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@@H]1CCCCO1 KMSKQZKKOZQFFG-YXRRJAAWSA-N 0.000 description 1
- RCFNNLSZHVHCEK-YGCMNLPTSA-N (7S,9S)-7-[(2S,4R,6S)-4-amino-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 RCFNNLSZHVHCEK-YGCMNLPTSA-N 0.000 description 1
- JVHPTYWUBOQMBP-RVFAQHLVSA-N (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride Chemical compound Cl.C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 JVHPTYWUBOQMBP-RVFAQHLVSA-N 0.000 description 1
- VHZXNQKVFDBFIK-NBBHSKLNSA-N (8R,9S,10R,13S,14S,16R)-16-fluoro-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C([C@H](F)C4)=O)[C@@H]4[C@@H]3CC=C21 VHZXNQKVFDBFIK-NBBHSKLNSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8S,11R,13R,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- VAPSMQAHNAZRKC-PQWRYPMOSA-N (8S,9S,10R,13S,14S,17S)-17-(tert-butylcarbamoyl)-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3-carboxylic acid Chemical compound C1C=C2C=C(C(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC2 VAPSMQAHNAZRKC-PQWRYPMOSA-N 0.000 description 1
- OJRZEKJECRTBPJ-NGAMADIESA-N (Z,5S)-5-acetamido-1-diazonio-6-hydroxy-6-oxohex-1-en-2-olate Chemical compound CC(=O)N[C@H](C(O)=O)CC\C([O-])=C\[N+]#N OJRZEKJECRTBPJ-NGAMADIESA-N 0.000 description 1
- NBEALWAVEGMZQY-UHFFFAOYSA-N 1,1-diphenylprop-2-ynyl N-cyclohexylcarbamate Chemical compound C=1C=CC=CC=1C(C#C)(C=1C=CC=CC=1)OC(=O)NC1CCCCC1 NBEALWAVEGMZQY-UHFFFAOYSA-N 0.000 description 1
- OUPZKGBUJRBPGC-HLTSFMKQSA-N 1,5-bis[[(2R)-oxiran-2-yl]methyl]-3-[[(2S)-oxiran-2-yl]methyl]-1,3,5-triazinane-2,4,6-trione Chemical compound O=C1N(C[C@H]2OC2)C(=O)N(C[C@H]2OC2)C(=O)N1C[C@H]1CO1 OUPZKGBUJRBPGC-HLTSFMKQSA-N 0.000 description 1
- UOAFGUOASVSLPK-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(2,2-dimethylpropyl)-1-nitrosourea Chemical compound CC(C)(C)CNC(=O)N(N=O)CCCl UOAFGUOASVSLPK-UHFFFAOYSA-N 0.000 description 1
- YQYBWJPESSJLTK-HXFLIBJXSA-N 1-(2-chloroethyl)-3-[(2R,3S,4R,6S)-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]-1-nitrosourea Chemical compound CO[C@@H]1C[C@@H](NC(=O)N(CCCl)N=O)[C@H](O)[C@@H](CO)O1 YQYBWJPESSJLTK-HXFLIBJXSA-N 0.000 description 1
- RCLLNBVPCJDIPX-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-(dimethylsulfamoyl)ethyl]-1-nitrosourea Chemical compound CN(C)S(=O)(=O)CCNC(=O)N(N=O)CCCl RCLLNBVPCJDIPX-UHFFFAOYSA-N 0.000 description 1
- JQJSFAJISYZPER-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-(2,3-dihydro-1H-inden-5-ylsulfonyl)urea Chemical compound C1=CC(Cl)=CC=C1NC(=O)NS(=O)(=O)C1=CC=C(CCC2)C2=C1 JQJSFAJISYZPER-UHFFFAOYSA-N 0.000 description 1
- NSMXQKNUPPXBRG-UHFFFAOYSA-N 1-(5-hydroxyhexyl)-3,7-dimethylpurine-2,6-dione Chemical compound O=C1N(CCCCC(O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-UHFFFAOYSA-N 0.000 description 1
- SNYUHPPZINRDSG-UHFFFAOYSA-N 1-(oxiran-2-ylmethyl)-4-[1-(oxiran-2-ylmethyl)piperidin-4-yl]piperidine Chemical compound C1CC(C2CCN(CC3OC3)CC2)CCN1CC1CO1 SNYUHPPZINRDSG-UHFFFAOYSA-N 0.000 description 1
- VKDGNNYJFSHYKD-UHFFFAOYSA-N 2,5-diamino-2-(difluoromethyl)pentanoic acid;hydron;chloride Chemical compound Cl.NCCCC(N)(C(F)F)C(O)=O VKDGNNYJFSHYKD-UHFFFAOYSA-N 0.000 description 1
- NJWBUDCAWGTQAS-UHFFFAOYSA-N 2-(chrysen-6-ylmethylamino)-2-methylpropane-1,3-diol;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 NJWBUDCAWGTQAS-UHFFFAOYSA-N 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- ARUGKOZUKWAXDS-SEWALLKFSA-N 2-[(2E)-2-[(3aS,4S,5R,6aS)-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-methylnona-1,6-diynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]ethoxy]acetic acid Chemical compound C1\C(=C/COCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)[C@@H](C)CC#CCC)[C@H](O)C[C@@H]21 ARUGKOZUKWAXDS-SEWALLKFSA-N 0.000 description 1
- JUNILAWHCDMYAE-HGJPKUQDSA-N 2-[(3E,7E,9E,17E)-14,19-dihydroxy-3,5,9,11,13,15,17-heptamethyl-12-oxononadeca-3,7,9,17-tetraenyl]-2,3-dihydropyran-6-one Chemical compound OC/C=C(C)/CC(C)C(O)C(C)C(=O)C(C)/C=C(\C)/C=C/CC(C)\C=C(/C)CCC1CC=CC(=O)O1 JUNILAWHCDMYAE-HGJPKUQDSA-N 0.000 description 1
- KPRFMAZESAKTEJ-UHFFFAOYSA-N 2-[1-amino-4-[2,5-dioxo-4-(1-phenylethyl)pyrrolidin-3-yl]-1-oxobutan-2-yl]-5-carbamoylheptanedioic acid;azane Chemical compound [NH4+].[NH4+].C=1C=CC=CC=1C(C)C1C(CCC(C(CCC(CC([O-])=O)C(N)=O)C([O-])=O)C(N)=O)C(=O)NC1=O KPRFMAZESAKTEJ-UHFFFAOYSA-N 0.000 description 1
- XXVLKDRPHSFIIB-UHFFFAOYSA-N 2-[2-(dimethylamino)ethyl]-5-nitrobenzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 XXVLKDRPHSFIIB-UHFFFAOYSA-N 0.000 description 1
- MHXVDXXARZCVRK-WCWDXBQESA-N 2-[2-[4-[(E)-3,3,3-trifluoro-1,2-diphenylprop-1-enyl]phenoxy]ethylamino]ethanol Chemical compound C1=CC(OCCNCCO)=CC=C1C(\C=1C=CC=CC=1)=C(C(F)(F)F)/C1=CC=CC=C1 MHXVDXXARZCVRK-WCWDXBQESA-N 0.000 description 1
- PXJJOGITBQXZEQ-JTHROIFXSA-M 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl-trimethylazanium;iodide Chemical compound [I-].C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCC[N+](C)(C)C)=CC=1)/C1=CC=CC=C1 PXJJOGITBQXZEQ-JTHROIFXSA-M 0.000 description 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N 2-[[2-[bis(2-hydroxyethyl)amino]-4-piperidin-1-ylpyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-N-[(3S,6S,7R,10S,16S)-3-[(2S)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-N-[(3S,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3H-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
- NIXVOFULDIFBLB-QVRNUERCSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purine-6-sulfinamide Chemical compound C12=NC(N)=NC(S(N)=O)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NIXVOFULDIFBLB-QVRNUERCSA-N 0.000 description 1
- WKNMKGVLOWGGOU-UHFFFAOYSA-N 2-aminoacetamide;hydron;chloride Chemical compound Cl.NCC(N)=O WKNMKGVLOWGGOU-UHFFFAOYSA-N 0.000 description 1
- OPKOKAMJFNKNAS-UHFFFAOYSA-O 2-hydroxyethyl(methyl)azanium Chemical compound C[NH2+]CCO OPKOKAMJFNKNAS-UHFFFAOYSA-O 0.000 description 1
- HVXBOLULGPECHP-WAYWQWQTSA-N 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
- DSWLRNLRVBAVFC-UHFFFAOYSA-N 2-methylsulfinyl-1-pyridin-2-ylethanone Chemical compound CS(=O)CC(=O)C1=CC=CC=N1 DSWLRNLRVBAVFC-UHFFFAOYSA-N 0.000 description 1
- GRLUHXSUZYFZCW-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-N,N-dimethylpropan-1-amine;dihydrochloride Chemical compound Cl.Cl.C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 GRLUHXSUZYFZCW-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- GTJXPMSTODOYNP-BTKVJIOYSA-N 3-[(E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 GTJXPMSTODOYNP-BTKVJIOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-PATWWPTKSA-N 3-[[2-[2-[2-[[(2R,3R)-2-[[(2R,3R,4S)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2R)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2S,3R,4R,5R,6R)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan- Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@@H](C)[C@H](O)[C@@H](C)C(=O)N[C@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)C(O[C@@H]1[C@@H]([C@H](O)[C@@H](O)[C@@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-PATWWPTKSA-N 0.000 description 1
- WELIVEBWRWAGOM-UHFFFAOYSA-N 3-amino-N-[2-[2-(3-aminopropanoylamino)ethyldisulfanyl]ethyl]propanamide Chemical compound NCCC(=O)NCCSSCCNC(=O)CCN WELIVEBWRWAGOM-UHFFFAOYSA-N 0.000 description 1
- XSCKKKKCZBNKQZ-UHFFFAOYSA-N 3-chloroquinoxaline-2-sulfonamide Chemical compound C1=CC=C2N=C(Cl)C(S(=O)(=O)N)=NC2=C1 XSCKKKKCZBNKQZ-UHFFFAOYSA-N 0.000 description 1
- HXZRMADPDYFMEB-MLTUFRGDSA-N 3-hydroxy-N-[3-[8-[(E)-6-hydroxy-3,5-dimethylhept-4-enyl]-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]propyl]-2-methyl-4-[[2-[3-methyl-6-[(Z)-2-oxopent-3-enyl]oxan-2-yl]acetyl]amino]butanamide Chemical compound O1C(CC(=O)\C=C/C)CCC(C)C1CC(=O)NCC(O)C(C)C(=O)NCCCC1C(C)CCC2(OC(CCC(C)\C=C(/C)C(C)O)CCC2)O1 HXZRMADPDYFMEB-MLTUFRGDSA-N 0.000 description 1
- PDQGEKGUTOTUNV-TZSSRYMLSA-N 4'-deoxy-4'-iododoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](I)[C@H](C)O1 PDQGEKGUTOTUNV-TZSSRYMLSA-N 0.000 description 1
- LIETVYHJBSLSSW-UHFFFAOYSA-N 4,6,9-trihydroxy-8-methyl-3,4-dihydro-2H-anthracen-1-one Chemical compound OC1CCC(=O)C2=C1C=C1C=C(O)C=C(C)C1=C2O LIETVYHJBSLSSW-UHFFFAOYSA-N 0.000 description 1
- NYVWYZMUMRFMRR-UHFFFAOYSA-N 4-(iminomethylideneamino)-N,N-dimethylpentan-1-amine Chemical compound N=C=NC(C)CCCN(C)C NYVWYZMUMRFMRR-UHFFFAOYSA-N 0.000 description 1
- HQFSNUYUXXPVKL-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl]-2-[1-(2-phenylethyl)azepan-4-yl]phthalazin-1-one Chemical compound C1=CC(F)=CC=C1CC(C1=CC=CC=C1C1=O)=NN1C1CCN(CCC=2C=CC=CC=2)CCC1 HQFSNUYUXXPVKL-UHFFFAOYSA-N 0.000 description 1
- OUQPTBCOEKUHBH-LSDHQDQOSA-N 4-[2-[4-[(E)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]phenoxy]ethyl]morpholine Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C(C=C1)=CC=C1OCCN1CCOCC1 OUQPTBCOEKUHBH-LSDHQDQOSA-N 0.000 description 1
- VAZAPHZUAVEOMC-UHFFFAOYSA-N 4-acetamido-N-(2-aminophenyl)benzamide Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- NSUDGNLOXMLAEB-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)pentanoic acid Chemical compound OC(=O)CCCCOC1=CC=CC(O)=C1C=O NSUDGNLOXMLAEB-UHFFFAOYSA-N 0.000 description 1
- PXLPCZJACKUXGP-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)-6-ethylpyrimidine-2,4-diamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 PXLPCZJACKUXGP-UHFFFAOYSA-N 0.000 description 1
- XESARGFCSKSFID-FLLFQEBCSA-N 5-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1H-pyrazole-3-carboxamide Chemical compound OC1=C(C(=O)N)NN=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XESARGFCSKSFID-FLLFQEBCSA-N 0.000 description 1
- APNRZHLOPQFNMR-WEIUTZTHSA-N 5-[(E)-5-[(1S)-2,2-dimethyl-6-methylidenecyclohexyl]-3-methylpent-2-enyl]phenazin-1-one Chemical compound C12=CC=CC=C2N=C(C(C=CC=2)=O)C=2N1C\C=C(/C)CC[C@@H]1C(=C)CCCC1(C)C APNRZHLOPQFNMR-WEIUTZTHSA-N 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N 5-ethynyl-1H-pyrimidine-2,4-dione Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- ZCJXQWYMBJYJNB-LRDBBFHQSA-N 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine;(2S,3S,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O.COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 ZCJXQWYMBJYJNB-LRDBBFHQSA-N 0.000 description 1
- PXBZKHOQHTVCSQ-QZTJIDSGSA-N 5-nitro-2-[(2R)-1-[2-[[(2R)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 PXBZKHOQHTVCSQ-QZTJIDSGSA-N 0.000 description 1
- BOJKULTULYSRAS-OTESTREVSA-N 5508-58-7 Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
- VJXSSYDSOJBUAV-UHFFFAOYSA-N 6-(2,5-Dimethoxy-Benzyl)-5-Methyl-Pyrido[2,3-D]Pyrimidine-2,4-Diamine Chemical compound COC1=CC=C(OC)C(CC=2C(=C3C(N)=NC(N)=NC3=NC=2)C)=C1 VJXSSYDSOJBUAV-UHFFFAOYSA-N 0.000 description 1
- ATCGGEJZONJOCL-UHFFFAOYSA-N 6-(2,5-dichlorophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(C=2C(=CC=C(Cl)C=2)Cl)=N1 ATCGGEJZONJOCL-UHFFFAOYSA-N 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purin-2-amine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- OTSZCHORPMQCBZ-UHFFFAOYSA-N 6-[(3-chlorophenyl)-imidazol-1-ylmethyl]-1H-benzimidazole;hydron;chloride Chemical compound Cl.ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 OTSZCHORPMQCBZ-UHFFFAOYSA-N 0.000 description 1
- LRHPCRBOMKRVOA-UHFFFAOYSA-N 6-[2-(2-hydroxyethylamino)ethyl]indeno[1,2-c]isoquinoline-5,11-dione Chemical compound C12=CC=CC=C2C(=O)N(CCNCCO)C2=C1C(=O)C1=CC=CC=C12 LRHPCRBOMKRVOA-UHFFFAOYSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- ZNTIXVYOBQDFFV-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.O=C1NC(N)=CC2=C1N=CN2 ZNTIXVYOBQDFFV-UHFFFAOYSA-N 0.000 description 1
- GFYRZTLCYQQVHZ-UHFFFAOYSA-N 6-hydroxy-4-oxo-N-phenyl-2-sulfanylidene-1H-pyrimidine-5-carboxamide Chemical compound N1C(=S)NC(=O)C(C(=O)NC=2C=CC=CC=2)=C1O GFYRZTLCYQQVHZ-UHFFFAOYSA-N 0.000 description 1
- GOYNNCPGHOBFCK-UHFFFAOYSA-N 7-[4-(dimethylamino)-5-[(2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl)oxy]-6-methyloxan-2-yl]oxy-9-ethyl-4,6,9,10,11-pentahydroxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1C(O)=C1C(OC3OC(C)C(OC4OC(C)C5OC6OC(C)C(=O)CC6OC5C4)C(C3)N(C)C)CC(CC)(O)C(O)C1=C2O GOYNNCPGHOBFCK-UHFFFAOYSA-N 0.000 description 1
- GOJJWDOZNKBUSR-UHFFFAOYSA-N 7-sulfamoyloxyheptyl sulfamate Chemical compound NS(=O)(=O)OCCCCCCCOS(N)(=O)=O GOJJWDOZNKBUSR-UHFFFAOYSA-N 0.000 description 1
- LPDLEICKXUVJHW-QJILNLRNSA-N 78NZ2PMP25 Chemical compound OS(O)(=O)=O.O([C@]12[C@H](OC(C)=O)[C@]3(CC)C=CCN4CC[C@@]5([C@H]34)[C@H]1N(C)C1=C5C=C(C(=C1)OC)[C@]1(C(=O)OC)C3=C(C4=CC=CC=C4N3)CCN3C[C@H](C1)C[C@@](C3)(O)CC)C(=O)N(CCCl)C2=O LPDLEICKXUVJHW-QJILNLRNSA-N 0.000 description 1
- TWHSQQYCDVSBRK-UHFFFAOYSA-N 9-[4-(methanesulfonamido)-2-methoxyanilino]-N,5-dimethylacridine-4-carboxamide Chemical compound C12=CC=CC(C)=C2N=C2C(C(=O)NC)=CC=CC2=C1NC1=CC=C(NS(C)(=O)=O)C=C1OC TWHSQQYCDVSBRK-UHFFFAOYSA-N 0.000 description 1
- QAWIHIJWNYOLBE-OKKQSCSOSA-N ACIVICIN Chemical compound OC(=O)[C@@H](N)[C@@H]1CC(Cl)=NO1 QAWIHIJWNYOLBE-OKKQSCSOSA-N 0.000 description 1
- 229950008427 ACIVICIN Drugs 0.000 description 1
- 108060005293 AGA Proteins 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N AMRUBICIN Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 229960003272 ASPARAGINASE Drugs 0.000 description 1
- 229950004810 ATAMESTANE Drugs 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N Abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- SMPZPKRDRQOOHT-UHFFFAOYSA-N Acronine Chemical compound CN1C2=CC=CC=C2C(=O)C2=C1C(C=CC(C)(C)O1)=C1C=C2OC SMPZPKRDRQOOHT-UHFFFAOYSA-N 0.000 description 1
- 229950000616 Acronine Drugs 0.000 description 1
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 1
- DPGOLRILOKERAV-AAWJQDODSA-N Adecypenol Chemical compound OC1C(CO)=CCC1(O)N1C(N=CNC[C@H]2O)C2N=C1 DPGOLRILOKERAV-AAWJQDODSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 210000000577 Adipose Tissue Anatomy 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N Alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 229950010949 Ambamustine Drugs 0.000 description 1
- 229950004821 Ambomycin Drugs 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N Amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960001097 Amifostine Drugs 0.000 description 1
- 229960003437 Aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N Aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N Anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- 208000000058 Anaplasia Diseases 0.000 description 1
- BOJKULTULYSRAS-QPSYGYIJSA-N Andrographolide Natural products C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1\[C@H](O)COC1=O BOJKULTULYSRAS-QPSYGYIJSA-N 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N Anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- IOASYARYEYRREA-LQAJYKIKSA-N Aphidicolin glycinate Chemical compound C1[C@]23[C@]4(C)CC[C@H](O)[C@](C)(CO)[C@H]4CC[C@@H]3C[C@@H]1[C@@](COC(=O)CN)(O)CC2 IOASYARYEYRREA-LQAJYKIKSA-N 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- 229920002395 Aptamer Polymers 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 108010075389 Aspergillus restrictus MITF protein Proteins 0.000 description 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N Atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
- 229950006933 Atrimustine Drugs 0.000 description 1
- 241001263178 Auriparus Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- PICZCWCKOLHDOJ-GHTSNYPWSA-N Axinastatin 1 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)=O)C(C)C)C(C)C)C(C)C)C1=CC=CC=C1 PICZCWCKOLHDOJ-GHTSNYPWSA-N 0.000 description 1
- OXNAATCTZCSVKR-AVGVIDKOSA-N Axinastatin 2 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)C(C)C)=O)CC(C)C)C(C)C)C1=CC=CC=C1 OXNAATCTZCSVKR-AVGVIDKOSA-N 0.000 description 1
- ANLDPEXRVVIABH-WUUSPZRJSA-N Axinastatin 3 Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)C(C)C)=O)[C@@H](C)CC)C1=CC=CC=C1 ANLDPEXRVVIABH-WUUSPZRJSA-N 0.000 description 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N Azasetron Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
- 229950005951 Azasetron Drugs 0.000 description 1
- MIXLRUYCYZPSOQ-HXPMCKFVSA-N Azatoxin Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@@H]3N2C(OC3)=O)=C1 MIXLRUYCYZPSOQ-HXPMCKFVSA-N 0.000 description 1
- 229950004295 Azotomycin Drugs 0.000 description 1
- 229950005567 BENZODEPA Drugs 0.000 description 1
- 229950002370 BISNAFIDE Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N BRL-49594 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- XYUFCXJZFZPEJD-PGRDOPGGSA-N Balanol Chemical compound OC(=O)C1=CC=CC(O)=C1C(=O)C1=C(O)C=C(C(=O)O[C@H]2[C@H](CNCCC2)NC(=O)C=2C=CC(O)=CC=2)C=C1O XYUFCXJZFZPEJD-PGRDOPGGSA-N 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N Betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- QGJZLNKBHJESQX-CASBDLHJSA-N Betulinic acid Natural products O=C(O)[C@@]12[C@@H]([C@@H](C(=C)C)CC1)[C@@H]1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC1)CC2 QGJZLNKBHJESQX-CASBDLHJSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 229960004395 Bleomycin Sulfate Drugs 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000000133 Brain Stem Anatomy 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 229950002361 Budotitane Drugs 0.000 description 1
- 208000009899 Burkitt Lymphoma Diseases 0.000 description 1
- KJQFBVYMGADDTQ-UHFFFAOYSA-N Buthionine sulfoximine Chemical compound CCCCS(=N)(=O)CCC(N)C(O)=O KJQFBVYMGADDTQ-UHFFFAOYSA-N 0.000 description 1
- WWGXKJMSVQDWTQ-UHFFFAOYSA-O C(C)(=O)ONC(=O)C1=NC=C(C=C1O)C1=CC(=CC=C1)F.[NH4+] Chemical compound C(C)(=O)ONC(=O)C1=NC=C(C=C1O)C1=CC(=CC=C1)F.[NH4+] WWGXKJMSVQDWTQ-UHFFFAOYSA-O 0.000 description 1
- SGMVOYGHPYEIIT-UHFFFAOYSA-N C(C)(=O)ONC(=O)C1=NC=C(C=C1O)C1=CC(=CC=C1)F.[Na] Chemical compound C(C)(=O)ONC(=O)C1=NC=C(C=C1O)C1=CC(=CC=C1)F.[Na] SGMVOYGHPYEIIT-UHFFFAOYSA-N 0.000 description 1
- PLDDRSAQGWQSQX-UHFFFAOYSA-L C(C)(=O)ONC(=O)C1=NC=C(C=C1[O-])C1=CC(=CC=C1)F.[K+].[K+].FC=1C=C(C=CC1)C=1C=C(C(=NC1)C(=O)NOC(C)=O)[O-] Chemical compound C(C)(=O)ONC(=O)C1=NC=C(C=C1[O-])C1=CC(=CC=C1)F.[K+].[K+].FC=1C=C(C=CC1)C=1C=C(C(=NC1)C(=O)NOC(C)=O)[O-] PLDDRSAQGWQSQX-UHFFFAOYSA-L 0.000 description 1
- FTMFRJLIJLSFGI-UHFFFAOYSA-L C(C)(=O)ONC(=O)C1=NC=C(C=C1[O-])C1=CC(=CC=C1)F.[K+].[Na+].FC=1C=C(C=CC1)C=1C=C(C(=NC1)C(=O)NOC(C)=O)[O-] Chemical compound C(C)(=O)ONC(=O)C1=NC=C(C=C1[O-])C1=CC(=CC=C1)F.[K+].[Na+].FC=1C=C(C=CC1)C=1C=C(C(=NC1)C(=O)NOC(C)=O)[O-] FTMFRJLIJLSFGI-UHFFFAOYSA-L 0.000 description 1
- BEXVELDLCGNSAU-UHFFFAOYSA-N C(C)(=O)ONC(=O)C1=NC=C(C=C1[O-])C1=CC(=CC=C1)F.[NH4+].[K] Chemical compound C(C)(=O)ONC(=O)C1=NC=C(C=C1[O-])C1=CC(=CC=C1)F.[NH4+].[K] BEXVELDLCGNSAU-UHFFFAOYSA-N 0.000 description 1
- LBAMTIVSPZZAKO-UHFFFAOYSA-N C(C)(=O)ONC(=O)C1=NC=C(C=C1[O-])C1=CC(=CC=C1)F.[NH4+].[NH4+].FC=1C=C(C=CC1)C=1C=C(C(=NC1)C(=O)NOC(C)=O)[O-] Chemical compound C(C)(=O)ONC(=O)C1=NC=C(C=C1[O-])C1=CC(=CC=C1)F.[NH4+].[NH4+].FC=1C=C(C=CC1)C=1C=C(C(=NC1)C(=O)NOC(C)=O)[O-] LBAMTIVSPZZAKO-UHFFFAOYSA-N 0.000 description 1
- RCMNVBOGHXZOPT-UHFFFAOYSA-N C(C)(=O)ONC(=O)C1=NC=C(C=C1[O-])C1=CC(=CC=C1)F.[NH4+].[Na] Chemical compound C(C)(=O)ONC(=O)C1=NC=C(C=C1[O-])C1=CC(=CC=C1)F.[NH4+].[Na] RCMNVBOGHXZOPT-UHFFFAOYSA-N 0.000 description 1
- ZIWXKGQDQBLUMV-JUDXGUMMSA-N C(C)(=O)[C@@]1([C@]([C@@](O[C@@H]1CO)(N1C(=O)NC(=O)C=C1)C(C)=O)(O)C(C)=O)O Chemical compound C(C)(=O)[C@@]1([C@]([C@@](O[C@@H]1CO)(N1C(=O)NC(=O)C=C1)C(C)=O)(O)C(C)=O)O ZIWXKGQDQBLUMV-JUDXGUMMSA-N 0.000 description 1
- VPPKFDWTPOXVMQ-UHFFFAOYSA-N C1=C(O)C(NCC(=O)OC)=NC=C1C1=CC=CC(F)=C1 Chemical compound C1=C(O)C(NCC(=O)OC)=NC=C1C1=CC=CC(F)=C1 VPPKFDWTPOXVMQ-UHFFFAOYSA-N 0.000 description 1
- VZZZFDNCYNBQAK-UHFFFAOYSA-N C1=C(O)C([N-]CC(=O)N(C(C)C)C(C)C)=NC=C1C1=CC=CC(F)=C1 Chemical compound C1=C(O)C([N-]CC(=O)N(C(C)C)C(C)C)=NC=C1C1=CC=CC(F)=C1 VZZZFDNCYNBQAK-UHFFFAOYSA-N 0.000 description 1
- BQJYEWOFOSQDCJ-UHFFFAOYSA-N C1=C(O)C([N-]CC(=O)N(C(C)C)CC)=NC=C1C1=CC=CC(F)=C1 Chemical compound C1=C(O)C([N-]CC(=O)N(C(C)C)CC)=NC=C1C1=CC=CC(F)=C1 BQJYEWOFOSQDCJ-UHFFFAOYSA-N 0.000 description 1
- CUEQUIDZINNPRF-UHFFFAOYSA-N C1=C(O)C([N-]CC(=O)N(C)C)=NC=C1C1=CC=CC(F)=C1 Chemical compound C1=C(O)C([N-]CC(=O)N(C)C)=NC=C1C1=CC=CC(F)=C1 CUEQUIDZINNPRF-UHFFFAOYSA-N 0.000 description 1
- SXXKHBUGPXKTPT-UHFFFAOYSA-N C1=C(O)C([N-]CC(=O)N(CC)CC)=NC=C1C1=CC=CC(F)=C1 Chemical compound C1=C(O)C([N-]CC(=O)N(CC)CC)=NC=C1C1=CC=CC(F)=C1 SXXKHBUGPXKTPT-UHFFFAOYSA-N 0.000 description 1
- MJZYGBZPCGBYFC-UHFFFAOYSA-M C1=C(O)C([N-]CC(=O)NCCC)=NC=C1C1=CC=CC(F)=C1 Chemical compound C1=C(O)C([N-]CC(=O)NCCC)=NC=C1C1=CC=CC(F)=C1 MJZYGBZPCGBYFC-UHFFFAOYSA-M 0.000 description 1
- VCVXQGWKMUTOOW-UHFFFAOYSA-M C1=C(O)C([N-]CC(=O)NCCCC)=NC=C1C1=CC=CC(F)=C1 Chemical compound C1=C(O)C([N-]CC(=O)NCCCC)=NC=C1C1=CC=CC(F)=C1 VCVXQGWKMUTOOW-UHFFFAOYSA-M 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N CARUBICIN Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 229950001725 CARUBICIN Drugs 0.000 description 1
- PUDHBTGHUJUUFI-PURAGXGVSA-N CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 Chemical compound CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 PUDHBTGHUJUUFI-PURAGXGVSA-N 0.000 description 1
- HZCWPKGYTCJSEB-UHFFFAOYSA-N CHEMBL118841 Chemical compound C12=CC(OC)=CC=C2NC2=C([N+]([O-])=O)C=CC3=C2C1=NN3CCCN(C)C HZCWPKGYTCJSEB-UHFFFAOYSA-N 0.000 description 1
- RWXRJSRJIITQAK-ZSBIGDGJSA-N CHEMBL2105109 Chemical compound C12=CC=CC=C2NC(=O)N1C(=O)N[C@H](C1)C[C@H]2CC[C@@H]1N2C RWXRJSRJIITQAK-ZSBIGDGJSA-N 0.000 description 1
- 102100016705 COL18A1 Human genes 0.000 description 1
- 229950007258 CRISNATOL Drugs 0.000 description 1
- LUEYTMPPCOCKBX-KWYHTCOPSA-N CURACIN-A Chemical compound C=CC[C@H](OC)CC\C(C)=C\C=C\CC\C=C/[C@@H]1CSC([C@H]2[C@H](C2)C)=N1 LUEYTMPPCOCKBX-KWYHTCOPSA-N 0.000 description 1
- 229950009908 Cactinomycin Drugs 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N Calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N Calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 Calusterone Drugs 0.000 description 1
- 229940088954 Camptosar Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229960004117 Capecitabine Drugs 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 229950009338 Caracemide Drugs 0.000 description 1
- 229950005155 Carbetimer Drugs 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 1
- WNRZHQBJSXRYJK-UHFFFAOYSA-N Carboxyamidotriazole Chemical compound NC1=C(C(=O)N)N=NN1CC(C=C1Cl)=CC(Cl)=C1C(=O)C1=CC=C(Cl)C=C1 WNRZHQBJSXRYJK-UHFFFAOYSA-N 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 210000000845 Cartilage Anatomy 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
- JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108050004290 Cecropins Proteins 0.000 description 1
- 229950010667 Cedefingol Drugs 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 1
- 229950000634 Cicaprost Drugs 0.000 description 1
- 229950011359 Cirolemycin Drugs 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N Clomifene Chemical class C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- GLESHRYLRAOJPS-DHCFDGJBSA-N Conagenin Chemical compound C[C@@H](O)[C@H](C)[C@@H](O)C(=O)N[C@@](C)(CO)C(O)=O GLESHRYLRAOJPS-DHCFDGJBSA-N 0.000 description 1
- SBRXTSOCZITGQG-UHFFFAOYSA-N Crisnatol Chemical compound C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 SBRXTSOCZITGQG-UHFFFAOYSA-N 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N Cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- TYVRUMCYJWCOOO-TVEJMLEISA-N Cypemycin Chemical compound C1S\C=C/NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(C(C)CC)NC(=O)C(=C\C)/NC(=O)C(CO)NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C(C(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)C(NC(=O)C(\NC(=O)C1N(CCC1)C(=O)C(\NC(=O)C(C)NC(=O)C1N(CCC1)C(=O)C(\NC(=O)C(C)N(C)C)=C/C)=C/C)=C/C)C(C)C)CC1=CC=CC=C1 TYVRUMCYJWCOOO-TVEJMLEISA-N 0.000 description 1
- 229960000684 Cytarabine Drugs 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101710004105 DCT Proteins 0.000 description 1
- 102100007097 DCT Human genes 0.000 description 1
- 108010084740 Daclizumab Proteins 0.000 description 1
- 229960003109 Daunorubicin Hydrochloride Drugs 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960000605 Dexrazoxane Drugs 0.000 description 1
- 229950005878 Dexverapamil Drugs 0.000 description 1
- 229950010621 Dezaguanine Drugs 0.000 description 1
- KYHUYMLIVQFXRI-SJPGYWQQSA-N Didemnin B Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)[C@H](C)O KYHUYMLIVQFXRI-SJPGYWQQSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Didronel Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- NOPFSRXAKWQILS-UHFFFAOYSA-N Docosanol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 1
- CGHRJBLSXVCYQF-YXSUXZIUSA-N Dolasetron Chemical compound C1=CC=C[C]2C(C(O[C@@H]3C[C@@H]4C[C@@H]5C[C@@H](N4CC5=O)C3)=O)=CN=C21 CGHRJBLSXVCYQF-YXSUXZIUSA-N 0.000 description 1
- 229960002918 Doxorubicin Hydrochloride Drugs 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N Drostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 229950005133 Duazomycin Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N Duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229950011461 EDELFOSINE Drugs 0.000 description 1
- 229950001022 ENPROMATE Drugs 0.000 description 1
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 229950010033 Ebselen Drugs 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselenum Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 229950005678 Ecomustine Drugs 0.000 description 1
- MHFRGQHAERHWKZ-UHFFFAOYSA-N Edelfosine Chemical compound CCCCCCCCCCCCCCCCCCOCC(OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-UHFFFAOYSA-N 0.000 description 1
- 108010070635 Edrecolomab Proteins 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N Eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229960002046 Eflornithine Hydrochloride Drugs 0.000 description 1
- MGQRRMONVLMKJL-KWJIQSIXSA-N Elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
- 229950002339 Elsamitrucin Drugs 0.000 description 1
- 229950005450 Emitefur Drugs 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 229950010625 Enloplatin Drugs 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 206010014968 Ependymoma malignant Diseases 0.000 description 1
- 229950004926 Epipropidine Drugs 0.000 description 1
- 229960003265 Epirubicin Hydrochloride Drugs 0.000 description 1
- 210000000981 Epithelium Anatomy 0.000 description 1
- 229950009537 Epristeride Drugs 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- KLEPCGBEXOCIGS-QPPBQGQZSA-N Erbulozole Chemical compound C1=CC(NC(=O)OCC)=CC=C1SC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C=CC(OC)=CC=2)OC1 KLEPCGBEXOCIGS-QPPBQGQZSA-N 0.000 description 1
- 229950001426 Erbulozole Drugs 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 229960001842 Estramustine Drugs 0.000 description 1
- 229960001766 Estramustine Phosphate Sodium Drugs 0.000 description 1
- 229940009626 Etidronate Drugs 0.000 description 1
- ISVXIZFUEUVXPG-UHFFFAOYSA-N Etiopurpurin Chemical compound CC1C2(CC)C(C(=O)OCC)=CC(C3=NC(C(=C3C)CC)=C3)=C2N=C1C=C(N1)C(CC)=C(C)C1=CC1=C(CC)C(C)=C3N1 ISVXIZFUEUVXPG-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 102100008634 FGF2 Human genes 0.000 description 1
- 101700082364 FGF2 Proteins 0.000 description 1
- 229950010404 FOSTRIECIN Drugs 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229960004177 Filgrastim Drugs 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N Finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229950006000 Flezelastine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 Floxuridine Drugs 0.000 description 1
- 229950005682 Flurocitabine Drugs 0.000 description 1
- 229950004217 Forfenimex Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N Formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- UXTSQCOOUJTIAC-UHFFFAOYSA-N Fosquidone Chemical compound C=1N2CC3=CC=CC=C3C(C)C2=C(C(C2=CC=C3)=O)C=1C(=O)C2=C3OP(O)(=O)OCC1=CC=CC=C1 UXTSQCOOUJTIAC-UHFFFAOYSA-N 0.000 description 1
- 229950005611 Fosquidone Drugs 0.000 description 1
- 101710037135 GAPC2 Proteins 0.000 description 1
- 101710037116 GAPC3 Proteins 0.000 description 1
- 101710025049 GAPDG Proteins 0.000 description 1
- 101710008404 GAPDH Proteins 0.000 description 1
- 102100006425 GAPDH Human genes 0.000 description 1
- 229950004410 Galocitabine Drugs 0.000 description 1
- 101710010461 Gapdh1 Proteins 0.000 description 1
- 229960005144 Gemcitabine hydrochloride Drugs 0.000 description 1
- 210000004907 Glands Anatomy 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- BNQSTAOJRULKNX-UHFFFAOYSA-N Hexamethylene bisacetamide Chemical compound CC(=O)NCCCCCCNC(C)=O BNQSTAOJRULKNX-UHFFFAOYSA-N 0.000 description 1
- 206010020118 Histiocytosis Diseases 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-O Htris Chemical compound OCC([NH3+])(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-O 0.000 description 1
- 229940088013 Hycamtin Drugs 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 102100014263 IGF1R Human genes 0.000 description 1
- 101700025802 IGF1R Proteins 0.000 description 1
- 229950007654 ITASETRON Drugs 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- 229960001176 Idarubicin Hydrochloride Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- 229950002248 Idoxifene Drugs 0.000 description 1
- 229950009926 Idramantone Drugs 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- NITYDPDXAAFEIT-DYVFJYSZSA-N Ilomastat Chemical compound C1=CC=C2C(C[C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)CC(=O)NO)=CNC2=C1 NITYDPDXAAFEIT-DYVFJYSZSA-N 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N Imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000020344 Insulin-Like Growth Factor Binding Proteins Human genes 0.000 description 1
- 108091022066 Insulin-Like Growth Factor Binding Proteins Proteins 0.000 description 1
- 229960003521 Interferon Alfa-2a Drugs 0.000 description 1
- 229960003507 Interferon Alfa-2b Drugs 0.000 description 1
- 108010054698 Interferon Alfa-n3 Proteins 0.000 description 1
- 229940109242 Interferon Alfa-n3 Drugs 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 229940117681 Interleukin-12 Drugs 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229940047122 Interleukins Drugs 0.000 description 1
- PDWUPXJEEYOOTR-UHFFFAOYSA-N Iobenguane Chemical compound NC(=N)NCC1=CC=CC(I)=C1 PDWUPXJEEYOOTR-UHFFFAOYSA-N 0.000 description 1
- 229950010897 Iproplatin Drugs 0.000 description 1
- 229960000779 Irinotecan hydrochloride Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N Irinotecan hydrochloride Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 229950000855 Iroplact Drugs 0.000 description 1
- 229950010984 Irsogladine Drugs 0.000 description 1
- 210000000244 Kidney Pelvis Anatomy 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- GSDBGCKBBJVPNC-BYPYZUCNSA-N L-lombricine dizwitterion Chemical compound NC(=[NH2+])NCCOP([O-])(=O)OC[C@H]([NH3+])C([O-])=O GSDBGCKBBJVPNC-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 108010043135 L-methionine gamma-lyase Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZHTRILQJTPJGNK-FYBAATNNSA-N LEINAMYCIN Chemical compound N([C@@H](C=1SC=C(N=1)\C=C/C=C/C(=O)[C@H](O)/C=C(C)/CC1)C)C(=O)C[C@@]21S(=O)SC(=O)[C@]2(C)O ZHTRILQJTPJGNK-FYBAATNNSA-N 0.000 description 1
- 229950005634 LOXORIBINE Drugs 0.000 description 1
- POCZBHBFCIWCCV-UHFFFAOYSA-N Lamellarin N Chemical compound C1=C(O)C(OC)=CC=C1C1=C2C3=CC(OC)=C(O)C=C3C=CN2C2=C1C(C=C(OC)C(O)=C1)=C1OC2=O POCZBHBFCIWCCV-UHFFFAOYSA-N 0.000 description 1
- 201000005099 Langerhans-cell histiocytosis Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 1
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 1
- 229940008250 Leuprolide Drugs 0.000 description 1
- 229940089022 Leuprolide Acetate Drugs 0.000 description 1
- KDQAABAKXDWYSZ-SDCRJXSCSA-N Leurosidine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-SDCRJXSCSA-N 0.000 description 1
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levotetramisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- UGFHIPBXIWJXNA-UHFFFAOYSA-N Liarozole Chemical compound ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 UGFHIPBXIWJXNA-UHFFFAOYSA-N 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- RBBBWKUBQVARPL-SWQMWMPHSA-N Lissoclinamide 7 Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C2=N[C@@H]([C@H](O2)C)C(=O)N[C@@H](C=2SC[C@H](N=2)C(=O)N[C@H](CC=2C=CC=CC=2)C=2SC[C@H](N=2)C(=O)N1)C(C)C)C1=CC=CC=C1 RBBBWKUBQVARPL-SWQMWMPHSA-N 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 229950008991 Lobaplatin Drugs 0.000 description 1
- 229950000909 Lometrexol Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N Lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N Losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 229950008745 Losoxantrone Drugs 0.000 description 1
- XDMHALQMTPSGEA-UHFFFAOYSA-N Losoxantrone hydrochloride Chemical compound Cl.Cl.OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO XDMHALQMTPSGEA-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N Lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 229950002654 Lurtotecan Drugs 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- VQJHOPSWBGJHQS-UHFFFAOYSA-N METOPRINE, METHODICHLOROPHEN Chemical compound CC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 VQJHOPSWBGJHQS-UHFFFAOYSA-N 0.000 description 1
- 101710025050 MK0970 Proteins 0.000 description 1
- 108090000028 MMP12 Proteins 0.000 description 1
- 229950010718 MOPIDAMOL Drugs 0.000 description 1
- 101710017915 MT-A Proteins 0.000 description 1
- 102100006003 MT3 Human genes 0.000 description 1
- 229950001474 Maitansine Drugs 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N Marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 229950008959 Marimastat Drugs 0.000 description 1
- 102000001544 Maspin Human genes 0.000 description 1
- 102000004318 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 229960002868 Mechlorethamine hydrochloride Drugs 0.000 description 1
- 229960004296 Megestrol Acetate Drugs 0.000 description 1
- 229960003194 Meglumine Drugs 0.000 description 1
- 229960003846 Melengestrol Acetate Drugs 0.000 description 1
- UDKABVSQKJNZBH-DWNQPYOZSA-N Melengestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 UDKABVSQKJNZBH-DWNQPYOZSA-N 0.000 description 1
- 208000002030 Merkel Cell Carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 229960003058 Methotrexate Sodium Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N Metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N Mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N Miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229950008541 Mirimostim Drugs 0.000 description 1
- DRCJGCOYHLTVNR-ZUIZSQJWSA-N Mitindomide Chemical compound C1=C[C@@H]2[C@@H]3[C@H]4C(=O)NC(=O)[C@H]4[C@@H]3[C@H]1[C@@H]1C(=O)NC(=O)[C@H]21 DRCJGCOYHLTVNR-ZUIZSQJWSA-N 0.000 description 1
- 229950001314 Mitindomide Drugs 0.000 description 1
- 229950002137 Mitocarcin Drugs 0.000 description 1
- 229950000911 Mitogillin Drugs 0.000 description 1
- 229960003539 Mitoguazone Drugs 0.000 description 1
- 229950007612 Mitomalcin Drugs 0.000 description 1
- 229950001745 Mitonafide Drugs 0.000 description 1
- 229950005715 Mitosper Drugs 0.000 description 1
- 229960000350 Mitotane Drugs 0.000 description 1
- 229960004169 Mitoxantrone Hydrochloride Drugs 0.000 description 1
- 229950008012 Mofarotene Drugs 0.000 description 1
- VAZLWPAHMORDGR-UHFFFAOYSA-L Motexafin gadolinium Chemical compound C1=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=C1[N]1=CC3=[N]4[Gd]11(N56)(OC(=O)C)(OC(=O)C)[N]2=CC(C(C)=C2CCCO)=[N]1C2=CC6=C(CC)C(CC)=C5C=C4C(CCCO)=C3C VAZLWPAHMORDGR-UHFFFAOYSA-L 0.000 description 1
- ISYPMTHOLIXZHJ-UHFFFAOYSA-N Motexafin lutetium Chemical compound [Lu].CC(O)=O.CC(O)=O.C1=NC2=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C2N=CC(C(=C2CCCO)C)=NC2=CC(C(CC)=C2CC)=NC2=CC2=C(CCCO)C(C)=C1N2 ISYPMTHOLIXZHJ-UHFFFAOYSA-N 0.000 description 1
- 206010028193 Multiple endocrine neoplasia syndrome Diseases 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 229960000951 Mycophenolic Acid Drugs 0.000 description 1
- PAVKBQLPQCDVNI-UHFFFAOYSA-N N',N'-diethyl-N-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)propane-1,3-diamine Chemical compound N1C2=CC=C(OC)C=C2C2=C1C(C)=C1C=CN=C(NCCCN(CC)CC)C1=C2C PAVKBQLPQCDVNI-UHFFFAOYSA-N 0.000 description 1
- USVMJSALORZVDV-SDBHATRESA-N N(6)-(Delta(2)-isopentenyl)adenosine Chemical compound C1=NC=2C(NCC=C(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O USVMJSALORZVDV-SDBHATRESA-N 0.000 description 1
- QJMCKEPOKRERLN-UHFFFAOYSA-N N,3,4-trihydroxybenzamide Chemical compound ONC(=O)C1=CC=C(O)C(O)=C1 QJMCKEPOKRERLN-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-PMACEKPBSA-N N-[(2S,3S)-1,3-dihydroxyoctadecan-2-yl]acetamide Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-PMACEKPBSA-N 0.000 description 1
- NKFHKYQGZDAKMX-PPRKPIOESA-N N-[(E)-1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethylideneamino]benzamide;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 NKFHKYQGZDAKMX-PPRKPIOESA-N 0.000 description 1
- TVYPSLDUBVTDIS-FUOMVGGVSA-N N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC=2C(=CN(C(=O)N=2)[C@H]2[C@@H]([C@H](O)[C@@H](C)O2)O)F)=C1 TVYPSLDUBVTDIS-FUOMVGGVSA-N 0.000 description 1
- ARKYUICTMUZVEW-UHFFFAOYSA-N N-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methylpyrrole-2-carboxamide Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)C=2N(C=C(NC(=O)C=3C=CC(=CC=3)N(CCCl)CCCl)C=2)C)=CN1C ARKYUICTMUZVEW-UHFFFAOYSA-N 0.000 description 1
- HRXVDDOKERXBEY-UHFFFAOYSA-N N-[bis(aziridin-1-yl)phosphoryl]-N-ethyl-1,3,4-thiadiazol-2-amine Chemical compound C1CN1P(=O)(N1CC1)N(CC)C1=NN=CS1 HRXVDDOKERXBEY-UHFFFAOYSA-N 0.000 description 1
- WRINSSLBPNLASA-FOCLMDBBSA-N N-methyl-N-[(E)-(N-methylanilino)diazenyl]aniline Chemical compound C=1C=CC=CC=1N(C)\N=N\N(C)C1=CC=CC=C1 WRINSSLBPNLASA-FOCLMDBBSA-N 0.000 description 1
- AAFYOVPTFNNVDN-UHFFFAOYSA-N N-methyl-N-phenacylnitrous amide Chemical compound O=NN(C)CC(=O)C1=CC=CC=C1 AAFYOVPTFNNVDN-UHFFFAOYSA-N 0.000 description 1
- JPASRFGVACYSJG-UHFFFAOYSA-N N1=C2C=CC3=NC=NC3=C2C=C2C1=CCC(=O)C2 Chemical class N1=C2C=CC3=NC=NC3=C2C=C2C1=CCC(=O)C2 JPASRFGVACYSJG-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-O NCC[OH2+] Chemical compound NCC[OH2+] HZAXFHJVJLSVMW-UHFFFAOYSA-O 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 229960002333 Nafarelin Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N Naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 Naloxone Drugs 0.000 description 1
- JZGDNMXSOCDEFQ-UHFFFAOYSA-N Napavin Chemical compound C1C(CC)(O)CC(C2)CN1CCC(C1=CC=CC=C1N1)=C1C2(C(=O)OC)C(C(=C1)OC)=CC2=C1N(C)C1C2(C23)CCN3CC=CC2(CC)C(O)C1(O)C(=O)NCCNC1=CC=C(N=[N+]=[N-])C=C1[N+]([O-])=O JZGDNMXSOCDEFQ-UHFFFAOYSA-N 0.000 description 1
- 229950010676 Nartograstim Drugs 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 206010028767 Nasal sinus cancer Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 229940086322 Navelbine Drugs 0.000 description 1
- 229950007221 Nedaplatin Drugs 0.000 description 1
- 229950010159 Nemorubicin Drugs 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N Neocarzinostatin Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N Neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N Nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 229950006344 Nocodazole Drugs 0.000 description 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 1
- KRWMERLEINMZFT-UHFFFAOYSA-N O(6)-benzylguanine; Chemical compound C=12NC=NC2=NC(N)=NC=1OCC1=CC=CC=C1 KRWMERLEINMZFT-UHFFFAOYSA-N 0.000 description 1
- KQSWXGRFFUBJBN-UHFFFAOYSA-M OC1=CC(C=2C=C(F)C=CC=2)=CN=C1[N-]CC(=O)NC1CC1 Chemical compound OC1=CC(C=2C=C(F)C=CC=2)=CN=C1[N-]CC(=O)NC1CC1 KQSWXGRFFUBJBN-UHFFFAOYSA-M 0.000 description 1
- 101710003000 ORF1/ORF2 Proteins 0.000 description 1
- 229950000370 OXISURAN Drugs 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 229960002700 Octreotide Drugs 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229950011093 Onapristone Drugs 0.000 description 1
- 229960003104 Ornithine Drugs 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZLLOIFNEEWYATC-XMUHMHRVSA-N Osaterone Chemical compound C1=C(Cl)C2=CC(=O)OC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 ZLLOIFNEEWYATC-XMUHMHRVSA-N 0.000 description 1
- 229950006466 Osaterone Drugs 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 206010033268 Ovarian low malignant potential tumour Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 229950000039 PELDESINE Drugs 0.000 description 1
- 229950003180 PEPLOMYCIN Drugs 0.000 description 1
- 102100012884 PF4 Human genes 0.000 description 1
- 101710014074 PF4 Proteins 0.000 description 1
- 102100012897 PGF Human genes 0.000 description 1
- 101710014083 PGF Proteins 0.000 description 1
- HRWCSYMVAIWIDX-UHFFFAOYSA-N PS51OZG63Z Chemical compound Cl.Cl.OCCNCCN1NC2=C3C(=O)C=CC(=O)C3=C(O)C3=C2C1=CC=C3NCCCN HRWCSYMVAIWIDX-UHFFFAOYSA-N 0.000 description 1
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N PUROMYCIN Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 1
- 229950010131 PUROMYCIN Drugs 0.000 description 1
- VYOQBYCIIJYKJA-VORKOXQSSA-N Palau'amine Chemical compound N([C@@]12[C@@H](Cl)[C@@H]([C@@H]3[C@@H]2[C@]24N=C(N)N[C@H]2N2C=CC=C2C(=O)N4C3)CN)C(N)=N[C@H]1O VYOQBYCIIJYKJA-VORKOXQSSA-N 0.000 description 1
- ZFYKZAKRJRNXGF-XRZRNGJYSA-N Palmitoyl rhizoxin Chemical compound O1C(=O)C2OC2CC(CC(=O)O2)CC2C(C)\C=C\C2OC2(C)C(OC(=O)CCCCCCCCCCCCCCC)CC1C(C)C(OC)C(\C)=C\C=C\C(\C)=C\C1=COC(C)=N1 ZFYKZAKRJRNXGF-XRZRNGJYSA-N 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- RDIMTXDFGHNINN-IKGGRYGDSA-N Panaxytriol Chemical compound CCCCCCC[C@H](O)[C@@H](O)CC#CC#C[C@H](O)C=C RDIMTXDFGHNINN-IKGGRYGDSA-N 0.000 description 1
- RDIMTXDFGHNINN-BRWVUGGUSA-N Panaxytriol Natural products CCCCCCC[C@@H](O)[C@H](O)CC#CC#C[C@H](O)C=C RDIMTXDFGHNINN-BRWVUGGUSA-N 0.000 description 1
- 229950003440 Panomifene Drugs 0.000 description 1
- 208000003154 Papilloma Diseases 0.000 description 1
- LPHSYQSMAGVYNT-UHFFFAOYSA-N Pazelliptine Chemical compound N1C2=CC=NC=C2C2=C1C(C)=C1C=CN=C(NCCCN(CC)CC)C1=C2 LPHSYQSMAGVYNT-UHFFFAOYSA-N 0.000 description 1
- 229950006361 Pazelliptine Drugs 0.000 description 1
- DOHVAKFYAHLCJP-UHFFFAOYSA-N Peldesine Chemical compound C1=2NC(N)=NC(=O)C=2NC=C1CC1=CC=CN=C1 DOHVAKFYAHLCJP-UHFFFAOYSA-N 0.000 description 1
- 229950006960 Peliomycin Drugs 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- 229940083984 Penicillin G Sodium Drugs 0.000 description 1
- 239000004107 Penicillin G sodium Substances 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 229960002340 Pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- WTWWXOGTJWMJHI-UHFFFAOYSA-N Perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
- 206010034800 Phaeochromocytoma Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 229960002139 Pilocarpine Hydrochloride Drugs 0.000 description 1
- QCHFTSOMWOSFHM-WPRPVWTQSA-N Pilopine HS Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N Pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229950001030 Piritrexim Drugs 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- JKPDEYAOCSQBSZ-OEUJLIAZSA-N Plomestane Chemical compound O=C1CC[C@]2(CC#C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKPDEYAOCSQBSZ-OEUJLIAZSA-N 0.000 description 1
- 229950004541 Plomestane Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N Podophyllotoxin Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229960001586 Procarbazine Hydrochloride Drugs 0.000 description 1
- RJKFOVLPORLFTN-STHVQZNPSA-N Progesterone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1 RJKFOVLPORLFTN-STHVQZNPSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 229940024999 Proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 229960004356 RIBOPRINE Drugs 0.000 description 1
- NTHPAPBPFQJABD-LLVKDONJSA-N Ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 description 1
- 108090000231 Ras GTPase-activating proteins Proteins 0.000 description 1
- 102000003901 Ras GTPase-activating proteins Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038038 Rectal cancer Diseases 0.000 description 1
- 229950002225 Retelliptine Drugs 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N Rhenium Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N Rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- KNUXHTWUIVMBBY-JRJYXWDASA-N Rintatolimod Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1.O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1.O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 KNUXHTWUIVMBBY-JRJYXWDASA-N 0.000 description 1
- SGOOQMRIPALTEL-UHFFFAOYSA-N Roquinimex Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102100017879 S100A9 Human genes 0.000 description 1
- CGFVUVWMYIHGHS-UHFFFAOYSA-N SAINTOPIN Chemical compound C1=C(O)C=C2C=C(C(=O)C=3C(=C(O)C=C(C=3)O)C3=O)C3=C(O)C2=C1O CGFVUVWMYIHGHS-UHFFFAOYSA-N 0.000 description 1
- 108010005173 SERPIN-B5 Proteins 0.000 description 1
- 229950001403 SIZOFIRAN Drugs 0.000 description 1
- 229950007841 SULOFENUR Drugs 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 229950009089 Simtrazene Drugs 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 229950004225 Sonermin Drugs 0.000 description 1
- 229950004796 Sparfosic Acid Drugs 0.000 description 1
- XKLZIVIOZDNKEQ-CLQLPEFOSA-N Sparsomycin Chemical compound CSC[S@](=O)C[C@H](CO)NC(=O)\C=C\C1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-CLQLPEFOSA-N 0.000 description 1
- 229950009641 Sparsomycin Drugs 0.000 description 1
- YBZRLMLGUBIIDN-UHFFFAOYSA-N Spicamycin Chemical compound O1C(C(O)CO)C(NC(=O)CNC(=O)CCCCCCCCCCCCC(C)C)C(O)C(O)C1NC1=NC=NC2=C1NC=N2 YBZRLMLGUBIIDN-UHFFFAOYSA-N 0.000 description 1
- 206010062261 Spinal cord neoplasm Diseases 0.000 description 1
- 229950004330 Spiroplatin Drugs 0.000 description 1
- HAOCRCFHEPRQOY-JKTUOYIXSA-N Spongistatin-1 Chemical compound C([C@@H]1C[C@@H](C[C@@]2(C[C@@H](O)C[C@@H](C2)\C=C/CCC[C@@H]2[C@H](C)[C@@H](O)C[C@](O2)(O)[C@H]2O)O1)OC)C(=O)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)C(=C)C[C@H](O1)C[C@](C)(O)C[C@@]1(O1)C[C@@H](OC(C)=O)C[C@@H]1CC(=O)O[C@H]1[C@H](O)[C@@H](CC(=C)C(C)[C@H](O)\C=C\C(Cl)=C)O[C@@H]2[C@@H]1C HAOCRCFHEPRQOY-JKTUOYIXSA-N 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- 229950001248 Squalamine Drugs 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 229960002385 Streptomycin Sulfate Drugs 0.000 description 1
- 229960001052 Streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N Suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 Suramin Drugs 0.000 description 1
- FXUAIOOAOAVCGD-FKSUSPILSA-N Swainsonine Chemical compound C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Syngestrets Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- URLYINUFLXOMHP-HTVVRFAVSA-N TCN-P Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O URLYINUFLXOMHP-HTVVRFAVSA-N 0.000 description 1
- 102100002607 TIMP1 Human genes 0.000 description 1
- 102100006014 TIMP2 Human genes 0.000 description 1
- 101700019638 TRPC4 Proteins 0.000 description 1
- 229950002687 Talisomycin Drugs 0.000 description 1
- 229950005667 Tallimustine Drugs 0.000 description 1
- VOKSWYLNZZRQPF-UHFFFAOYSA-N Talwin Chemical compound C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-UHFFFAOYSA-N 0.000 description 1
- 229950010168 Tauromustine Drugs 0.000 description 1
- RNVNXVVEDMSRJE-UHFFFAOYSA-N Teloxantrone hydrochloride Chemical compound Cl.Cl.OCCNCCN1NC2=C3C(=O)C=CC(=O)C3=C(O)C3=C2C1=CC=C3NCCNC RNVNXVVEDMSRJE-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 229950008703 Teroxirone Drugs 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 229960005353 Testolactone Drugs 0.000 description 1
- 229940033529 Tetrahydrocannabinol Drugs 0.000 description 1
- WXZSUBHBYQYTNM-WMDJANBXSA-N Tetrazomine Chemical compound C=1([C@@H]2CO[C@@H]3[C@H]4C[C@@H](CO)[C@H](N4C)[C@@H](N23)CC=1C=C1)C(OC)=C1NC(=O)C1NCCC[C@H]1O WXZSUBHBYQYTNM-WMDJANBXSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- UPGGKUQISSWRJJ-XLTUSUNSSA-N Thiocoraline Chemical compound O=C([C@H]1CSSC[C@@H](N(C(=O)CNC2=O)C)C(=O)N(C)[C@@H](C(SC[C@@H](C(=O)NCC(=O)N1C)NC(=O)C=1C(=CC3=CC=CC=C3N=1)O)=O)CSC)N(C)[C@H](CSC)C(=O)SC[C@@H]2NC(=O)C1=NC2=CC=CC=C2C=C1O UPGGKUQISSWRJJ-XLTUSUNSSA-N 0.000 description 1
- 229960005454 Thioguanine Drugs 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N Thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229960001196 Thiotepa Drugs 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N Thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 208000008732 Thymoma Diseases 0.000 description 1
- 229950010183 Thymotrinan Drugs 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 229950011457 Tiamiprine Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N Tiazofurin Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- TVPNFKRGOFJQOO-UHFFFAOYSA-N Topsentin B1 Chemical compound C1=CC=C2C(C3=CN=C(N3)C(=O)C=3C4=CC=C(C=C4NC=3)O)=CNC2=C1 TVPNFKRGOFJQOO-UHFFFAOYSA-N 0.000 description 1
- 229960004167 Toremifene Citrate Drugs 0.000 description 1
- 210000003014 Totipotent Stem Cells Anatomy 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 206010044407 Transitional cell cancer of the renal pelvis and ureter Diseases 0.000 description 1
- 229950003873 Triciribine Drugs 0.000 description 1
- DRDCQJADRSJFFD-UHFFFAOYSA-N Tris-Hydroxymethyl-Methyl-Ammonium Chemical compound OC[N+](C)(CO)CO DRDCQJADRSJFFD-UHFFFAOYSA-N 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- WMPQMBUXZHMEFZ-YJPJVVPASA-N Turosteride Chemical compound CN([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)N(C(C)C)C(=O)NC(C)C)[C@@]2(C)CC1 WMPQMBUXZHMEFZ-YJPJVVPASA-N 0.000 description 1
- 229950007816 Turosteride Drugs 0.000 description 1
- 229950009811 UBENIMEX Drugs 0.000 description 1
- 101710009757 UROD Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 210000000626 Ureter Anatomy 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 229960005356 Urokinase Drugs 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 206010046766 Uterine cancer Diseases 0.000 description 1
- 102100015313 VIP Human genes 0.000 description 1
- 101700003320 VIP Proteins 0.000 description 1
- 206010046885 Vaginal cancer Diseases 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 229950008261 Velaresol Drugs 0.000 description 1
- 229960004982 Vinblastine Sulfate Drugs 0.000 description 1
- 229960002110 Vincristine Sulfate Drugs 0.000 description 1
- AQTQHPDCURKLKT-PNYVAJAMSA-N Vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-PNYVAJAMSA-N 0.000 description 1
- 229960005212 Vindesine Sulfate Drugs 0.000 description 1
- BCXOZISMDZTYHW-IFQBWSDRSA-N Vinepidine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@H](C2)CC)N2CCC2=C1NC1=CC=CC=C21 BCXOZISMDZTYHW-IFQBWSDRSA-N 0.000 description 1
- UNMODLJJNIJIBD-OTBVPMHJSA-N Vinglycinate sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(=O)CN(C)C)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 UNMODLJJNIJIBD-OTBVPMHJSA-N 0.000 description 1
- 229950009832 Vinleurosine Drugs 0.000 description 1
- 229960002166 Vinorelbine tartrate Drugs 0.000 description 1
- GBABOYUKABKIAF-IWWDSPBFSA-N VinorelbineTartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000008383 Wilms Tumor Diseases 0.000 description 1
- 229950005561 ZANOTERONE Drugs 0.000 description 1
- 101710010406 ZBP14 Proteins 0.000 description 1
- MHDDZDPNIDVLNK-ZGIWMXSJSA-N Zanoterone Chemical compound C1C2=NN(S(C)(=O)=O)C=C2C[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CC[C@H]21 MHDDZDPNIDVLNK-ZGIWMXSJSA-N 0.000 description 1
- FYQZGCBXYVWXSP-STTFAQHVSA-N Zinostatin stimalamer Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1OC1C/2=C/C#C[C@H]3O[C@@]3([C@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(C)C=CC2=C(C)C=C(OC)C=C12 FYQZGCBXYVWXSP-STTFAQHVSA-N 0.000 description 1
- 229950009233 Zinostatin stimalamer Drugs 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- ZMQRJWIYMXZORG-GZIFKOAOSA-N [(1E,3R,4R,6R,7Z,9Z,11E)-3,6,13-trihydroxy-3-methyl-1-[(2S)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] dihydrogen phosphate Chemical compound OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)(O)=O)[C@@](O)(C)\C=C\[C@@H]1CC=CC(=O)O1 ZMQRJWIYMXZORG-GZIFKOAOSA-N 0.000 description 1
- ZZWKZQDOSJAGGF-BVTJJHQYSA-N [(1S,2Z,7S,10Z,12R,13R,15S)-12-hydroxy-7-methyl-9-oxo-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-15-yl] 2-(dimethylamino)acetate Chemical compound O[C@@H]1\C=C/C(=O)O[C@@H](C)CCC\C=C/[C@@H]2C[C@H](OC(=O)CN(C)C)C[C@H]21 ZZWKZQDOSJAGGF-BVTJJHQYSA-N 0.000 description 1
- SPKNARKFCOPTSY-XWPZMVOTSA-N [(2R,3S)-2-[(2S,3R)-3-methyloxiran-2-yl]-6-oxo-2,3-dihydropyran-3-yl] acetate Chemical compound C[C@H]1O[C@@H]1[C@H]1[C@@H](OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-XWPZMVOTSA-N 0.000 description 1
- YJTVZHOYBAOUTO-URBBEOKESA-N [(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl octadecyl hydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(=O)OCCCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 YJTVZHOYBAOUTO-URBBEOKESA-N 0.000 description 1
- VUPBDWQPEOWRQP-YDYCAPBPSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1R)-3-[[5-[[1-[[2-[4-[4-[[4-amino-6-[3-(4-aminobutylamino)propylamino]-6-oxohexyl]carbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]-1-[(2S,3R,4R,5S,6S)-5-amino-3,4-dihydroxy-6-methyloxan-2-yl]oxy-2-hydroxyethyl]amino Chemical compound O([C@H]1[C@@H]([C@H](O)[C@H](N)[C@H](C)O1)O)C(C(O)C=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCC(N)CC(=O)NCCCNCCCCN)NC(=O)C(C(O)C)NC(=O)CC(O)C(C)NC(=O)C([C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C VUPBDWQPEOWRQP-YDYCAPBPSA-N 0.000 description 1
- ZHHIHQFAUZZMTG-BSVJBJGJSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1R,2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[[(2R,3S,4S)-3-hydroxy-5-[[(2S,3R)-3-hydroxy-1-oxo-1-[2-[4-[4-[3-[[(1S)-1-phenylethyl] Chemical compound OS(O)(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C ZHHIHQFAUZZMTG-BSVJBJGJSA-N 0.000 description 1
- IVCRCPJOLWECJU-WJTCVZFGSA-N [(7R,8R,9S,13S,14S,17S)-7,13-dimethyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1C[C@]2(C)[C@@H](OC(C)=O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CCC3[C@H]21 IVCRCPJOLWECJU-WJTCVZFGSA-N 0.000 description 1
- PQNNIEWMPIULRS-SUTYWZMXSA-N [(8E,10E,12E)-7-hydroxy-6-methyl-2-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)tetradeca-8,10,12-trien-5-yl] dihydrogen phosphate Chemical compound C\C=C\C=C\C=C\C(O)C(C)C(OP(O)(O)=O)CCC(C)C1OC(=O)C=CC1C PQNNIEWMPIULRS-SUTYWZMXSA-N 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8R,9S,13S,14S,17S)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- XASGSSXPZXRXFL-UHFFFAOYSA-L [1-(aminomethyl)cyclohexyl]methanamine;platinum(2+);sulfate Chemical compound [Pt+2].[O-]S([O-])(=O)=O.NCC1(CN)CCCCC1 XASGSSXPZXRXFL-UHFFFAOYSA-L 0.000 description 1
- JJULHOZRTCDZOH-JGJFOBQESA-N [1-[[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-3-octadecylsulfanylpropan-2-yl] hexadecanoate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(CSCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 JJULHOZRTCDZOH-JGJFOBQESA-N 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N [3-[4-(3-methylsulfonyloxypropanoyl)piperazin-1-yl]-3-oxopropyl] methanesulfonate Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- ASQRQYODAQUVBR-UHFFFAOYSA-L [4-(aminomethyl)oxan-4-yl]methanamine;cyclobutane-1,1-dicarboxylate;platinum(2+) Chemical compound [Pt+2].NCC1(CN)CCOCC1.[O-]C(=O)C1(C([O-])=O)CCC1 ASQRQYODAQUVBR-UHFFFAOYSA-L 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N [4-[2-[4-(2-methylpropoxycarbonyloxymethyl)-3,5-dioxopiperazin-1-yl]ethyl]-2,6-dioxopiperazin-1-yl]methyl 2-methylpropyl carbonate Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- JURAJLFHWXNPHG-UHFFFAOYSA-N [acetyl(methylcarbamoyl)amino] N-methylcarbamate Chemical compound CNC(=O)ON(C(C)=O)C(=O)NC JURAJLFHWXNPHG-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- DEXPIBGCLCPUHE-UISHROKMSA-N acetic acid;(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound CC(O)=O.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 DEXPIBGCLCPUHE-UISHROKMSA-N 0.000 description 1
- IAGMBSXKAGFBJT-UHFFFAOYSA-N acetic acid;1,4-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione Chemical compound CC(O)=O.O=C1C2=CC=CC=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO IAGMBSXKAGFBJT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N aminolevulinic acid Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 229960003942 amphotericin B Drugs 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229940121369 angiogenesis inhibitors Drugs 0.000 description 1
- 230000002491 angiogenic Effects 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 108010070670 antarelix Proteins 0.000 description 1
- 230000002280 anti-androgenic Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001833 anti-estrogenic Effects 0.000 description 1
- 230000002622 anti-tumorigenesis Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 102000025417 antigen binding proteins Human genes 0.000 description 1
- 108091000829 antigen binding proteins Proteins 0.000 description 1
- 229940045696 antineoplastic drugs Podophyllotoxin derivatives Drugs 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229950011088 asulacrine Drugs 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 108010093161 axinastatin 1 Proteins 0.000 description 1
- 108010093000 axinastatin 2 Proteins 0.000 description 1
- 108010092978 axinastatin 3 Proteins 0.000 description 1
- OPWOOOGFNULJAQ-UHFFFAOYSA-L azane;cyclopentanamine;2-hydroxybutanedioate;platinum(2+) Chemical compound N.[Pt+2].NC1CCCC1.[O-]C(=O)C(O)CC([O-])=O OPWOOOGFNULJAQ-UHFFFAOYSA-L 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- OVMSOCFBDVBLFW-VHLOTGQHSA-N baccatin III derivatives Chemical class [H][C@]12[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](O)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C OVMSOCFBDVBLFW-VHLOTGQHSA-N 0.000 description 1
- VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl N-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000003460 beta-lactamyl group Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N bondronat Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 201000008873 bone osteosarcoma Diseases 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004649 calcipotriene Drugs 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- LSUTUUOITDQYNO-UHFFFAOYSA-N calphostin C Chemical compound C=12C3=C4C(CC(C)OC(=O)C=5C=CC=CC=5)=C(OC)C(O)=C(C(C=C5OC)=O)C4=C5C=1C(OC)=CC(=O)C2=C(O)C(OC)=C3CC(C)OC(=O)OC1=CC=C(O)C=C1 LSUTUUOITDQYNO-UHFFFAOYSA-N 0.000 description 1
- 229930016259 castanospermine Natural products 0.000 description 1
- 101710025091 cbbGC Proteins 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 201000008522 childhood cerebral astrocytoma Diseases 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 201000009047 chordoma Diseases 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 150000004814 combretastatins Chemical class 0.000 description 1
- 108010006226 cryptophycin Proteins 0.000 description 1
- 108010090203 cryptophycin 8 Proteins 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 108010041566 cypemycin Proteins 0.000 description 1
- 229950006614 cytarabine ocfosfate Drugs 0.000 description 1
- 230000001461 cytolytic Effects 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 229960005408 deslorelin Drugs 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 229950001640 dexormaplatin Drugs 0.000 description 1
- SGTNSNPWRIOYBX-HHHXNRCGSA-N dexverapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCC[C@@](C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-HHHXNRCGSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- GNVRJGIVDSQCOP-UHFFFAOYSA-O diethyl(methyl)azanium Chemical compound CC[NH+](C)CC GNVRJGIVDSQCOP-UHFFFAOYSA-O 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-O diethylazanium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-O dimethylaminium Chemical compound C[NH2+]C ROSDSFDQCJNGOL-UHFFFAOYSA-O 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- SVJSWELRJWVPQD-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C1NC=2NC(N)=NC(=O)C=2CC1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 SVJSWELRJWVPQD-UHFFFAOYSA-L 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229940017743 dromostanolone propionate Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- 210000002257 embryonic structures Anatomy 0.000 description 1
- 230000002357 endometrial Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 201000008228 ependymoblastoma Diseases 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229960004750 estramustine phosphate Drugs 0.000 description 1
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- HWMJAPURZLIYQA-JPFZJSEDSA-L ethanolate;(Z)-3-oxo-1-phenylbut-1-en-1-olate;titanium(4+) Chemical compound [Ti+4].CC[O-].CC[O-].CC(=O)\C=C(/[O-])C1=CC=CC=C1.CC(=O)\C=C(/[O-])C1=CC=CC=C1 HWMJAPURZLIYQA-JPFZJSEDSA-L 0.000 description 1
- XPGDODOEEWLHOI-GSDHBNRESA-N ethyl (2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-fluorophenyl)propanoyl]amino]-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)OCC)NC(=O)[C@@H](N)CC=1C=CC(F)=CC=1)C1=CC=CC(N(CCCl)CCCl)=C1 XPGDODOEEWLHOI-GSDHBNRESA-N 0.000 description 1
- YLOCAUYZANGQJG-UHFFFAOYSA-N ethyl 2-[[3,5-bis(phenylmethoxy)pyridine-2-carbonyl]amino]acetate Chemical compound C1=C(OCC=2C=CC=CC=2)C(C(=O)NCC(=O)OCC)=NC=C1OCC1=CC=CC=C1 YLOCAUYZANGQJG-UHFFFAOYSA-N 0.000 description 1
- HZQPPNNARUQMJA-IMIWJGOWSA-N ethyl N-[4-[[(2R,4R)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methylsulfanyl]phenyl]carbamate;hydrochloride Chemical compound Cl.C1=CC(NC(=O)OCC)=CC=C1SC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 HZQPPNNARUQMJA-IMIWJGOWSA-N 0.000 description 1
- SPDZFJLQFWSJGA-UHFFFAOYSA-N ethyl N-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
- QTFKTBRIGWJQQL-UHFFFAOYSA-N ethyl N-bis(2,2-dimethylaziridin-1-yl)phosphorylcarbamate Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 1
- DAZXVJBJRMWXJP-UHFFFAOYSA-O ethyl(dimethyl)azanium Chemical compound CC[NH+](C)C DAZXVJBJRMWXJP-UHFFFAOYSA-O 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-O ethylaminium Chemical compound CC[NH3+] QUSNBJAOOMFDIB-UHFFFAOYSA-O 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 229960003794 ganirelix Drugs 0.000 description 1
- 101710025070 gapdh-2 Proteins 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000002406 gelatinase inhibitor Substances 0.000 description 1
- OKKDEIYWILRZIA-OSZBKLCCSA-N gemcitabine hydrochloride Chemical compound [H+].[Cl-].O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 OKKDEIYWILRZIA-OSZBKLCCSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 108010075381 growth inhibitory factor Proteins 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- SOCGJDYHNGLZEC-UHFFFAOYSA-N hydron;N-methyl-N-[4-[(7-methyl-3H-imidazo[4,5-f]quinolin-9-yl)amino]phenyl]acetamide;chloride Chemical compound Cl.C1=CC(N(C(C)=O)C)=CC=C1NC1=CC(C)=NC2=CC=C(NC=N3)C3=C12 SOCGJDYHNGLZEC-UHFFFAOYSA-N 0.000 description 1
- COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- TZBDEVBNMSLVKT-UHFFFAOYSA-N idramantone Chemical compound C1C(C2)CC3CC1(O)CC2C3=O TZBDEVBNMSLVKT-UHFFFAOYSA-N 0.000 description 1
- 229960003696 ilomastat Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000003344 immunostimulant Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960004061 interferon alfa-n1 Drugs 0.000 description 1
- 108010006088 interferon alfa-n1 Proteins 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 229960003795 iobenguane (123I) Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 238000005184 irreversible process Methods 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- GQWYWHOHRVVHAP-DHKPLNAMSA-N jaspamide Chemical compound C1([C@@H]2NC(=O)[C@@H](CC=3C4=CC=CC=C4NC=3Br)N(C)C(=O)[C@H](C)NC(=O)[C@@H](C)C/C(C)=C/[C@H](C)C[C@@H](OC(=O)C2)C)=CC=C(O)C=C1 GQWYWHOHRVVHAP-DHKPLNAMSA-N 0.000 description 1
- 108010052440 jasplakinolide Proteins 0.000 description 1
- 108010091711 kahalalide F Proteins 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 229960001739 lanreotide acetate Drugs 0.000 description 1
- 101710017890 large T Proteins 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229950007056 liarozole Drugs 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 108010020270 lissoclinamide 7 Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- 230000000527 lymphocytic Effects 0.000 description 1
- 230000002101 lytic Effects 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitors Drugs 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- 201000008203 medulloepithelioma Diseases 0.000 description 1
- KPQJSSLKKBKWEW-RKDOVGOJSA-N methanesulfonic acid;5-nitro-2-[(2R)-1-[2-[[(2R)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.[O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 KPQJSSLKKBKWEW-RKDOVGOJSA-N 0.000 description 1
- DASQOOZCTWOQPA-GXKRWWSZSA-L methotrexate disodium Chemical compound [Na+].[Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 DASQOOZCTWOQPA-GXKRWWSZSA-L 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-O methylammonium Chemical compound [NH3+]C BAVYZALUXZFZLV-UHFFFAOYSA-O 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 229950009847 meturedepa Drugs 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- 230000002438 mitochondrial Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 108010026677 mitomalcin Proteins 0.000 description 1
- 229950010088 mitopodozide Drugs 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- VOWOEBADKMXUBU-UHFFFAOYSA-J molecular oxygen;tetrachlorite;hydrate Chemical compound O.O=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O VOWOEBADKMXUBU-UHFFFAOYSA-J 0.000 description 1
- 108010032806 molgramostim Proteins 0.000 description 1
- 229960003063 molgramostim Drugs 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 229940035032 monophosphoryl lipid A Drugs 0.000 description 1
- 230000001002 morphogenetic Effects 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 201000003793 myelodysplastic syndrome Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 108010032539 nartograstim Proteins 0.000 description 1
- 230000019261 negative regulation of glycolysis Effects 0.000 description 1
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- MAZYQGHSTXUZJF-ZBRHGPMOSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](O)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@]5(C)C[C@H](C[C@@H](O5)CC4=C3C3=O)N(C)C)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 MAZYQGHSTXUZJF-ZBRHGPMOSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000008042 ovarian germ cell cancer Diseases 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- 201000007052 paranasal sinus cancer Diseases 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 235000019369 penicillin G sodium Nutrition 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 229960003820 pentosan polysulfate sodium Drugs 0.000 description 1
- 229960001217 perflubron Drugs 0.000 description 1
- 229930007643 perillyl alcohol Natural products 0.000 description 1
- 235000005693 perillyl alcohol Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 201000008006 pharynx cancer Diseases 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-M phenylacetate Chemical compound [O-]C(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-M 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- FXSKHQLAUMGYJK-UHFFFAOYSA-J platinum(4+);propan-2-amine;dichloride;dihydroxide Chemical compound [OH-].[OH-].[Cl-].[Cl-].[Pt+4].CC(C)N.CC(C)N FXSKHQLAUMGYJK-UHFFFAOYSA-J 0.000 description 1
- 201000008199 pleuropulmonary blastoma Diseases 0.000 description 1
- 108010049948 plitidepsin Proteins 0.000 description 1
- 239000003600 podophyllotoxin derivative Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- DERJYEZSLHIUKF-UHFFFAOYSA-N procarbazine hydrochloride Chemical compound Cl.CNNCC1=CC=C(C(=O)NC(C)C)C=C1 DERJYEZSLHIUKF-UHFFFAOYSA-N 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- UQOQENZZLBSFKO-POPPZSFYSA-N prostaglandin J2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O UQOQENZZLBSFKO-POPPZSFYSA-N 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 description 1
- 239000000784 purine nucleoside phosphorylase inhibitor Substances 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229950001588 ramosetron Drugs 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229940100552 retinamide Drugs 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 101710004466 rgy Proteins 0.000 description 1
- 101710030364 rgy1 Proteins 0.000 description 1
- 101710030359 rgy2 Proteins 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 229920002033 ribozyme Polymers 0.000 description 1
- 229950003733 romurtide Drugs 0.000 description 1
- 229960003522 roquinimex Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- 229940006198 sodium phenylacetate Drugs 0.000 description 1
- HZOREEUASZHZBI-UHFFFAOYSA-M sodium;2-phenylacetate Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1 HZOREEUASZHZBI-UHFFFAOYSA-M 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- PZOHOALJQOFNTB-UHFFFAOYSA-M sodium;6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylate Chemical compound [Na+].N1=C2C=CC(F)=CC2=C(C([O-])=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PZOHOALJQOFNTB-UHFFFAOYSA-M 0.000 description 1
- XBUIKNRVGYFSHL-IAVQPKKASA-M sodium;[(1E,3R,4R,6R,7Z,9Z,11E)-3,6,13-trihydroxy-3-methyl-1-[(2R)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] hydrogen phosphate Chemical compound [Na+].OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)([O-])=O)[C@@](O)(C)\C=C\[C@H]1CC=CC(=O)O1 XBUIKNRVGYFSHL-IAVQPKKASA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 108010032486 splenopentin Proteins 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000024642 stem cell division Effects 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 108091007018 stromelysin Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229930003522 swainsonine Natural products 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 108010021891 tallimustine Proteins 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- ZCTJIMXXSXQXRI-KYJUHHDHSA-N thalicarpine Chemical compound CN1CCC2=CC(OC)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(OC2=C(C[C@H]3C4=CC(OC)=C(OC)C=C4CCN3C)C=C(C(=C2)OC)OC)=C1 ZCTJIMXXSXQXRI-KYJUHHDHSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 108010062880 thiocoraline Proteins 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- 201000009365 thymic carcinoma Diseases 0.000 description 1
- 108010013515 thymopoietin receptor Proteins 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- FQYFLFUZRJOLBC-UHFFFAOYSA-N titanocene Chemical compound C12C3C4C5C1[Ti]16782345C2C7C6C1C82 FQYFLFUZRJOLBC-UHFFFAOYSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-M triacetate(1-) Chemical compound CC(=O)CC(=O)CC([O-])=O ILJSQTXMGCGYMG-UHFFFAOYSA-M 0.000 description 1
- HOGVTUZUJGHKPL-HTVVRFAVSA-N triciribine Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOGVTUZUJGHKPL-HTVVRFAVSA-N 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-O trimethylammonium Chemical compound C[NH+](C)C GETQZCLCWQTVFV-UHFFFAOYSA-O 0.000 description 1
- 229960000538 trimetrexate glucuronate Drugs 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-O tris(2-hydroxyethyl)azanium Chemical compound OCC[NH+](CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-O 0.000 description 1
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- 101710042243 trpE(G) Proteins 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229950006929 uredepa Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- KDQAABAKXDWYSZ-JKDPCDLQSA-N vincaleukoblastine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 KDQAABAKXDWYSZ-JKDPCDLQSA-N 0.000 description 1
- COFJBSXICYYSKG-FJFFLIEUSA-N vindesine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 COFJBSXICYYSKG-FJFFLIEUSA-N 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- CILBMBUYJCWATM-IJDPFCGHSA-N vinorelbine L-tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-IJDPFCGHSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Abstract
Disclosed herein is {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino} acetic acid and it's compositions, that can stabilize hypoxia inducible factor-2 alpha (HIF-2a) and thereby provide a method for treating cancer. Further disclosed are compositions which comprise {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino} acetic acid and/or a prodrug thereof which can be used to treat cancer. roxypyridine-2-carbonyl]-amino} acetic acid and/or a prodrug thereof which can be used to treat cancer.
Description
COMPOUNDS AND COMPOSITIONS FOR STABILIZING HYPOXIA
INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR TREATING CANCER
PRIORITY
This application claims the benefit of Provisional Application Serial number
61/493,534, filed on June 6, 2011, the entirety of which is incorporated herein by reference.
FIELD
Disclosed herein is {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]-amino}
acetic acid and the ester and amide prodrugs thereof, that can stabilize hypoxia inducible
factor-2 alpha (HIF-2a) and thereby provide a method for treating cancer. Further
disclosed are compositions which comprise {[5-(3-fluorophenyl)hydroxypyridine
carbonyl]-amino} acetic acid and/or a prodrug thereof which can be used to treat cancer.
BACKGROUND
Nobel Prize winner Dr. Judah Folkman first proposed in 1971 that all cancer tumors
were angiogenesis-dependent and therefore targeting angiogenesis was a potential means
for treating cancer. Angiogenesis is the growth of new capillaries from pre-existent
microvasculature. A wide range of pathological conditions, from atherosclerosis to cancer,
are associated with either excessive or deficient angiogenesis.
It is now widely accepted that tumor growth beyond a few cubic millimeters cannot
occur without the induction of a new vascular supply. Therefore, inhibition of new
vasculature (antiangiognesis) can provide a non-chemotherapy or non-radiation therapy
approach to the treatment of cancer by denying tumors the nutrient supply necessary for the
tumors to grow. Although normally quiescent, endothelial cells are responsible for the
formation of new vasculature in response to various stimuli. These stimuli can have their
genesis in many forms.
The endothelial cells which form new vascular networks in tumors respond to
angiogenic stimuli produced by the tumor itself. The best known of these stimuli is
vascular endothelial growth factor (VEGF). Found to be ubiquitous in human tumors,
increasing levels of VEGF correlate with an increasing rate of tumor growth. Therefore,
suppression of VEGF represents a method for controlling the growth rate of tumors
(primary and metastatic) and offers a possible means for shrinking existing tumors.
Therefore, there is a long felt need for compounds, compositions, and methods for
suppressing VEGF expression by tumor cells. It is an object of the present invention to go
some way towards meeting this need, and/or to at least provide the public with a useful
choice.
In one aspect, the present invention provides a use of a compound of the structure:
or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for
treating cancer, wherein the cancer is selected from the group consisting of malignant
melanoma, breast cancer and ovarian cancer.
In a further aspect, the present invention provides a composition comprising:
A) a compound of the structure:
;
or a pharmaceutically acceptable salt thereof; and
B) Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF).
The present invention also provides the composition of the invention for treating
cancer.
In another aspect, the present invention provides a use of:
A) a compound of the structure:
or a pharmaceutically acceptable salt thereof; and
B) Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF),
in the manufacture of a medicament for treating cancer.
In another aspect, the present invention provides a use of a compound of the
structure:
or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for
increasing soluble vascular endothelial growth factor receptor-1 (sVEGF-1) secreted from a
cell.
In another aspect, the present invention provides a use of a compound of the
structure:
or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for
downregulating phosphoglycerate kinase (PGK) in a cell.
In another aspect, the present invention provides a use of a compound of the
structure:
or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for
downregulating phosphoglycerate kinase (PGK) in a cell and increasing soluble vascular
endothelial growth factor receptor-1 (sVEGF-1) secreted from a cell.
In the description in this specification reference may be made to subject matter
which is not within the scope of the appended claims. That subject matter should be readily
identifiable by a person skilled in the art and may assist in putting into practice the
invention as defined in the appended claims.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1A depicts the reduction in mRNA expression of VEGF in wild type murine
embryonic fibroblasts under normoxia (21% O ) vs. cells under hypoxic conditions (1% O )
at various concentrations of HIF-2a stabilizer, {[5-(3-fluorophenyl)hydroxypyridine
carbonyl]-amino} acetic acid. The disclosed HIF-2a stabilizer was tested at 1, 10 and 100
mM concentrations vs. control. The data indicate the relative amounts of VEGF mRNA and
are as follows from left to right normoxia control (solid black), HIF2-a stabilizer normoxia,
hypoxia control and HIF2-a stabilizer hypoxia. The amount of VEGF mRNA present is
dramatically reduced at all concentrations of HIF-2a stabilizer under hypoxic conditions
(far right data for each concentration).
Figure 1B depicts the reduction in mRNA expression of VEGF in murine
embryonic fibroblasts having deletion of HIF1-a, i.e., HIF-1a fibroblasts under normoxia
(21% O ) vs. cells under hypoxic conditions (1% O ) at various concentrations of HIF-2a
stabilizer, {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]-amino} acetic acid. The
disclosed HIF-2a stabilizer was tested at 1, 10 and 100 mM concentrations vs. control. The
data indicate the relative amount of VEGF mRNA and are as follows from left to right
normoxia control (solid black), HIF2-a stabilizer normoxia, hypoxia control and HIF2-a
stabilizer hypoxia. The amount of VEGF mRNA present is dramatically reduced at all
concentrations of HIF-2a stabilizer under hypoxic conditions even in mice having deletion
of HIF1-a (far right data for each concentration).
Figure 2A depicts the reduction in mRNA expression of phosphoglycerate kinase
(PGK) in wild type murine embryonic fibroblasts under normoxia (21% O ) vs. cells under
hypoxic conditions (1% O ) at various concentrations of HIF-2a stabilizer, {[5-(3-
fluorophenyl)hydroxypyridinecarbonyl]-amino} acetic acid. The disclosed HIF-2a
stabilizer was tested at 1, 10 and 100 mM concentrations vs. control. The data indicate the
relative amounts of PGK present and are as follows from left to right normoxia control
(solid black), HIF2-a stabilizer normoxia, hypoxia control and HIF2-a stabilizer hypoxia.
The amount of phosphoglycerate kinase (PGK) mRNA present is dramatically reduced at
all concentrations of HIF-2a stabilizer under hypoxic conditions.
Figure 2B depicts the reduction in mRNA expression of phosphoglycerate kinase
(PGK) in murine embryonic fibroblasts having deletion of HIF1-a, i.e., HIF-1a
fibroblasts under normoxia (21% O ) vs. cells under hypoxic conditions (1% O ) at various
concentrations of HIF-2a stabilizer, {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]-
amino} acetic acid. The disclosed HIF-2a stabilizer was tested at 1, 10 and 100 mM
concentrations vs. control. The data indicate the relative amounts of PGK present and are
as follows from left to right normoxia control (solid black), HIF2-a stabilizer normoxia,
hypoxia control and HIF2-a stabilizer hypoxia (Bar D, lightest gray). The amount of
phosphoglycerate kinase (PGK) mRNA present is dramatically reduced at all concentrations
of HIF-2a stabilizer under hypoxic conditions even in mice having deletion of HIF1-a (far
right data for each concentration).
Figure 3 depicts the reduction in tumor growth in C57BL/6 mice bearing B16F10
melanoma tumors as compared to treatment with granulocyte-macrophage colony-
stimulating factor (GM-CSF). Figure 3 indicates that the disclosed HIF-2a stabilizer
reduces tumor growth alone ( ) comparable to GM-CSF alone ( ■) and the inhibition of
tumor growth is additive when the disclosed HIF-2a stabilizer is used in combination with
GM-CSF (X) vs. phosphate buffered saline (PBS) (control) ( ♦).
Figure 4 depicts a comparison of GM-CSF delivery via intraperitoneal (I.P.) vs.
intratumor (I.T.) in evaluating the effectiveness of delivery mode in reducing tumor volume.
The disclosed HIF-2a stabilizer was delivered I.P. in all cases. The data depicted by ( )
represents the disclosed HIF-2a stabilizer in combination with GM-CSF, both delivered
I.P., data depicted by ( ♦) represents GM-CSF plus vehicle, both delivered I.P., data depicted
by ( ■) represents GM-CSF delivered I.T. plus vehicle delivered I.P., and data depicted by
(x) represent the disclosed HIF-2a stabilizer delivered I.P. in combination with GM-CSF
delivered I.T.
Figure 5 depicts the amount of relative metastasis to the lung as determined using
Pmel17 mRNA expression for the methods of injection depicted in Figure 3 wherein the
disclosed HIF-2a stabilizer was administered IP and the GM-CSF was administered IT.
Group A is the vehicle control for both the disclosed HIF-2a stabilizer and GM-CSF.
Group B represents GM-CSF plus 20% PEG in 5% dextran (vehicle for administration of
the disclosed HIF-2a stabilizer). Group C represents the disclosed HIF-2a stabilizer plus
PBS (vehicle for administration of GM-CSF). Group D represents the disclosed HIF-2a
stabilizer and GM-CSF. The disclosed HIF-2a stabilizer was delivered in its vehicle (20%
PEG in 5% dextran) and administered I.P. and GM-CSF was delivered in its vehicle (PBS)
and administered I.T. Note that only the groups with the disclosed HIF-2a stabilizer
showed reduced metastasis as measured by Pmel 17 mRNA expression.
Figure 6 depicts the reduction in tumor volume for C57BL/6 mice orthotopically
injected with cells from MMTV-PyMT transgenic mice into a single mammary gland.
Animals are treated three times a week with vehicle ( ♦), 12 mg/kg of the disclosed HIF-2a
stabilizer ( ■), or 17.5 g/kg of the disclosed HIF-2a stabilizer ( ●).
Figure 7 depicts the number of surviving animals during the course of a study
wherein mice are inoculated with approximately 10 A2780/CP tumor cells as disclosed
herein. The line indicated by ( ) represent the control group, the line indicated by ( )
represents the group that received 18 mg/kg of the disclosed HIF-2a stabilizer and the line
indicated by ( ) represents the group that received 36 mg/kg of the disclosed HIF-2a
stabilizer.
Figure 8 depicts the change in tumor mass of A2780/CP treated mice over the
course of the disclosed study. The control group is represented by ( ), the group
receiving18 mg/kg of disclosed HIF-2a stabilizer is represented by ( ) and the group
receiving 36 mg/kg of disclosed HIF-2a stabilizer is represented by ( ).
Figure 9 depicts the change in percent body mass of A2780/CP treated mice over
the course of the disclosed study. The control group is represented by ( ), the group
receiving18 mg/kg of disclosed HIF-2a stabilizer is represented by ( ) and the group
receiving 36 mg/kg of disclosed HIF-2a stabilizer is represented by ( ).
Figure 10 depicts the induction of s-VEGFR-1 in human peripheral blood
monocytes at 10 mM versus control (vehicle).
Figure 11A - an increase in HIF-2 α protein in cells treated with disclosed HIF-2a
stabilizer (p = 0.001), with no corresponding increase in HIF-1 α (p = 0.105).
Figure 11B - sVEGFR-1 production by GM-CSF-treated monocytes increased
significantly when monocytes were also treated with disclosed HIF-2a stabilizer, at both the
protein and the transcript level (p = 0.007 and p = 0.033, respectively).
Figure 11C - evaluation of VEGF transcript levels by real-time PCR revealed that
while GM-CSF increased VEGF production, there was no difference in VEGF production
between monocytes stimulated with GM-CSF alone or with GM-CSF and disclosed HIF-2a
stabilizer, at either the protein or the transcript level (p = 0.133 and 0.556, respectively).
Figure 11D - there was no difference in sVEGFR-1 production from monocytes
stimulated with GM-CSF alone or monocytes co-stimulated with disclosed HIF-2a
stabilizer, at either the protein or transcript level (p = 0.306 and p = 0.566, respectively).
Figure 11E - disclosed HIF-2a stabilizer increased monocyte production of VEGF
protein and mRNA (p = 0.011 and p = 0.007, respectively).
Figure 11F - disclosed HIF-2a stabilizer induced sVEGFR-1 transcription from
control macrophages (p = 0.036), but not from HIF-2 α-deficient macrophages (p = 0.881).
Figure 12A - combined treatment with GM-CSF and disclosed HIF-2a stabilizer
disclosed HIF-2a stabilizer further decreased tumor growth compared to either treatment
alone (p < 0.001).
Figure 12B - a 3-day increase in median survival (which was defined as the time to
a tumor diameter of 20 mm ) in mice treated with disclosed HIF-2a stabilizer (p = 0.023).
Figure 13A - Increased levels of sVEGFR-1 were detected within the tumors of
mice treated with both GM-CSF and disclosed HIF-2a stabilizer (p = 0.031).
Figure 13B - GM-CSF (alone or in combination with disclosed HIF-2a stabilizer
failed to increase levels of intratumoral VEGF over the levels observed in vehicle
control-treated mice (p = 0.490).
Figure 13C - combination treatment with GM-CSF and disclosed HIF-2a stabilizer
significantly reduced tumor vascularity in melanoma-bearing mice, possibly through the
induction of sVEGFR-1 (p < 0.001).
Figure 13D – depicts the significantly reduced levels of the melanoma-specific gene
Pmel17 that were detected within the lungs of mice treated with GM-CSF and the disclosed HIF-2 α
stabilizer, as compared to vehicle control-treated mice.
Figure 14A - disclosed HIF-2a stabilizer decreased tumor growth in mice treated
with an isotype control antibody (p < 0.001), but had no effect on tumor growth in mice also
treated with the anti-sVEGFR-1 neutralizing antibody (p = 0.245).
Figure 14B - disclosed HIF-2a stabilizer decreased tumor vascularity in the mice
treated with the control antibody (p = 0.022) but not in the mice treated with the sVEGFR-1
neutralizing Ab.
Figure 15 - disclosed HIF-2a stabilizer inhibited tumor growth in LysMcre control
mice (which contain LysM-driven cre recombinase but no floxed alleles).
DETAILED DESCRIPTION
The materials, compounds, compositions, articles, and methods described herein
may be understood more readily by reference to the following detailed description of
specific aspects of the disclosed subject matter and the Examples included therein.
Before the present materials, compounds, compositions, articles, devices, and methods are
disclosed and described, it is to be understood that the aspects described below are not
limited to specific synthetic methods or specific reagents, as such may, of course, vary. It is
also to be understood that the terminology used herein is for the purpose of describing
particular aspects only and is not intended to be limiting.
Also, throughout this specification, various publications are referenced. The
disclosures of these publications in their entireties are hereby incorporated by reference into
this application in order to more fully describe the state of the art to which the disclosed
matter pertains. The references disclosed are also individually and specifically incorporated
by reference herein for the material contained in them that is discussed in the sentence in
which the reference is relied upon.
General Definitions
In this specification and in the claims that follow, reference will be made to a
number of terms, which shall be defined to have the following meanings:
All percentages, ratios and proportions herein are by weight, unless otherwise specified. All
temperatures are in degrees Celsius ( C) unless otherwise specified.
By "pharmaceutically acceptable" is meant a material that is not biologically or
otherwise undesirable, i.e., the material can be administered to an individual along with the
relevant active compound without causing clinically unacceptable biological effects or
interacting in a deleterious manner with any of the other components of the pharmaceutical
composition in which it is contained.
A weight percent of a component, unless specifically stated to the contrary, is based
on the total weight of the formulation or composition in which the component is included.
By “effective amount” as used herein means “an amount of one or more of the
disclosed compounds, effective at dosages and for periods of time necessary to achieve the
desired or therapeutic result.” An effective amount may vary according to factors known in
the art, such as the disease state, age, sex, and weight of the human or animal being treated.
Although particular dosage regimes may be described in examples herein, a person skilled
in the art would appreciate that the dosage regime may be altered to provide optimum
therapeutic response. For example, several divided doses may be administered daily or the
dose may be proportionally reduced as indicated by the exigencies of the therapeutic
situation. In addition, the compositions of this disclosure can be administered as frequently
as necessary to achieve a therapeutic amount.
“Admixture” or “blend” is generally used herein means a physical combination of
two or more different components
“Excipient” is used herein to include any other compound that may be contained in
or combined with one or more of the disclosed inhibitors that is not a therapeutically or
biologically active compound. As such, an excipient should be pharmaceutically or
biologically acceptable or relevant (for example, an excipient should generally be non-toxic
to the subject). “Excipient” includes a single such compound and is also intended to include
a plurality of excipients.
As used herein, by a “subject” is meant an individual. Thus, the “subject” can
include domesticated animals (e.g., cats, dogs, etc.), livestock (e.g., cattle, horses, pigs,
sheep, goats, etc.), laboratory animals (e.g., mouse, rabbit, rat, guinea pig, etc.), and birds.
“Subject” can also include a mammal, such as a primate or a human.
By “reduce” or other forms of the word, such as “reducing” or “reduction,” is meant
lowering of an event or characteristic (e.g., vascular leakage). It is understood that this is
typically in relation to some standard or expected value, in other words it is relative, but that
it is not always necessary for the standard or relative value to be referred to.
The term “treat” or other forms of the word such as “treated” or "treatment" is used
herein to mean that administration of a compound of the present invention mitigates a
disease or a disorder in a host and/or reduces, inhibits, or eliminates a particular
characteristic or event associated with a disorder (e.g., vascular leakage). Thus, the term
"treatment" includes, preventing a disorder from occurring in a host, particularly when the
host is predisposed to acquiring the disease, but has not yet been diagnosed with the disease;
inhibiting the disorder; and/or alleviating or reversing the disorder. Insofar as the methods
described herein are directed to preventing disorders, it is understood that the term
"prevent" does not require that the disease state be completely thwarted. Rather, as used
herein, the term preventing refers to the ability of the skilled artisan to identify a population
that is susceptible to disorders, such that administration of the compounds of the present
invention may occur prior to onset of a disease. The term does not imply that the disease
state be completely avoided.
Throughout the description and claims of this specification the word “comprise” and
other forms of the word, such as “comprising” and “comprises,” means including but not
limited to, and is not intended to exclude, for example, other additives, components,
integers, or steps.
As used in the description and the appended claims, the singular forms “a,” “an,”
and “the” include plural referents unless the context clearly dictates otherwise. Thus, for
example, reference to “a composition” includes mixtures of two or more such compositions,
reference to “a chemotherapeutic agent” includes mixtures of two or more such
chemotherapeutic agents, reference to “the compound” includes mixtures of two or more
such compounds, for example, salts thereof, and the like.
“Optional” or “optionally” means that the subsequently described event or
circumstance can or cannot occur, and that the description includes instances where the
event or circumstance occurs and instances where it does not.
Ranges can be expressed herein as from “about” one particular value, and/or to
“about” another particular value. When such a range is expressed, another aspect includes
from the one particular value and/or to the other particular value. Similarly, when values
are expressed as approximations, by use of the antecedent “about,” it will be understood that
the particular value forms another aspect. It will be further understood that the endpoints of
each of the ranges are significant both in relation to the other endpoint, and independently
of the other endpoint. It is also understood that there are a number of values disclosed
herein, and that each value is also herein disclosed as “about” that particular value in
addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is
also disclosed. It is also understood that when a value is disclosed, then “less than or equal
to” the value, “greater than or equal to the value,” and possible ranges between values are
also disclosed, as appropriately understood by the skilled artisan. For example, if the value
“10” is disclosed, then “less than or equal to 10” as well as “greater than or equal to 10” is
also disclosed. It is also understood that throughout the application data are provided in a
number of different formats and that this data represent endpoints and starting points and
ranges for any combination of the data points. For example, if a particular data point “10”
and a particular data point “15” are disclosed, it is understood that greater than, greater than
or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed
as well as between 10 and 15. It is also understood that each unit between two particular
units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are
also disclosed.
“VEGF-dependent cancer,” “VEGF dependent cancers,” VEGF-dependent tumor”
or “VEGF dependent tumors” refers to cancers that rely on VEGF to proliferate.
For the purposes of the present disclosure the term “C -C linear, C -C branched or
1 4 3 4
C -C cyclic alkyl” includes the following units methyl (C ), ethyl (C ), n-propyl (C ), iso-
3 4 1 2 3
propyl (C ), cyclopropyl (C ), n-butyl (C ), sec-butyl (C ), iso-butyl (C ), tert-butyl (C ) and
3 3 4 4 4 4
cyclobutyl (C ).
Disclosed herein are compounds having the formula:
N H O
wherein R is chosen from:
i) –OR ;
ii) –NR R ; or
iii) –OM ;
R is:
i) hydrogen; or
ii) C -C linear, C -C branched or C -C cyclic alkyl;
1 6 3 6 3 6
R and R are independently:
i) hydrogen;
ii) C -C linear, C -C branched or C -C cyclic alkyl; or
1 6 3 6 3 6
iii) R and R can be taken together to form a ring having from 2 to 7 carbon
atoms and from 1 to 3 heteroatoms chosen from nitrogen, oxygen and sulfur including the
nitrogen atom to which R and R are bonded.
M represents a cation as further described herein below.
R is chosen from:
i) –OH; or
ii) –OM ;
wherein M is a cation as further described herein below.
The disclosed compound {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]-
amino} acetic acid having the formula:
has been found to stabilize hypoxia inducible factor two-alpha (HIF-2a) and, as further
disclosed herein, exhibits anti-angiogenic behavior by inducing production of the
endogenous Vascular Endothelial Growth Factor inhibitor, s-VEGF-1.
Also disclosed are pharmaceutically acceptable salts of the disclosed stabilizer
having the formula:
1 2 + 2+
wherein M and M are each independently a mono-, di-, or tri-valent cation, i.e., M , M ,
or M .
One aspect of the disclosed salts relates to the stabilizer in the form of the mono-
valent salt having the formula:
One embodiment of this aspect relates to the disclosed stabilizer wherein M is an
inorganic cation. One iteration of relates to inorganic cations chosen from sodium, lithium,
potassium, ammonium, and silver. Non-limiting examples include:
i) sodium {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]-amino} acetate;
ii) potassium {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]-amino} acetate; and
iii) ammonium {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]-amino} acetate.
Another embodiment of this aspect relates to the disclosed stabilizer wherein M is
an organic cation. One embodiment of relates to organic cations that are amines, for
example, salts having the formula:
a b c
R , R and R are each independently:
i) hydrogen;
ii) substituted or unsubstituted C -C linear, C -C branched, or C -C cyclic
1 12 3 12 3 12
alkyl;
iii) substituted or unsubstituted benzyl;
a b c
wherein one or more of R , R and R can be independently substituted by one or more units
chosen from:
i) C -C linear, C -C branched, or C -C cyclic alkoxy;
1 12 3 12 3 12
ii) C1-C12 linear, C3-C12 branched, or C3-C12 cyclic haloalkoxy;
iii) halogen;
iv) hydroxyl;
v) thio; or
a b c
vi) one or more of R , R and R can contain one or more units capable of
forming a cation, anion, or zwitterions.
a b c
One iteration of this embodiment relates to cations wherein each of R , R and R are
hydrogen or C -C linear alkyl. Non-limiting examples include methyl ammonium
1 12
+ + +
[HN H (CH )], dimethyl ammonium [HN H(CH ) ], trimethyl ammonium [HN (CH ) ],
2 3 3 2 3 3
ethyl ammonium [HN H (CH CH )], diethyl ammonium [HN H(CH CH ) ], triethyl
2 2 3 2 3 2
ammonium [HN (CH2CH3)3], dimethylethyl ammonium [HN (CH3)2(CH2CH3)], and
methyldiethyl ammonium [HN (CH )(CH CH ) ].
3 2 3 2
Another iteration of this embodiment relates to cations wherein one or more of R ,
R and R are chosen from hydrogen, unsubstituted C -C linear, C -C branched, or C -
1 12 3 12 3
C cyclic alkyl or substituted C -C linear, C -C branched, or C -C cyclic alkyl. One
12 1 12 3 12 3 12
embodiment relates to organic cations having one or more C -C linear, C -C branched,
1 12 3 12
or C -C cyclic alkyl chains substituted with hydroxy. Non-limiting examples include 2-
3 12
hydroxyethyl ammonium (cation of monoethanolamine, cholinate) [HN H (CH CH OH)],
2 2 2
methylhydroxyethyl ammonium [H N (CH )(CH CH OH)], di-(2-hydroxyethyl)
2 3 2 2
ammonium [H N (CH CH OH) ], tri-(2-hydroxyethyl) ammonium [HN (CH CH OH) ],
2 2 2 2 2 2 3
and tris-(hydroxymethyl)methyl ammonium (cation of tris-(hydroxymethyl)aminomethane)
[H N C[(CH OH)] ]. Also included are cations formed from amino sugars, for example,
3 2 3
amino sugars having the formula H N (CH )CH [(CHOH) CH OH] wherein n is from 1 to
2 3 2 n 2
7. A non-limiting example of an amino sugar suitable for forming an organic cation is
meglumine (1-deoxymethylamino-sorbitol).
A further iteration of this embodiment relates to cations formed from amino acids.
Non-limiting examples include lysine, ornithine, arginine, glutamine, and the like.
Another aspect of organic amines suitable for forming salts of the disclosed
a b c
stabilizer include amines wherein one or more of R , R and R are taken together to form a
heterocyclic ring that can comprise from 3 to 20 carbon atoms and one or more heteroatoms
chosen from nitrogen, oxygen and sulfur. Non-limiting examples include piperazine,
piperidine, morpholine, thiomorpholine, and the like.
Another organic amine suitable for use as a cation forming compound includes
benzathine. Benzathine can be a mono- or di-cation, for example, salts of N-benzyl
(benzylamino)ethanaminium having the formula:
N H O
OH O
or .
Another aspect of the disclosed salts relates to the stabilizer in the form of the di-
valent salt having the formula:
One embodiment of this aspect relates to the disclosed stabilizer wherein M is an
inorganic cation. One iteration of relates to inorganic cations chosen from calcium,
magnesium, barium, and the like. Non-limiting examples include:
i) calcium bis{[5-(3-fluorophenyl)hydroxypyridinecarbonyl]-amino} acetate;
ii) magnesium bis{[5-(3-fluorophenyl)hydroxypyridinecarbonyl]-amino} acetate;
iii) barium bis{[5-(3-fluorophenyl)hydroxypyridinecarbonyl]-amino} acetate.
Another aspect of the pharmaceutically acceptable salts relates to salts wherein R is
1 4 2
OM and R is OM , for example, salts having the formula:
A first embodiment relates to salts comprising a plurality of mono-valent inorganic
cations. For example:
i) disodium {[5-(3-fluorophenyl)oxidopyridinecarbonyl]-amino} acetate;
ii) dipotassium {[5-(3-fluorophenyl)oxidopyridinecarbonyl]-amino} acetate;
iii) diammonium {[5-(3-fluorophenyl)oxidopyridinecarbonyl]-amino} acetate;
iv) sodium potassium {[5-(3-fluorophenyl)oxidopyridinecarbonyl]-amino}
acetate;
v) sodium ammonium {[5-(3-fluorophenyl)oxidopyridinecarbonyl]-amino}
acetate; and
vi) potassium ammonium {[5-(3-fluorophenyl)oxidopyridinecarbonyl]-amino}
acetate.
In another embodiment, organic amines capable for forming di-cationic species, for
example, benzathine as disclosed herein can be used to form suitable pharmaceutically
acceptable salts of the disclosed stabilizer.
In addition, disclosed herein are prodrugs that are converted to the active compound
{[5-(3-fluorophenyl)hydroxypyridinecarbonyl]-amino} acetic acid in vivo. The
disclosed prodrugs have the formula:
N H O
OH O
wherein R is chosen from:
i) –OR ; or
ii) –NR R ;
R is C -C linear, C -C branched or C -C cyclic alkyl; and
1 6 3 6 3 6
R and R are independently:
i) hydrogen;
ii) C -C linear, C -C branched or C -C cyclic alkyl; or
1 6 3 6 3 6
iii) R and R can be taken together to form a ring having from 2 to 7 carbon
atoms and from 1 to 3 heteroatoms chosen from nitrogen, oxygen and sulfur including the
nitrogen atom to which R and R are bonded.
One aspect of the disclosed prodrugs relates to compounds that are esters, i.e., R is
C -C linear, C -C branched or C -C cyclic alkyl. In one embodiment, R is methyl (C )
1 6 3 6 3 6 1
thereby providing the prodrug methyl {[5-(3-fluorophenyl)hydroxypyridine
carbonyl]amino}acetate. In another embodiment, R is ethyl (C ) thereby providing the
prodrug ethyl {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]amino}acetate.
In a further embodiment, R is chosen from C -C linear, branched or cyclic alkyl,
for example, n-propyl (C ), iso-propyl (C ), cyclopropyl (C ), n-butyl (C ), sec-butyl (C ),
3 3 3 4 4
iso-butyl (C ), tert-butyl (C ) and cyclobutyl (C ).
4 4 4
Another aspect of the disclosed prodrugs relates to compounds that are amides, i.e.,
2 3 2 3
R is –NR R . In one embodiment of this aspect, R and R are both hydrogen wherein R is
–NH thereby affording the prodrug 5-(3-fluorophenyl)-N-(2-aminooxoethyl)
hydroxypyridinyl amide. In another embodiment, R is methyl (C ) and R is hydrogen
thereby affording the prodrug 5-(3-fluorophenyl)-N-(2-methylaminooxoethyl)
hydroxypyridinyl amide. A yet another embodiment, R and R are both methyl (C )
thereby affording the prodrug 5-(3-fluorophenyl)-N-(2-dimethylaminooxoethyl)
hydroxypyridinyl amide.
In a further embodiment of this aspect, R and R are each independently hydrogen,
ethyl, n-propyl (C ), iso-propyl (C ), cyclopropyl (C ), n-butyl (C ), sec-butyl (C ), iso-
3 3 3 4 4
butyl (C ), tert-butyl (C ) or cyclobutyl (C ). Non-limiting examples of prodrugs according
4 4 4
to this aspect include 5-(3-fluorophenyl)-N-(2-diethylaminooxoethyl)
hydroxypyridinyl amide; 5-(3-fluorophenyl)-N-(2-propylaminooxoethyl)
hydroxypyridinyl amide; 5-(3-fluorophenyl)-N-(N-ethyl-N-isopropylaminooxoethyl)-
3-hydroxypyridinyl amide; 5-(3-fluorophenyl)-N-(2-diisopropylaminooxoethyl)
hydroxypyridinyl amide; 5-(3-fluorophenyl)-N-(2-cyclopropylaminooxoethyl)
hydroxypyridinyl amide; and 5-(3-fluorophenyl)-N-(2-butylaminooxoethyl)
hydroxypyridinyl amide.
In a still further embodiment of this aspect, R and R can be taken together to form
a ring having from 2 to 7 carbon atoms and from 1 to 3 heteroatoms chosen from nitrogen,
oxygen and sulfur including the nitrogen atom to which R and R are bonded. In a first
iteration of this embodiment, R and R are taken together with the nitrogen atom to which
they are bonded to form a ring chosen from aziridinyl (C ), azetidinyl (C ), pyrrolidinyl (C )
2 3 4
and piperidinyl (C ).
In a further iteration of this embodiment, R and R are taken together with the
nitrogen atom to which they are bonded to form a ring comprising a second heteroatom
chosen from nitrogen, oxygen and sulfur. Non-limiting examples of these rings include
thiazolyl (C ), isothiazolyl (C ), oxazolyl (C ), isoxazolyl (C ), imidazolyl (C ),
3 3 3 3 3
morpholinyl (C ) and piperazinyl (C ).
The disclosed HIF-2a stabilizer, 6, and ester prodrugs, for example, compound 5,
can be prepared by the process outlined in Scheme I and further described in Example 1
herein below.
Scheme I
BnO HO
N O N O
OC H OC H
2 5 2 5
OBn O OH O
Reagents and conditions: (a) H : Pd/C, EtOH, rt, 16 hr.
SO CF
SO CF
Reagents and conditions: (b) (CF O S) O, Et N, CH Cl ;, rt, 16 hr.
3 2 2 3 2 2
Reagents and conditions: (c) Et N, Na CO , EtOH, rt, 16 hr.
3 2 3
F CO SO
OC H
ONa O
OC H
OH O
5
Reagents and conditions: (d) Pd(dppf)Cl , K PO ,H O, dioxane; 85 C, 16 hr.
2 3 4 2
Reagents and conditions: (e) (i) NaOH, THF; 30 min. (ii) HCl, THF, H O; 85 C, 16 hr.
EXAMPLE 1
{[5-(3-Fluorophenyl)hydroxypyridinecarbonyl]amino}acetic acid (6)
In the reactions described herein below, unless otherwise stated, temperatures are
given in degrees Celsius ( C); operations were carried out at room or ambient temperature,
“room temperature,” “rt,” or “RT” (typically a range of from about 18 C to about 25 C;
evaporation of solvent was carried out using a rotary evaporator under reduced pressure
(typically, 4.5-30 mm Hg) with a bath temperature of up to 60 C; the course of reactions
was typically followed by thin layer chromatography (TLC); products exhibited satisfactory
H NMR, HPLC, and/or LC-MS (GC-MS) data; and the following conventional
abbreviations are also used: L (liter(s)), mL (milliliters), mmol (millimoles), g (grams), and
mg (milligrams). Unless specified otherwise, all solvents and reagents were purchased from
suppliers and used without further purification. Reactions were conducted under a blanket
of nitrogen unless otherwise stated. Compounds were visualized under UV lamp (254 nm).
H NMR spectra were recorded on a 300 MHz NMR.
Preparation of [(3,5-dihydroxypyridinecarbonyl)-amino]-acetic acid ethyl ester
(2): To a 20 L round-bottomed flask was charged nitrogen and palladium on carbon (10%
Pd/C) (100 g, 60% wet paste) and ethanol (12 L), followed by the addition of [(3,5-bis-
benzyloxypyridinecarbonyl)-amino]-acetic acid ethyl ester, 1, (1000 g, 2.378 mol). The
resulting mixture was subjected to a vacuum-nitrogen purge cycle three times and a
vacuum-hydrogen purge cycle three times. A hydrogen atmosphere was introduced and the
reaction mixture was stirred at 1-25 C until the completion of the reaction by TLC analysis.
The reaction typically lasted 2 to 3 hours and a vigorous stirring was important to complete
the reaction. The reaction system was then subjected to a vacuum-nitrogen purge cycle to
remove hydrogen from the system. The reaction mixture was filtered and the filter-cake
was washed with ethanol (2 L). The combined filtrate was concentrated on a rotary
evaporator at up to 45 C bath temperature to a constant weight to provide 558 g (97.7%
yield) of the desired product as an off-white solid. MP: 138-140 C; MS(ESI+): m/z 241
(M+1); H NMR (300 MHz, DMSO-d ) d 12.28 (s, 1H), 10.79 (s, 1H), 9.09-9.05 (t, J = 6
Hz, 1H), 7.76-7.71 (d, J = 2.4 Hz, 1H), 6.68-6.67 (d, J = 2.1 Hz, 1H), 4.15-4.08 (q, J = 6.9
Hz, 2H), 4.02-4.00 (d, J = 6.3 Hz, 2H), 1.22-1.17 (t, J = 6.9 Hz, 2H).
Preparation of N-phenylbis(trifluoromethane-sulfinimide) (3): To a 10 L round-
bottomed flask was charged aniline (232.5 g, 2.5 mol), triethylamine (505 g, 5 mol) and
dichloromethane (5 L). The resulting mixture was cooled with an ice bath.
Trifluoromethanesulfonic anhydride (1410 g, 5 mol) in dichloromethane (1 L) was added
dropwise. The reaction mixture was allowed to warm to RT and stirred overnight. The
reaction was then added to crushed ice (4 kg) while stirring. The resulting biphasic mixture
was separated. The organic layer was washed with brine (2 L x 2), dried over Na SO ,
filtered and concentrated to form a crude solid product. The crude solid was washed with
ethanol to produce 767 g (86% yield) of the desired product as a white solid. MP: 96-98 C;
H NMR (300 MHz, CDCl3) d 7.64-7.51 (m, 3H), 7.44-7.42 (m, 2H).
Preparation of [(3-hydroxytrifluoromethanesulfonyloxypyridinecarbonyl)-
amino]-acetic acid ethyl ester sodium salt (4): To a 20 L round-bottomed flask was charged
[(3,5-dihydroxy-pyridinecarbonyl)-amino]-acetic acid ethyl ester, 2, (860 g, 3.58 mol)
and ethanol (11 L). The mixture was stirred to form a solution at 10 to 20 C.
Triethylamine (602 mL, 4.3 mol) was added. The resulting mixture was cooled to 0-5 C
and N-phenylbis(trifluoromethane-sulfinimide), 3, (1406 g, 3.94 mol) was added. After
addition, the reaction mixture was warmed to 35 to 40 C and stirred overnight. TLC
analysis indicated that the reaction was complete. The reaction mixture was then
concentrated by rotary evaporation at up to 40 C bath temperature. The residue (oily solid)
was treated with toluene (4.5 L) and concentrated to approximately 4.5 L. The toluene
solvent swap was repeated until residue ethanol level became less than 0.5% by H NMR
analysis. The toluene solution was treated with 10% w/w aqueous Na CO solution (5.5 L,
1.3 eq.). The resulting slurry was filtered and the filter cake was washed with water (2 x
2L) and then a mixture of toluene/TBME (1:2) (2 x 2 L). The solid product was dried to
afford 1156 g (82% yield) of the desired product as a white solid. MS(ESI+): m/z 373
(M+1); H NMR (300 MHz, DMSO-d ) d 12.13 (1 H, s), 7.43-7.42 (d, J = 2.1 Hz, 1H),
6.72-6.71 (d, J = 2.1 Hz, 2H), 4.12-4.05 (m, 4H), 1.21-1.15 (t, J = 6.9 Hz, 3).
Preparation of {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]amino}acetic
acid ethyl ester (5): To a 5 L round-bottomed flask was charged [(3-hydroxy
trifluoromethanesulfonyloxypyridinecarbonyl)-amino]-acetic acid ethyl ester sodium
salt, 4, (310 g, 0.78 mol), 1,4-dioxane (3 L) and water (150 mL). The solution was
subjected to a vaccum-nitrogen purge cycle, followed by the addition of potassium
phosphate (50 g, 0.234 mol) and 3-fluorophenylboronic acid (163 g, 1.17 mol). After
addition, the vacuum-nitrogen purge cycle was repeated once. 1,1-Bis(diphenyl-
phosphino)ferrocenepalladium (II) chloride CH Cl complex (72 g, 0.088 mol, 0.11 eq.)
was then added. After another vacuum-nitrogen purge cycle, the reaction mixture was then
heated to 75 to 85 C. The progress of the reaction was monitored by TLC. The reaction
was complete after 14-16 hours. The reaction was cooled to 15 to 25 C and concentrated
by rotary evaporation at up to 45 C bath temperature until solvent collection had ceased.
The residue was treated with an aquous solution of HCl (1M, 1.5 L) and ethyl acetate (1.5
L) and stirred for 30 minutes at room temperature. The layers were then separated. The
organic layer was washed with water (1.5 L), brine (1.5 L), dried over Na SO , filtered and
concentrated. The crude product was purified by silica gel column chromatography
(hexane/ethylacetate/acetic acid: 3:1:0.01 by vol/vol) to afford 226 g (90% yield) of the
desired product. MS(ESI+): m/z 319 (M+1); H NMR (300 MHz, CDCl ) d 11.88 (s, 1H),
8.44 (s, 1H), 8.32-.31 (d, J = 1.5 Hz, 1H), 7.51-7.44 (m, 2H), 7.40-7.37 (m, 1H), 7.32-7.27
(m, 1H), 7.17-7.13 (t, J = 6.6 Hz, 1H), 4.33-4.25 (m, 4H), 1.36-1.31 (t, J = 7.2 Hz, 3H).
Preparation of {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]amino}acetic
acid (6): To a slurry of {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]amino}acetic
acid ethyl ester, 5, (226 g, 0.71 mol) in THF (1 L) at room temperature was added an
aqueous solution of sodium hydroxide (1 M, 2 L) while maintaining the internal reaction
temperature below 25 C. The progress of the reaction was monitored by TLC. After 20-30
minutes, the reaction was completed. The pH of the reaction solution was adjusted using
concentrated HCl to 5-5.5 while maintaining the internal temperature below 25 C. The
reaction mixture was filtered to remove insoluble matter and the filtrate was concentrated
by rotary evaporation at up to 40 C bath temperature until all THF was removed. The
resulting solid was collected by vacuum filtration and washed with water (1 L). The solid
was then dissolved in a mixture of water (1.5 L) and THF (1.5 L) at room temperature. The
pH was adjusted from approximately 5 to approximately 2-2.25 with concentrated HCl.
The resulting mixture was stirred for 30 minutes, after which time the pH was confirmed in
the range of 2-2.5. The biphasic mixture was concentrated by rotary evaportation at up to
40 C bath temperature until the removal of THF ceased. The resulting solid was filtered,
washed with water (2 x 1 L), and dried to afford 115 g (55.8% yield) of the desired product
as a white solid. MP: 182-184 C; MS(ESI-): m/z 289 (M-1); H NMR (300 MHz, DMSO-
d ) d 12.90 (s, 1H), 12.38 (s, 1H), 9.39-9.37 (t, J = 6.3 Hz, 1H), 8.55 (s, 1H), 7.80-7.67 (m,
2H), 7.59-7.52 (m, 1H), 7.34-7.27 (m, 1H), 4.02-3.99 (m, 2H), 3.51 (s, 1H).
The amide prodrugs of the disclosed HIF-2a stabilizer can be prepared by the
process outlined in Scheme II and further described in Example 2 herein below.
Scheme II
Reagents and conditions: (a) CH NH HCl, EDCI, HOBt, DIPEA,DMF; 0 C to rt, 2 days
EXAMPLE 2
-(3-Fluorophenyl)-N-(2-methylaminooxoethyl)hydroxypyridinyl amide (7)
Preparation of 5-(3-fluorophenyl)-N-(2-methylaminooxoethyl)hydroxypyridin-
2-yl amide (7): To a solution of {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]-
amino}acetic acid, 6, (2.9 g, 10 mmol) in DMF (50 mL) at room temperature under N is
added 1-(3-dimethylamino-propyl)ethylcarbodiimide (EDCI) (2.33 g, 14.4 mmol), 1-
hydroxybenzotriazole (HOBt) (1.35 g, 10 mmol) and diisopropylethylamine (DIPEA)
(15.65 mL, 30 mmol). The reaction is stirred for 5 minutes then methylamine hydrochloride
(0.9 g, 130 mmol) is added. After stirring for 2 days, the solvent is removed under reduced
pressure and the residue partitioned between CH Cl and H O. The organic layer is
2 2 2
separated, washed with sat. NaCl, dried (Na SO ), filtered and concentrated under reduced
pressure. The crude product is purified over silica (MeOH:CH Cl 1:99) to afford the
desired compound.
The following describes a further process for preparing the disclosed HIF-2a
stabilizer and prodrugs thereof. In Scheme III the process for preparing an example of an
ester prodrug is outlined and described in Example 3.
Scheme III
Reagents and conditions: (a) K CO , PdCl (dppf), DMF, H O; 45 C, 18 hr.
2 3 2 2
Reagents and conditions: (b) NaOCH , CH OH; reflux, 20 hr.
9 10
Reagents and conditions: (c) 48% HBr; reflux, 20 hr.
11
Reagents and conditions: (d) CDI, DIPEA, DMSO; rt, 2.5 hr.
EXAMPLE 3
Methyl {[5-(3-fluorophenyl)hydroxypyridincarbonyl]amino}acetate (11)
Preparation of 5-(3-fluorophenyl)chlorocyanopyridine (8): To a 100 mL
round bottom flask that is adapted for magnetic stirring and equipped with a nitrogen inlet is
charged (3-fluorophenyl)boronic acid (4.48 g, 32 mmol), 3,5-dichlorocyanopyridine (5.8
g, 34 mmol), K CO (5.5 g, 40 mmol), [1,1’-bis(diphenylphosphino)ferrocene]dichloro-
palladium(II) [PdCl (dppf)] (0.1 g, 0.13 mmol), dimethylformamide (50 mL) and water
(5mL). The reaction solution is agitated and heated to 45 C and held at that temperature
for 18 hours after which the completeness of the reaction can be determined by the absence
of the starting material 3,5-dichlorocyanopyridine via TLC using ethyl acetate/methanol
(4:1) as the mobile phase and UV 435 nm to visualize any remaining starting material. The
reaction solution is then cooled to room temperature and the contents partitioned between
ethyl acetate (250 mL) and saturated aqueous NaCl (100 mL). The organic phase is isolated
and washed a second time with saturated aqueous NaCl (100 mL). The organic phase is
dried for 4 hours over MgSO , the MgSO is removed by filtration and the solvent is
removed under reduced pressure. The residue that remains is then slurried in methanol (50
mL) at room temperature for 20 hours. The resulting solid is collected by filtration and
washed with cold methanol (50 mL) then hexanes (60 mL) and dried to afford desired
product.
Preparation of 5-(3-fluorophenyl)methoxycyanopyridine (9): To a 500 mL
round bottom flask adapted for magnetic stirring and fitted with a reflux condenser and
nitrogen inlet is charged 5-(3-fluorophenyl)chlorocyanopyridine, 8, (9.28 g, 40
mmol), sodium methoxide (13.8 mL, 60 mmol) and methanol (200 mL). With stirring, the
reaction solution is heated to reflux for 20 hours. The reaction can be determined to be
complete due to the disappearance of 5-(3-fluorophenyl)chlorocyanopyridine as
measured by TLC analysis using hexane/ethyl acetate (6:3) as the mobile phase and UV 435
nm to visualize the reaction components. The reaction mixture is cooled to room
temperature and combined with water (500 mL). The mixture is cooled to 0 C to 5 C and
stirred for 3 hours. The resulting solid is collected by filtration and washed with water, then
hexane. The resulting cake is then dried in vacuo at 40 C to afford the desired product.
Preparation of 5-(3-fluorophenyl)hydroxypyridinecarboxylic acid (10): To a
50 mL round bottom flask adapted for magnetic stirring and fitted with a reflux condenser is
charged 5-(3-fluorophenyl)methoxycyanopyridine, 9, (0.912 g, 4 mmol) and a 48%
aqueous solution of HBr (10 mL). While being stirred, the reaction solution is heated to
reflux for 20 hours. The reaction can be determined to be complete due to the
disappearance of 5-(3-fluorophenyl)methoxycyanopyridine as measured by TLC
analysis using hexane/ethyl acetate (6:3) as the mobile phase and UV 435 nm to visualize
the reaction components. The reaction is then cooled to 0 C to 5 C with stirring and the
pH is adjusted to approximately 2 by the slow addition of 50% aqueous NaOH. Stirring is
then continued at 0 C to 5 C for 3 hours. The resulting solid is collected by filtration and
washed with water, then hexane. The resulting cake is dried in vacuo at 40 C to afford the
desired product.
Preparation of methyl {[5-(3-fluorophenyl)hydroxypyridincarbonyl]amino}-
acetate (11): To a 50 mL round bottom flask adapted for magnetic stirring and fitted with a
nitrogen inlet tube is charged 5-(3-fluorophenyl)hydroxypyridinecarboxylic acid, 10,
(0.932 gm, 4 mmol), N,N’-carbonyldiimidazole (CDI) (0.97 g, 6 mmol) and dimethyl
sulfoxide (5 mL). The reaction mixture is stirred at 45 C for about 1 hour then cooled to
room temperature. Glycine methyl ester hydrochloride (1.15 g, 12 mmol) is added followed
by the dropwise addition of diisopropylethylamine (3.2 mL, 19 mmol). The mixture is then
stirred for 2.5 hours at room temperature after which water (70 mL) is added. The contents
of the reaction flask is cooled to 0 C to 5 C and 1N HCl is added until the solution pH is
approximately 2. The solution is extracted with dichloromethane (100 mL) and the organic
layer dried over MgSO for 16 hours. Silica gel (3 g) is added and the solution slurried for
2 hours after which the solids are removed by filtration. The filtrate is concentrated to
dryness under reduced pressure and the resulting residue is slurried in methanol (10 mL) for
two hours. The resulting solid is collected by filtration and washed with cold methanol (20
mL) then hexane and the resulting cake is dried to afford the desired product.
Ester prodrug methyl {[5-(3-fluorophenyl)hydroxypyridinyl]amino}acetate,
11, can be converted to the disclosed HIF-2a stabilizer, {[5-(3-Fluorophenyl)
hydroxypyridinecarbonyl]amino}acetic acid, 6, by the procedure outlined in Scheme I
step (e) and described in Example 1.
Scheme IV herein below outlines and Example 4 describes a further non-limiting
example of a procedure for an amide prodrug of the disclosed HIF-2a stabilizer.
Scheme IV
10 12
Reagents and conditions: (a) EDCI, HOBt, DIPEA, DMF; rt.
EXAMPLE 4
-(3-Fluorophenyl)-N-(2-aminooxoethyl)hydroxylpyridinyl amide (12)
Preparation of 5-(3-fluorophenyl)-N-(2-aminooxoethyl)hydroxylpyridinyl
amide (6): To a solution of 5-(3-fluorophenyl)hydroxypyridinecarboxylic acid, 10,
(699 mg, 3 mmol) in DMF (20 mL) at room temperature under N is added 1-(3-dimethyl-
aminopropyl)ethylcarbodiimide (EDCI) (0.925 g, 5.97 mmol) and 1-hydroxybenzo-
triazole (HOBt) (0.806 g, 5.97 mmol). The resulting solution is stirred for 15 minutes then
2-aminoacetamide hydrochloride (0.66 g, 5.97 mmol) and diisopropylethylamine (1.56 ml,
8.96 mmol) are added. The reaction is monitored by TLC and when the reaction is
complete the reaction mixture is concentrated under reduced pressure and H O added. The
desired product can be isolated by normal work-up.
The present disclosure also includes pharmaceutically acceptable salts of the
disclosed stabilizer. The following is a non-limiting example of the preparation of a
pharmaceutically acceptable salt as depicted in Scheme V.
Scheme V
6 13
EXAMPLE 5
Sodium {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]amino}acetate (13)
To a vial containing NaHCO (41.09 mg) is added a solution of {[5-(3-fluoro-
phenyl)hydroxypyridinecarbonyl]-amino}acetic acid (6) in acetone (0.64 mL of a 400
mg sample in 5.12 mL). The solution is stirred and the desired product isolated by
concentration in vacuo.
METHODS
It is well known that cancer growth and metastasis is not exclusively controlled by
the aberrant regulation of metastasis promoting or suppressing genes in cancer cells. The
interaction between cancer cells and the stromal cells has been shown to promote cancer
growth and metastasis. The macrophages found within tumors, referred to as tumor-
associated macrophages (TAMs), are a pivotal member of stromal cells (See, Leek RD,
Harris AL, “Tumour associated macrophages in breast cancer,” J Mamm Gland Biol
Neoplasia 7: 177–189, 2002 and Lewis CE, Murdoch C., “Macrophage responses to
hypoxia: implications for tumor progression and anti-cancer therapies.” Am J Pathol 167:
627–635, 2005). TAMs are derived from peripheral blood monocytes recruited into the
tumor. Upon activation by cancer cells, the TAMs can release a diversity of factors inter
alia, growth factors, proteolytic enzymes, cytokines, and inflammatory mediators. Many of
these factors are key agents in promoting metastasis of cancer cells; in fact, extensive TAM
infiltration has been shown to correlate with cancer metastasis and poor prognosis in a
variety of human carcinomas. TAMs promote cancer metastasis through several
mechanisms including tumor angiogenesis, tumor growth, and tumor cell migration and
invasion. As such, control over the various factors released and/or stimulated by TAMs,
i.e., VEGF is an important method for reducing, stopping, or preventing tumor growth and
cancer cell metastasis.
Secretion of vascular endothelial growth factor (VEGF) by tumor-infiltrating
macrophages in response to the hypoxic tumor microenvironment is well known to induce
blood vessel formation (angiogenesis), which leads to increased tumor growth and
metastasis. It has been previously demonstrated that, in addition to producing VEGF,
mononuclear phagocytes stimulated with granulocyte-macrophage colony-stimulating factor
(GM-CSF) under hypoxic conditions also secrete high levels of a soluble form of the VEGF
receptor (sVEGFR-1), which neutralizes VEGF and inhibits biological activity (Eubank TD,
et al., “GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes
and inhibits angiogenesis in mice,” Immunity, 2004; 21(6): 8331-842). In addition, it was
found that hypoxia-inducible factor-1 alpha (HIF-1a) controls macrophage production of
VEGF, while hypoxia-inducible factor-2 alpha (HIF-2a) controls macrophage production of
sVEGFR-1, thereby demonstrating opposing roles for the HIFs in the regulation of
angiogenesis. Moreover, HIF-1a exhibits pro-angiogenic behavior via its effects on VEGF
and HIF-2a exhibits anti-angiogenic behavior by inducing production of the endogenous
VEGF inhibitor, sVEGFR-1 (Eubank TD, et al., “Opposing roles for HIF-1{alpha} and
HIF-2{alpha} in the regulation of angiogenesis by mononuclear phagocytes,” Blood, 2011;
117(1):323-332). Therefore, there are specific and independent roles for HIF-1a and HIF-
2a in the regulation of angiogenesis and tumor growth.
The hypoxia inducible factors HIF-1a and HIF-2a are constitutively transcribed;
however, both are rapidly degraded by a process that begins with hydroxylation of key HIF
proline amino acids. There are three known isoforms of the prolyl hydroxylase domain
(PHD) proteins (i.e., 4-prolyl hydroxylase enzymes) each of which acts to degrade different
HIF’s. For example, PHD2 hydroxylates HIF-1a whereas PHD3 hydroxylates HIF-2a.
Because stabilization of HIF-1a increases VEGF, inhibition of PHD2 increases
angiogenesis. In contrast, stabilization of HIF-2a decreases VEGF via macrophage
production of sVEGFR-1 and inhibition of PHD3 suppresses angiogenesis and provides a
method for treating cancer. (Prolyl hydroxylation generates a binding site for a ubiquitin
ligase complex containing the von Hippel-Lindau (VHL) tumor suppressor protein, which
results in HIF α destruction. In addition, the HIF α transcriptional activation function is
modulated further by asparagine hydroxylation by FIH (factor-inhibiting HIF), which
affects recruitment of the coactivators p300 and CBP. As such, hydroxylation of HIF by
PHD begins an irreversible process that depletes cellular levels of HIF.)
Disclosed herein are methods for affecting tumor growth by stabilizing HIF-2a.
Without wishing to be limited by theory, {[5-(3-fluorophenyl)hydroxypyridine
carbonyl]-amino}acetic acid stabilizes HIF-2a by inhibiting PHD3, thereby allowing
greater quantities of the VEGF suppressor sVEGFR-1 to be secreted by macrophages and
(and possibly other cells in the tumor inclusive of cancer cells and other stromal cells) .
In addition to the known regulation of sVEGFR-1, the HIF-2a stabilizer, {[5-(3-
fluorophenyl)hydroxypyridinecarbonyl]-amino} acetic acid, unexpectedly
downregulated VEGF in hypoxic embryonic fibroblasts (see Figure 1). This effect was
retained in embryonic fibroblasts lacking HIF-1a.
Disclosed herein are methods for affecting tumor growth by stabilizing HIF-2a.
Without wishing to be limited by theory, {[5-(3-fluorophenyl)hydroxypyridine
carbonyl]-amino} acetic acid stabilizes HIF-2a by inhibiting PHD3, thereby unexpectedly
suppressing VEGF production in tumor cells (inclusive of cancer cells and stromal cells).
In recent years, the Warburg hypothesis has re-gained attention due to discoveries
linking impaired mitochondrial function as well as impaired respiration to the growth,
division and expansion of tumor cells. The body often kills damaged cells by apoptosis, a
mechanism of self-destruction that involves mitochondria, but this mechanism may fail in
cancer cells where the mitochondria are shut down. The reactivation of mitochondria in
cancer cells could restart their apoptosis program. In addition to being simply a response to
impaired respiration, ramping up glycolysis in tumor cells could also provide the carbon-
containing building blocks required for cell replication.
In addition to downregulating VEGF the HIF-2a stabilizer {[5-(3-fluorophenyl)
hydroxypyridinecarbonyl]-amino} acetic acid unexpectedly down-regulated PGK a key
glycolytic enzyme in hypoxic embryonic fibroblasts (see Figure 2). This effect was retained
in embryonic fibroblasts lacking HIF-1a.
Disclosed herein are methods for affecting tumor growth by stabilizing HIF-2a.
Without wishing to be limited by theory, {[5-(3-fluorophenyl)hydroxypyridine
carbonyl]-amino} acetic acid stabilizes HIF-2a by inhibiting PHD3, thereby unexpectedly
suppressing PGK production in tumor cells.
The disclosed HIF-2a stabilizer and prodrugs thereof can be used to prevent, abate,
minimize, control, and/or lessen tumor growth and/or tumor metastasis in humans and
animals. The disclosed HIF-2a stabilizer and prodrugs thereof can also be used to slow the
rate of primary tumor growth. The disclosed HIF-2a stabilizer and prodrugs thereof when
administered to a subject in need of treatment can be used to stop the spread of cancer cells.
As such, the HIF-2a stabilizer and prodrugs thereof disclosed herein can be administered as
part of a combination therapy with one or more drugs or other pharmaceutical agents.
When used as part of the combination therapy, the decrease in metastasis and reduction in
primary tumor growth afforded by the disclosed HIF-2a stabilizer and prodrugs thereof
allows for a more effective and efficient use of any pharmaceutical or drug therapy being
used to treat the patient. In addition, control of metastasis by the disclosed HIF-2a
stabilizer and prodrugs thereof affords the subject a greater ability to limit the disease in one
location.
The disclosed compound, {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]-
amino}acetic acid, salts thereof, and ester and amide prodrug have anti-tumorigenic
properties in that the compounds:
1. Cause cells under hypoxic conditions to have a significant reduction in the
amount of Vascular Endothelial Growth Factor (VEGF) that is present, thereby removing
one factor that stimulates angiogenesis in the tumor microenvironment, and hence, reduces
the ability of tumor cells to use angiogenesis as a means of providing nutrients for growth.
This fact is evidenced in Figures 1A and 1B;
2. Causes cells under hypoxic conditions to display a significant reduction in
the amount of phosphoglycerate kinase present in the cell, wherein tumor cells have been
shown not to use oxidative phosphorylation as a source of energy, but instead glycolysis.
This therefore removes or reduces the tumor cell’s ability to produce energy for growth.
This fact is evidenced in Figures 2A and 2B; and
3. Causes the stimulation of s-VEGFR1 (soluble VEGF) which is a competing
receptor for VEGF and hence reduces the amount of VEGF that can stimulate angiogenesis.
This fact is evidenced in Figure 10.
As such, the disclosed compounds provide a three-pronged attack against tumor
cells; overcoming PGK, and thus obviating a primary source of energy, reducing VEGF and
thus providing for a reduced capacity of tumor cells to gain nutrients and blood supply via
angiogenesis, and by increasing s-VEGF which further reduces the ability of tumors to
induce angiogenesis.
Disclosed herein are methods for preventing metastasis of malignant tumors or other
cancerous cells as well as to reduce the rate of tumor growth. The methods comprise
administering an effective amount of one or more of the disclosed compounds to a subject
diagnosed with a malignant tumor or cancerous cells or to a subject having a tumor or
cancerous cells. For example, a method for treating a subject diagnosed with a malignant
tumor or cancerous cells, comprising administering to the subject an effective amount of
{[5-(3-fluorophenyl)hydroxypyridinecarbonyl]amino}acetic acid. In another
example, a method for treating a subject having a malignant tumor or cancerous cells,
comprising administering to the subject an effective amount of {[5-(3-fluorophenyl)
hydroxypyridinecarbonyl]amino}acetic acid.
Disclosed herein is a method for stabilizing hypoxia inducible factor-2 alpha (HIF-
2a), comprising administering to a subject an effective amount of the disclosed HIF-2a
stabilizer and/or prodrugs thereof. For example, a method for stabilizing hypoxia inducible
factor-2 alpha (HIF-2a), comprising administering to a subject an effective amount of {[5-
(3-fluorophenyl)hydroxypyridinecarbonyl]amino}acetic acid.
Further disclosed herein is a method for treating cancer, comprising administering to
a subject an effective amount of the disclosed HIF-2a stabilizer and/or prodrugs thereof.
For example, a method for treating cancer, comprising administering to a subject an
effective amount of {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]amino}acetic acid.
Also disclosed herein is a method for decreasing tumor angiogenesis in a subject
having cancer, comprising administering to a subject an effective amount of the disclosed
HIF-2a stabilizer and/or prodrugs thereof. For example, a method for decreasing tumor
angiogenesis in a subject having cancer, comprising administering to a subject an effective
amount of {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]amino}acetic acid.
Yet further disclosed herein is a method for decreasing tumor angiogenesis in a
subject diagnosed with cancer, comprising administering to a subject an effective amount of
the disclosed HIF-2a stabilizer and/or prodrugs thereof. For example, a method for
decreasing tumor angiogenesis in a subject diagnosed with cancer, comprising
administering to a subject an effective amount of {[5-(3-fluorophenyl)hydroxypyridine-
2-carbonyl]amino}acetic acid.
Still further disclosed herein is a method for decreasing vascular endothelial growth
factor (VEGF) in a cell in vitro, in vivo or ex vivo by inhibiting the binding of VEGF to
VEGFRs, comprising administering to the cell an effective amount of the disclosed HIF-2a
stabilizer and/or prodrugs thereof. In one embodiment, the cell is a cancer cell. In another
embodiment, the cell is a human cell. In as still further embodiment, the cell is a human
cancer cell. For example, a method for decreasing vascular endothelial growth factor
(VEGF) in a cell in vitro, in vivo or ex vivo, comprising administering to the cell an
effective amount of {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]amino}acetic acid.
Also further disclosed herein is a method for increasing secretion of soluble vascular
endothelial growth factor receptor-1 (sVEGF-1) from a cell in vitro, in vivo or ex vivo,
comprising administering to the cell an effective amount of the disclosed HIF-2a stabilizer
and/or prodrugs thereof. In one embodiment, the cell is a tumor associated cell. In another
embodiment, the cell is a human tumor associated cell. In as still further embodiment, the
cell is a human cancer cell. For example, a method for increasing secretion of soluble
vascular endothelial growth factor receptor-1 (sVEGF-1) from a cell in vitro, in vivo or ex
vivo, comprising administering to the cell an effective amount of {[5-(3-fluorophenyl)
hydroxypyridinecarbonyl]amino}acetic acid.
Still yet further disclosed is a method for controlling tumor growth in a subject,
comprising administering to the subject an effective amount of he disclosed HIF-2a
stabilizer and/or a prodrug thereof.
Disclosed herein is the use of the disclosed HIF-2a stabilizer and/or a prodrug
thereof for making a medicament for treating cancer. For example, the use of {[5-(3-
fluorophenyl)hydroxypyridinecarbonyl]amino}acetic acid for making a medicament
for treating cancer.
Further disclosed herein is the use of the disclosed HIF-2a stabilizer and/or
prodrugs thereof for making a medicament for preventing metastasis of malignant tumors or
other cancerous cells and for slowing tumor growth. For example, the use of {[5-(3-
fluorophenyl)hydroxypyridinecarbonyl]amino}acetic acid for making a medicament
for preventing metastasis of malignant tumors or other cancerous cells and for slowing
tumor growth.
Disclosed herein is the use of the disclosed HIF-2a stabilizer and/or a prodrug
thereof for treating cancer. For example, the use of {[5-(3-fluorophenyl)
hydroxypyridinecarbonyl]amino}acetic acid for treating cancer.
Further disclosed herein is the use of the disclosed HIF-2a stabilizer and/or a
prodrug thereof for preventing metastasis of malignant tumors or other cancerous cells and
for slowing tumor growth. For example, the use of {[5-(3-fluorophenyl)
hydroxypyridinecarbonyl]amino}acetic acid for preventing metastasis of malignant
tumors or other cancerous cells and for slowing tumor growth.
Further still disclosed herein is the use of the disclosed HIF-2a stabilizer and/or a
prodrug thereof for decreasing tumor angiogenesis. For example, the use of {[5-(3-
fluorophenyl)hydroxypyridinecarbonyl]amino}acetic acid for decreasing tumor
angiogenesis.
Further still disclosed herein is the use of the disclosed HIF-2a stabilizer and/or a
prodrug thereof for making a medicament for decreasing tumor angiogenesis. For example,
the use of {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]amino}acetic acid for
making a medicament for decreasing tumor angiogenesis.
Still yet further disclosed herein is a method for treating cancer, comprising
administering to a subject an effective amount of the disclosed HIF-2a stabilizer and/or
prodrugs thereof and an effective amount of one or more chemotherapeutic agents, wherein
the disclosed HIF-2a stabilizer and/or prodrugs thereof and the one or more
chemotherapeutic agents are administered in any order. For example, a method for treating
cancer, comprising administering to a subject an effective amount of {[5-(3-fluorophenyl)-
3-hydroxypyridinecarbonyl]amino}acetic acid and an effective amount of one or more
chemotherapeutic agents. Non-limiting examples of chemotherapeutic agents include taxol,
IL-2, gemcitabine, erlotinib, doxil, irinortecan, and bevacizumab.
Still also yet further disclosed herein is a method for preventing metastasis of cancer
cells, comprising administering to a subject having cancer an effective amount of the
disclosed HIF-2a stabilizer and/or prodrugs thereof and an effective amount of one or more
chemotherapeutic agents, wherein the disclosed HIF-2a stabilizer and/or prodrugs thereof
and the one or more chemotherapeutic agents are administered in any order. For example, a
method for preventing metastasis of cancer cells, comprising administering to a subject
having cancer an effective amount of {[5-(3-fluorophenyl)hydroxypyridine
carbonyl]amino}acetic acid and an effective amount of one or more chemotherapeutic
agents. Non-limiting examples of chemotherapeutic agents include taxol, IL-2,
gemcitabine, erlotinib, doxil, irinortecan, and bevacizumab.
Also still yet further disclosed herein is a method for treating a subject diagnosed
with cancer, comprising administering to a subject diagnosed with cancer an effective
amount of the disclosed HIF-2a stabilizer and/or prodrugs thereof and an effective amount
of one or more chemotherapeutic agents, wherein the disclosed HIF-2a stabilizer and/or
prodrugs thereof and the one or more chemotherapeutic agents are administered in any
order. For example, a method for treating a subject diagnosed with cancer, comprising
administering to a subject diagnosed with cancer an effective amount of {[5-(3-
fluorophenyl)hydroxypyridinecarbonyl]amino}acetic acid and an effective amount of
one or more chemotherapeutic agents. Non-limiting examples of chemotherapeutic agents
include taxol, IL-2, gemcitabine, erlotinib, doxil, irinortecan, and bevacizumab.
The following are non-limiting examples of cancers that can be treated by the disclosed
methods and compositions: Acute Lymphoblastic; Acute Myeloid Leukemia;
Adrenocortical Carcinoma; Adrenocortical Carcinoma, Childhood; Appendix Cancer; Basal
Cell Carcinoma; Bile Duct Cancer, Extrahepatic; Bladder Cancer; Bone Cancer;
Osteosarcoma and Malignant Fibrous Histiocytoma; Brain Stem Glioma, Childhood; Brain
Tumor, Adult; Brain Tumor, Brain Stem Glioma, Childhood; Brain Tumor, Central
Nervous System Atypical Teratoid/Rhabdoid Tumor, Childhood; Central Nervous System
Embryonal Tumors; Cerebellar Astrocytoma; Cerebral Astrocytoma/Malignant Glioma;
Craniopharyngioma; Ependymoblastoma; Ependymoma; Medulloblastoma;
Medulloepithelioma; Pineal Parenchymal Tumors of Intermediate Differentiation;
Supratentorial Primitive Neuroectodermal Tumors and Pineoblastoma; Visual Pathway and
Hypothalamic Glioma; Brain and Spinal Cord Tumors; Breast Cancer; Bronchial Tumors;
Burkitt Lymphoma; Carcinoid Tumor; Carcinoid Tumor, Gastrointestinal; Central Nervous
System Atypical Teratoid/Rhabdoid Tumor; Central Nervous System Embryonal Tumors;
Central Nervous System Lymphoma; Cerebellar Astrocytoma; Cerebral
Astrocytoma/Malignant Glioma, Childhood; Cervical Cancer; Chordoma, Childhood;
Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic
Myeloproliferative Disorders; Colon Cancer; Colorectal Cancer; Craniopharyngioma;
Cutaneous T-Cell Lymphoma; Esophageal Cancer; Ewing Family of Tumors; Extragonadal
Germ Cell Tumor; Extrahepatic Bile Duct Cancer; Eye Cancer, Intraocular Melanoma; Eye
Cancer, Retinoblastoma; Gallbladder Cancer; Gastric (Stomach) Cancer; Gastrointestinal
Carcinoid Tumor; Gastrointestinal Stromal Tumor (GIST); Germ Cell Tumor, Extracranial;
Germ Cell Tumor, Extragonadal; Germ Cell Tumor, Ovarian; Gestational Trophoblastic
Tumor; Glioma; Glioma, Childhood Brain Stem; Glioma, Childhood Cerebral Astrocytoma;
Glioma, Childhood Visual Pathway and Hypothalamic; Hairy Cell Leukemia; Head and
Neck Cancer; Hepatocellular (Liver) Cancer; Histiocytosis, Langerhans Cell; Hodgkin
Lymphoma; Hypopharyngeal Cancer; Hypothalamic and Visual Pathway Glioma;
Intraocular Melanoma; Islet Cell Tumors; Kidney (Renal Cell) Cancer; Langerhans Cell
Histiocytosis; Laryngeal Cancer; Leukemia, Acute Lymphoblastic; Leukemia, Acute
Myeloid; Leukemia, Chronic Lymphocytic; Leukemia, Chronic Myelogenous; Leukemia,
Hairy Cell; Lip and Oral Cavity Cancer; Liver Cancer; Lung Cancer, Non-Small Cell; Lung
Cancer, Small Cell; Lymphoma, AIDS-Related; Lymphoma, Burkitt; Lymphoma,
Cutaneous T-Cell; Lymphoma, Hodgkin; Lymphoma, Non-Hodgkin; Lymphoma, Primary
Central Nervous System; Macroglobulinemia, Waldenström; Malignant Fibrous
Histiocytoma of Bone and Osteosarcoma; Medulloblastoma; Melanoma; Melanoma,
Intraocular (Eye); Merkel Cell Carcinoma; Mesothelioma; Metastatic Squamous Neck
Cancer with Occult Primary; Mouth Cancer; Multiple Endocrine Neoplasia Syndrome,
(Childhood); Multiple Myeloma/Plasma Cell Neoplasm; Mycosis Fungoides;
Myelodysplastic Syndromes; Myelodysplastic/-Myeloproliferative Diseases; Myelogenous
Leukemia, Chronic; Myeloid Leukemia, Adult Acute; Myeloid Leukemia, Childhood
Acute; Myeloma, Multiple; Myeloproliferative Disorders, Chronic; Nasal Cavity and
Paranasal Sinus Cancer; Nasopharyngeal Cancer; Neuroblastoma; Non-Small Cell Lung
Cancer; Oral Cancer; Oral Cavity Cancer; Oropharyngeal Cancer; Osteosarcoma and
Malignant Fibrous Histiocytoma of Bone; Ovarian Cancer; Ovarian Epithelial Cancer;
Ovarian Germ Cell Tumor; Ovarian Low Malignant Potential Tumor; Pancreatic Cancer;
Pancreatic Cancer, Islet Cell Tumors; Papillomatosis; Parathyroid Cancer; Penile Cancer;
Pharyngeal Cancer; Pheochromocytoma; Pineal Parenchymal Tumors of Intermediate
Differentiation; Pineoblastoma and Supratentorial Primitive Neuroectodermal Tumors;
Pituitary Tumor; Plasma Cell Neoplasm/Multiple Myeloma; Pleuropulmonary Blastoma;
Primary Central Nervous System Lymphoma; Prostate Cancer; Rectal Cancer; Renal Cell
(Kidney) Cancer; Renal Pelvis and Ureter, Transitional Cell Cancer; Respiratory Tract
Carcinoma Involving the NUT Gene on Chromosome 15; Retinoblastoma;
Rhabdomyosarcoma; Salivary Gland Cancer; Sarcoma, Ewing Family of Tumors; Sarcoma,
Kaposi; Sarcoma, Soft Tissue; Sarcoma, Uterine; Sézary Syndrome; Skin Cancer
(Nonmelanoma); Skin Cancer (Melanoma); Skin Carcinoma, Merkel Cell; Small Cell Lung
Cancer; Small Intestine Cancer; Soft Tissue Sarcoma; Squamous Cell Carcinoma,
Squamous Neck Cancer with Occult Primary, Metastatic; Stomach (Gastric) Cancer;
Supratentorial Primitive Neuroectodermal Tumors; T-Cell Lymphoma, Cutaneous;
Testicular Cancer; Throat Cancer; Thymoma and Thymic Carcinoma; Thyroid Cancer;
Transitional Cell Cancer of the Renal Pelvis and Ureter; Trophoblastic Tumor, Gestational;
Urethral Cancer; Uterine Cancer, Endometrial; Uterine Sarcoma; Vaginal Cancer; Vulvar
Cancer; Waldenström Macroglobulinemia; and Wilms Tumor.
Also disclosed herein are methods for treating cancer, comprising administering to a
subject an effective amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof.
The cancer can be any cancer described herein, including VEGF-dependent cancers.
Because oxygen diffusion distance is approximately 150µm, cells that comprise a solid
tumor that grows beyond 2 mm cannot proliferate without access to nearby vasculature to
exchange oxygen and waste. In this instance, low oxygen stabilizes HIF-1 α in the tumor
cells and produces vascular endothelial growth factor (VEGF), which is a proliferating
factor for endothelial cells in which blood vessels are comprised. Because VEGF is the key
regulator of angiogenesis, the sequestration of VEGF by the soluble form of VEGF
receptor-1 (sVEGFR-1) regulates angiogenesis. The inhibition of prolyl hydroxylase 3
(PHD3) by one or more of the compounds disclosed herein stabilizes HIF-2 α. While tumor
cells themselves do not produce sVEGFR-1, the compounds disclosed herein can increase
the production of sVEGFR-1 from the monocytes and macrophages which arrive at the
tumors in response to inflammatory signals. Thus, any tumors that rely on VEGF to
proliferate are potential targets for the compounds disclosed herein because their activity
can, in part, increase sVEGFR-1 production.
COMPOSITIONS
Disclosed herein are compositions which can be used to treat cancer in a subject,
treat cancer in a subject diagnosed with cancer, to prevent tumor growth in a subject, to
prevent metastasis of cancer cells in a subject, the compositions comprising an effective
amount of one or more of the compounds disclosed herein. Further disclosed herein are
compositions that can be used to treat tumors in a human or other mammal.
One aspect relates to a composition comprising:
a) an effective amount of one or more the disclosed HIF-2a stabilizer and/or
prodrugs thereof; and
b) one or more pharmaceutically acceptable ingredients.
Another aspect relates a composition comprising:
a) an effective amount of one or more the disclosed HIF-2a stabilizer and/or
prodrugs thereof; and
b) an effective amount of one or more additional chemotherapeutic agent;
wherein the disclosed compounds and the one or more additional chemotherapeutic
agent can be administered together or in any order.
One embodiment relates to a composition comprising:
a) an effective amount of one or more the disclosed HIF-2a stabilizer and/or
prodrugs thereof; and
b) an effective amount of taxol;
wherein the disclosed compounds and taxol can be administered together or in any
order.
Another embodiment relates to a composition comprising:
a) an effective amount of one or more the disclosed HIF-2a stabilizer and/or
prodrugs thereof; and
b) an effective amount of gemcitabine;
wherein the disclosed compounds and gemcitabine can be administered together or
in any order.
A further embodiment relate to a composition comprising:
a) an effective amount of one or more the disclosed HIF-2a stabilizer and/or
prodrugs thereof; and
b) an effective amount of erlotinib;
wherein the disclosed compounds and erlotinib can be administered together or in
any order.
A yet further embodiment relate to a composition comprising:
a) an effective amount of one or more the disclosed HIF-2a stabilizer and/or
prodrugs thereof; and
b) an effective amount of doxil;
wherein the disclosed compounds and doxil can be administered together or in any
order.
A still further embodiment relate to a composition comprising:
a) an effective amount of one or more the disclosed HIF-2a stabilizer and/or
prodrugs thereof; and
b) an effective amount of irinortecan;
wherein the disclosed compounds and irinortecan can be administered together or in
any order.
A still yet further embodiment relate to a composition comprising:
a) an effective amount of one or more the disclosed HIF-2a stabilizer and/or
prodrugs thereof; and
b) an effective amount of bevacizumab;
wherein the disclosed compounds and bevacizumab can be administered together or
in any order.
A “chemotherapeutic agent” or “chemotherapeutic compound” is a chemical
compound useful in the treatment of cancer. Chemotherapeutic cancer agents that can be
used in combination with those disclosed herein include, but are not limited to, mitotic
inhibitors (vinca alkaloids). These include vincristine, vinblastine, vindesine and
Navelbine (vinorelbine-5'-noranhydroblastine). In yet other embodiments,
chemotherapeutic cancer agents include topoisomerase I inhibitors, such as camptothecin
compounds. As used herein, “camptothecin compounds” include Camptosar (irinotecan
HCL), Hycamtin (topotecan HCL) and other compounds derived from camptothecin and
its analogues. Another category of chemotherapeutic cancer agents that may be used in the
methods and compositions of the present disclosure are podophyllotoxin derivatives, such
as etoposide, teniposide and mitopodozide. The present disclosure further encompasses
other chemotherapeutic cancer agents known as alkylating agents, which alkylate the
genetic material in tumor cells. These include without limitation cisplatin,
cyclophosphamide, nitrogen mustard, trimethylene thiophosphoramide, carmustine,
busulfan, chlorambucil, belustine, uracil mustard, chlomaphazin, and dacarbazine. The
present disclosure encompasses antimetabolites as chemotherapeutic agents. Examples of
these types of agents include cytosine arabinoside, fluorouracil, methotrexate,
mercaptopurine, azathioprime, and procarbazine. An additional category of
chemotherapeutic cancer agents that may be used in the methods and compositions of the
present disclosure include antibiotics. Examples include without limitation doxorubicin,
bleomycin, dactinomycin, daunorubicin, mithramycin, mitomycin, mytomycin C, and
daunomycin. There are numerous liposomal formulations commercially available for these
compounds. The present disclosure further encompasses other chemotherapeutic cancer
agents including without limitation anti-tumor antibodies, dacarbazine, azacytidine,
amsacrine, melphalan, ifosfamide and mitoxantrone.
The disclosed compounds herein can be administered alone or in combination with
other anti-tumor agents, including cytotoxic/antineoplastic agents and anti-angiogenic
agents. Cytotoxic/anti-neoplastic agents are defined as agents which attack and kill cancer
cells. Some cytotoxic/anti-neoplastic agents are alkylating agents, which alkylate the
genetic material in tumor cells, e.g., cisplatin, cyclophosphamide, nitrogen mustard,
trimethylene thiophosphoramide, carmustine, busulfan, chlorambucil, belustine, uracil
mustard, chlomaphazin, and dacabazine. Other cytotoxic/anti-neoplastic agents are
antimetabolites for tumor cells, e.g., cytosine arabinoside, fluorouracil, methotrexate,
mercaptopuirine, azathioprime, and procarbazine. Other cytotoxic/anti-neoplastic agents
are antibiotics, e.g., doxorubicin, bleomycin, dactinomycin, daunorubicin, mithramycin,
mitomycin, mytomycin C, and daunomycin. There are numerous liposomal formulations
commercially available for these compounds. Still other cytotoxic/anti-neoplastic agents
are mitotic inhibitors (vinca alkaloids). These include vincristine, vinblastine and
etoposide. Miscellaneous cytotoxic/anti-neoplastic agents include taxol and its derivatives,
L-asparaginase, anti-tumor antibodies, dacarbazine, azacytidine, amsacrine, melphalan,
VM-26, ifosfamide, mitoxantrone, and vindesine.
Anti-angiogenic agents are well known to those of skill in the art. Suitable anti-
angiogenic agents for use in the methods and compositions of the present disclosure include
anti-VEGF antibodies, including humanized and chimeric antibodies, anti-VEGF aptamers
and antisense oligonucleotides. Other known inhibitors of angiogenesis include angiostatin,
endostatin, interferons, interleukin 1 (including α and β) interleukin 12, retinoic acid, and
tissue inhibitors of metalloproteinase-1 and -2. (TIMP-1 and -2). Small molecules, including
topoisomerases such as razoxane, a topoisomerase II inhibitor with anti-angiogenic activity,
can also be used.
Other anti-cancer agents that can be used in combination with the disclosed
compounds include, but are not limited to: acivicin; aclarubicin; acodazole hydrochloride;
acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate;
aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin;
azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene
hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium;
bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin;
carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin;
cisplatin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine;
dactinomycin; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine;
dezaguanine mesylate; diaziquone; docetaxel; doxorubicin; doxorubicin hydrochloride;
droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate;
eflornithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin
hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate
sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride;
fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine;
fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea;
idarubicin hydrochloride; ifosfamide; ilmofosine; interleukin II (including recombinant
interleukin II, or rIL2), interferon alfa-2a; interferon alfa-2b; interferon alfa-n1; interferon
alfa-n3; interferon beta-I a; interferon gamma-I b; iproplatin; irinotecan hydrochloride;
lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium;
lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine
hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril;
mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide;
mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane;
mitoxantrone hydrochloride; mycophenolic acid; nocodazole; nogalamycin; ormaplatin;
oxisuran; paclitaxel; pegaspargase; peliomycin; pentamustine; peplomycin sulfate;
perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin;
plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride;
puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol;
safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin;
spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin;
sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin;
teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin;
tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate;
trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa;
vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate;
vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate;
vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin
hydrochloride. Other anti-cancer drugs include, but are not limited to: 20-epi-1,25
dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol;
adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox;
amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole;
andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-
dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen;
antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene
modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase;
asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron;
azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists;
benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin
B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine;
bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine;
calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine;
carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage
derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B;
cetrorelix; chlorlns; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine;
clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4;
combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8;
cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin;
cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin
B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone;
didemnin B; didox; diethylnorspermine; dihydroazacytidine; dihydrotaxol, 9-;
dioxamycin; diphenyl spiromustine; docetaxel; docosanol; dolasetron; doxifluridine;
droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab;
eflornithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen
agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole;
fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone;
fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin;
fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase
inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene
bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine;
ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth
factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane;
iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B;
itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin;
lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte
alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole;
linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds;
lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin;
loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine;
mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix
metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase;
metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double
stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin
fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal
antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell
wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1-
based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract;
myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip;
naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin;
neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators;
nitroxide antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides;
onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin;
osaterone; oxaliplatin; oxaunomycin; paclitaxel; paclitaxel analogues; paclitaxel
derivatives; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene;
parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin;
pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate;
phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim;
placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum
compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone;
propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune
modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein
tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins;
pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists;
raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP
inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII
retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl;
safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine;
senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal
transduction modulators; single chain antigen binding protein; sizofiran; sobuzoxane;
sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein;
sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1;
squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin
inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista;
suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide;
tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors;
temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine;
thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor
agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine;
titanocene bichloride; topsentin; toremifene; totipotent stem cell factor; translation
inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron;
turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital
sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin
B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin;
vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin
stimalamer. In one embodiment, the anti-cancer drug is 5-fluorouracil, taxol, or leucovorin.
PROCEDURES
Otto Warburg (Warburg O. "On the origin of cancer cells," Science 123 (3191):
309–14 (1956)) first observed that most cancer cells produce energy by using anaerobic
glycolysis rather than the more energy efficient aerobic conditions of normal cells. Xu has
reported (Xu R-H et al., “Inhibition of Glycolysis in Cancer Cells: A Novel Strategy to
Overcome Drug Resistance Associated with Mitochondrial Respiratory Defect and
Hypoxia.” Cancer Res. 65:(2), 613-621 (2005)) that hypoxia is an important factor that
contributes to the “Warburg Effect” allowing cancer cells to grow and form tumor masses
that outpace the normal generation of new vasculature.
This rapid expansion of tumors leaves the cancerous cells in a microenvironment
with limited blood supply, and, thus, a limited ability to grow using aerobic conditions. In
order to maintain a sufficient energy source, tumor cells maintain hypoxic conditions in
their microenvironment and thereby use the resulting increased glycolytic activity as a
means for energy production, as well as a method for stimulating angiogenesis. Vander
Heiden (Van Heiden, M.G., et al., “Evidence for an Alternative Glycolytic Pathway in
Rapidly Proliferating Cells,” Science, 329, 1492-1499 (2010)) reported that proliferating
cells, which includes cancer cells, “primarily metabolize glucose by glycolysis, whereas
most normal cells completely catabolize glucose by oxidative phosphorylation.”
Phosphoglycerate kinase is a transferase enzyme that in one of the final steps of
glycolysis serves to a transfer a phosphate group to ADP thereby forming ATP which is the
ubiquitous source of metabolic energy. Without wishing to be limited by theory, decreasing
the concentration of the enzyme phosphoglycerate kinase in hypoxic cells would provide a
method of making the anaerobic glycolysis pathway unavailable to proliferating cells, i.e.,
cancer cells as an energy source. Further without wishing to be limited by theory, by
inhibiting or reducing the hypoxic environment found in tumor cells, the amount of vascular
endothelial growth factor (VEGF) which is produced in response to the hypoxic
microenvironment is reduced thereby having the effect of decreasing the formation of new
vasculature that would aid in cancer cell proliferation.
Without wishing to be limited by theory, anaplasia is a characteristic of cancer cells.
Because cancer cells remain in a highly energized metabolic microenvironment, i.e.,
hypoxic environment, cancer cells lack the ability to enter a more quiescent stage whereby
the cells can become mature, for example, to begin to differentiate in the manner of normal
cells. Moreover, suppressing PGK concentrations in the tumor mass microenvironment can
serve as a method of reducing or eliminating the conditions present in the cancer cell
induced hypoxic environment resulting in slowing or stopping tumor growth.
Soluble VEGF receptor-1 (sVEGFR1) is a truncated approximately 110-kDa splice
variant of the 180-kDa membrane-spanning VEGFR1. As reported by Wu (Wu F.T.H et
al., “A systems biology perspective on sVEGFR1: its biological function, pathogenic role &
therapeutic use,” J. Cell Mol Med. 2010 March 14(3): 528-552) the anti-angiogenic effects
have not been well-elucidated, but are believed to include: (1) sequestration of VEGF
ligands, much like VEGFR1 does, and effectively reducing VEGF-mediated activation of
pro-angiogenic receptors; and (2) heterodimerization with full-length VEGFR monomers to
render the receptor dimer inactive, since sVEGFR1 lacks the intracellular tyrosine kinase
domain needed to transphosphorylate its full-length partner. The precise molecular
mechanisms by which sVEGFR1 exerts inhibitory effects on VEGF-dependent signaling are
unclear. Nevertheless, two mechanisms have been proposed: (1) direct ligand trapping of
VEGF family members (including VEGF-A and PlGF), i.e., lowering the effective
concentrations of free VEGF available for receptor activation; and (2) heterodimerization
with surface VEGFRs to form dominant-negative complexes, i.e., lowering the effective
density of unoccupied VEGFR available for ligand activation.
Without being limited by theory, stabilization of HIF-2a by the disclosed stabilizer
results in an increased concentration of soluble vascular endothelial growth factor
(sVEGFR-1) which results in a reduced concentration of VEGF. Figure 1A depicts the
reduction in mRNA expression of VEGF in wild type murine embryonic fibroblasts under
normoxia (21% O ) [Bar A, black] and wild type murine embryonic fibroblasts under
hypoxic conditions (1% O ) [Bar C, light gray] at various concentrations of HIF-2a
stabilizer, {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]-amino} acetic acid. Under
hypoxic conditions, there is a dramatic reduction in VEGF mRNA at 1, 10 and 100 mM
concentrations [Bar D, lightest gray] vs. hypoxia control [Bar C].
Figure 1B depicts the reduction in mRNA expression of VEGF in fibroblasts having
deletion of HIF1-a, i.e., HIF-1a fibroblasts under normoxia (21% O ) [Bar A, black] and
fibroblasts having deletion of HIF1-a, i.e., HIF-1a fibroblasts under hypoxic conditions
(1% O ) [Bar C, light gray] at various concentrations of HIF-2a stabilizer, {[5-(3-
fluorophenyl)hydroxypyridinecarbonyl]-amino} acetic acid. Under hypoxic
conditions, there is a dramatic reduction in VEGF mRNA at 1, 10 and 100 mM
concentrations [Bar D, lightest gray] vs. hypoxia control [Bar C].
Figure 2A depicts the reduction in mRNA expression of phosphoglycerate kinase
PGK) in wild type murine embryonic fibroblasts under normoxia (21% O ) [Bar A, black]
and wild type murine embryonic fibroblasts under hypoxic conditions (1% O ) [Bar C, light
gray] at various concentrations of HIF-2a stabilizer, {[5-(3-fluorophenyl)
hydroxypyridinecarbonyl]-amino} acetic acid. Under hypoxic conditions, there is a
dramatic reduction in PGK mRNA at 1, 10 and 100 mM concentrations [Bar D, lightest
gray] vs. hypoxia control [Bar C].
Figure 2B depicts the reduction in mRNA expression of phosphoglycerate kinase
(PGK) in fibroblasts having deletion of HIF1-a, i.e., HIF-1a fibroblasts under normoxia
(21% O ) [Bar A, black] and fibroblasts having deletion of HIF1-a, i.e., HIF-1a
fibroblasts under hypoxic conditions (1% O ) [Bar C, light gray] at various concentrations
of HIF-2a stabilizer, {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]-amino} acetic
acid. Under hypoxic conditions, there is a dramatic reduction in PGK mRNA at 1, 10 and
100 mM concentrations [Bar D, lightest gray] vs. hypoxia control [Bar C].
The effectiveness of the disclosed HIF-2a stabilizer as a treatment for melanoma
was studied.
Quantitative PCR Analysis of Gene Expression
Total RNA was isolated from tissues and cells by using TRIzol Reagent
(Invitrogen) and the RNeasy kit (Qiagen), respectively. 1 mg RNA was used for reverse
transcription using SuperScript II First-Strand Synthersis System (Invitrogen). cDNA’s
were amplified in a SYR Green or TaqMan Universal Master Mix (Applied Biosystems).
Quantitative PCR (qPCR) was performed on ABI Prism 7700 sequence detection system.
PCR conditions are: 10 min at 95 C, 40 cycles of 15 seconds at 95 C and 1 minute at 60
C. The relative amount of mRNA was calculated after normalization to b-actin.
Cell Culture, Immortalization of Fibroblasts
Cells were cultured in DMEM (#11965-092, Invitrogen) supplemented with 10%
fetal bovine serum (Invitrogen), 100 U/mL penicillin and 100 mg/mL streptomycin. For
glucose deprivation, DMEM without glucose (#11966-025, Invitrogen) was used.
Mouse embryonic fibroblasts (MEFs) were isolated from E12.5 embryos and
immortalized by stable transfection with SV40 large T antigen.
Murine melanoma tumor model.
Mice were injected with 1 x 10 B16F10 murine melanoma cells murine
subcutaneously on the left flank. Once tumors become palpable (approximately 5 days),
mice were randomly allocated to receive treatment with either: 20% polyethylene glycol
(PEG) in 5% dextran (vehicle control for the disclosed HIF-2a stabilizer) and PBS (vehicle
control for GM-CSF), 20% PEG and GM-CSF (100 ng per mouse in a 50 µL volume), the
disclosed HIF-2a stabilizer (17.5 mg/kg in a 100 µL volume) and PBS, or the disclosed
HIF-2a stabilizer and GM-CSF (same doses). The PBS and GM-CSF were administered
intratumorally, while the 20% PEG and the disclosed HIF-2a stabilizer were administered
intraperitoneally. Mice were treated 3 times per week until tumors reached a size of 20 mm
in any dimension (approximately 2.5 weeks), at which point mice were euthanized, in
accordance with institutional policy. Tumor diameters were measured 3 times per week
with calipers, and tumor volumes were calculated as follows: Tumor volume = 0.5 x [(large
diameter) x (small diameter) ].
Evaluation of lung metastases
Lung metastases were evaluated by detection of mRNA for melanocyte-specific
proteins within the lungs of tumor-bearing mice. B16F10 tumor-bearing mice were treated
with GM-CSF and/or the disclosed HIF-2a stabilizer, as depicted in Figure 3. At the time
of sacrifice, lungs were excised and flash-frozen in liquid nitrogen. Frozen lungs were
homogenized in liquid nitrogen and the pulverized material was dissolved in TRIzol
reagent (Invitrogen). RNA was extracted in chloroform and purified using the RNeasy
Minikit (Qiagen). cDNA was generated from 1 µg of RNA using the Superscript First
Strand Synthesis System (Invitrogen) and used for real-time PCR using SYBR Green PCR
MasterMix (Applied Biosciences) according to the manufacturers’ instructions. The
melanocyte-specific Pmel17 was detected by nested PCR using a modification of the
protocol described by Tsukamoto et al. For the initial reaction, 30 cycles of PCR were
carried out (95°C for 1 minute, 58 °C for 1 min, 72°C for 1 min) in a 20 µL reaction volume
containing 2 µL of cDNA. For reamplification with the nested primers, 1 µL of the first
reaction product was amplified in a 20 µL reaction volume for a further 30 cycles. Data
were analyzed according to the comparative threshold method and normalized against the
GAPDH internal control transcript. Results are semi-quantitative and represent the fold
difference in transcript levels in vehicle-treated control mice as compared with levels in
mice treated with the disclosed HIF-2a stabilizer and/or GM-CSF.
Murine breast cancer model
PyMT transgenic mice, in which the polyoma middle T antigen is expressed from
the murine mammary tumor virus (MMTV) promoter, have been previously described (Lin
EY, Am J Pathol, 2003 included herein by reference in its entirety). These mice
spontaneously develop carcinoma of the mammary epithelium in all 10 mammary glands.
An immortalized cell line derived from a late-stage tumor from a C57BL/6 PyMT
transgenic mouse was utilized. 5 x 10 C57BL/6 PyMT tumor cells were injected
orthotopically into the #4 mammary fat pad of wildtype C57BL/6 mice. Once tumors
became palpable (approximately 3 weeks), mice were randomized to receive treatment with
either vehicle control (20% PEG in 5% dextran) or 12 or 17.5 mg/kg of the disclosed HIF-
2a stabilizer. Mice were treated 3 times per week and tumor volumes were calculated as
described herein above.
Figure 3 shows the results of this study for the high dose (17 mg/kg) of the HIF-2a
stabilizer. These data indicate that the disclosed HIF-2a stabilizer reduces tumor growth
alone ( ) and is comparable to the reduction in tumor volume seen when animals are
treated with GM-CSF alone ( ■). In addition, the reduction in tumor growth is additive
when the disclosed HIF-2a stabilizer is used in combination with GM-CSF (X). These
results are compared to control animals ( ♦) which only received the dosing vehicle
phosphate buffered saline (PBS).
This study was repeated comparing the dosing protocols, i.e., whether dosing was
done via intraperitoneal (I.P.) or via intratumor (I.T.) injection. No control group was used
for this repeated study. Figure 4 shows the results of this study for the high dose (17
mg/kg) of the HIF-2a stabilizer. These data indicate that injections I.T. provide greater
tumor volume reduction than injections I.P. For example, there was a greater reduction of
tumor volume when GM-CSF was administered I.T. ( ♦) vs. administration I.P. ( ). These
results were confirmed for treatments constituting the disclosed HIF-2a stabilizer and GM-
CSF when administered I.T. (x) vs. administration I.P. ( ■).
Figure 5 depicts the amount of relative metastasis to the lung as determined using
Pmel17 mRNA expression for the methods of injection depicted in Figure 3 wherein the
disclosed HIF-2a stabilizer was administered IP and the GM-CSF was administered I.T..
Group A is the vehicle control for both the disclosed HIF-2a stabilizer and GM-CSF.
Group B represents GM-CSF plus 20% PEG in 5% dextran (vehicle for administration of
the disclosed HIF-2a stabilizer). Group C represents the disclosed HIF-2a stabilizer plus
PBS (vehicle for administration of GM-CSF). Group D represents the disclosed HIF-2a
stabilizer and GM-CSF. The disclosed HIF-2a stabilizer was delivered in its vehicle (20%
PEG in 5% dextran) and administered I.P. and GM-CSF was delivered in its vehicle (PBS)
and administered I.T. Note that only the groups with the disclosed HIF-2a stabilizer
showed reduced metastasis as measured by Pmel17 mRNA expression.
Figure 6 depicts the reduction in tumor volume for C57BL/6 mice orthotopically
injected with cells from MMTV-PyMT transgenic mice into a single mammary gland.
Animals are treated three times a week with vehicle ( ♦), 12 mg/kg of the disclosed HIF-2a
stabilizer ( ■), or 17.5 g/kg of the disclosed HIF-2a stabilizer ( ●).
Human Ovarian Xenograft Study
Reagents and Test Compound
The compound tested, {[5-(3-fluorophenyl)hydroxypyridinecarbonyl]-amino}
acetic acid, was formulated in a 0.25% hydroxypropyl methyl cellulose/0.1% Tween 80
solution in reverse osmosis deionized water. The test compound was reconstituted at
concentrations of 1.8 and 3.6 mg/ml as instructed on each vial to deliver doses of 18 and 36
mg/kg, respectively, at a 10 mg/kg dose volume. Solutions of the test compound were
prepared weekly and stored at 4 °C protected from light. All formulations were removed
from the refrigerator and stirred for 30 minutes before dosing, and continuously stirred
during dosing.
The vehicle control was prepared by making a solution of 0.25% hydroxypropyl
methyl cellulose/0.1% Tween 80 solution in reverse osmosis deionized water.
Cell Culture
A2780/CP ovarian tumor cell line was received from Sigma-Aldrich (St. Louis,
MO). Cultures were maintained in RPMI 1640 (Hyclone, Logan, UT), supplemented with
% fetal bovine serum, and housed in a 5% CO atmosphere. The cultures were expanded
in tissue culture flasks at a 1:3 split ratio until a sufficient yield of cells was achieved.
Animals
Female athymic nude mice were supplied by Harlan (Indianapolis, IN). Mice were
received at four to five weeks of age, 12 -15 grams in weight, and were acclimated for
seven days prior to handling. The mice were housed in microisolator cages and maintained
under specific pathogen-free conditions. The mice were fed Tekland Global Diet 2920x
irradiated laboratory animal diet (Harlan, Indianapolis, IN) and autoclaved water was freely
available.
A2780/CP Ovarian Tumor Xenograft Model
Sixty female mice were inoculated subcutaneously in the right flank with 0.1 ml of a
50% RPMI / 50% Matrigel™ (BD Biosciences, Bedford, MA) mixture containing a
suspension of A2780/CP tumor cells (approximately 1.0 x 10 cells/mouse).
Three days following inoculation, tumors were measured using calipers and tumor
weight was calculated using the animal study management software. Thirty mice with
tumor sizes of 80.4 - 170.6 mg were randomized into three groups of ten mice (Groups 1-3)
by random equilibration. Body weights were recorded when the mice were randomized and
were taken twice per week thereafter in conjunction with tumor measurements.
Animals were treated until the study endpoint. Group I received only vehicle
(control). Group II was given doses of 1.8 mg/mL {[5-(3-fluorophenyl)hydroxypyridine-
2-carbonyl]-amino} acetic acid while Group III was given doses of 3.6 mg/mL {[5-(3-
fluorophenyl)hydroxypyridinecarbonyl]-amino} acetic acid. All doses were given via
oral administration (PO). The administered volume of each dose was approximately 1
mL/100 g body weight of animal.
Tumor mass (mg) was determined using the formula:
where “a” is the largest diameter and “b” is the smallest diameter. Measurements were
made using calipers. The mean tumor size when study began was 100-125 mg. On day one
of the study, animals were randomly assigned to the three groups described above.
Tumors were collected from Groups 1-3 of the main study when individual tumors
reached a tumor weight of ≥ 2000 mg by using the procedure above. Tumor size
measurements and animal body weight were taken twice weekly. Table I below and
Figures 7 to 9 summarize the results of this study.
TABLE I
No. Surviving Mean Tumor Median Tumor
Study Day Wgt % change
Animals Mass (mg) Mass (mg)
CONTROL
1 -- -- 119.8 118.0
4 1.99 9 189.6 170.7
8 5.79 9 493.4 423.9
11 8.54 9 1124.5 962.4
16 19.71 9 3700.8 3231.1
18 mg/kg COMPOUND QD
1 -- -- 119.6 121.3
4 -0.31 10 188.2 191.0
8 4.40 10 326.9 243.8
11 6.02 10 682.8 528.0
16 16.40 10 2508.0 1826.2
19 16.82 6 2647.4 3030.1
22 19.43 1 1761.6 1761.6
19.43 1 2838.3 2838.3
36 mg/kg COMPOUND QD
1 -- -- 120.3 123.3
4 -0.41 10 186.4 182.8
8 4.04 10 312.8 323.4
11 5.48 10 708.1 830.4
16 15.86 10 2354.5 2441.8
19 12.79 4 1858.8 1568.0
22 8.50 3 2456.9 2384.6
Figure 7 indicates the number of surviving animals at each evaluation point in the
study. The line indicated by ( ) represent the control group, the line indicated by ( )
represents the group that received 18 mg/kg of compound and the line indicated by ( )
represents the group that received 36 mg/kg of compound.
Figure 8 depicts the change in tumor mass over the course of the study for the
control group ( ), the group receiving18 mg/kg of compound ( ) and the group receiving
36 mg/kg of compound ( ).
Figure 9 depicts the change in percent body mass for the control group ( ), the
group receiving18 mg/kg of compound ( ) and the group receiving 36 mg/kg of compound
( ).
As can be seen from Figures 7 to 9 and the above-data in Table I, the rate of tumor
mass growth was significantly reduced compared to the control group, all of which had
tumors masses exceeding 2,000 mg (study end point) by day 16.
Purification of peripheral blood monocytes and generation of monocyte-derived
macrophages.
Human peripheral blood mononuclear cells (PBMCs) were isolated from fresh
peripheral blood leukocyte source packs (American Red Cross, Columbus OH) by density
gradient centrifugation over Lymphocyte Separation Medium (Cellgro). Monocytes were
purified from total PBMCs by layering over FBS. Monocytes were cultured in endotoxin-
free RPMI-1640 supplemented with 1% fetal bovine serum (FBS), 0.1% human serum
albumin (HSA), and 10 mg/mL of the endotoxin inhibitor polymyxin B. In some
experiments, freshly isolated monocytes were differentiated into macrophages by three-day
culture in media containing 10% FBS, 1% PSA (penicillin G sodium, streptomycin sulfate,
and amphotericin B), and 20 ng/mL M-CSF. Macrophages were serum-starved for 2 hours
prior to stimulation. Monocytes or monocyte-derived macrophages were treated for 24
hours with 10 ng/mL GM-CSF, 10 µM disclosed HIF-2a stabilizer, or an equivalent
volume of the vehicle controls (PBS or DMSO, respectively). Cell-free culture supernatants
were harvested and analyzed for VEGF or sVEGFR-1 by ELISA (R&D Systems).
flox/flox
Generation of HIF-2 α /LysMcre mice and culture of bone marrow-derived
macrophages.
flox/flox
HIF-2 α mice (originally developed by Dr. Celeste Simon, University of
Pennsylvania) and LysMcre recombinase mice (originally developed by Irmgard Foerster,
University of Duesseldorf) (both purchased from The Jackson Laboratory, Bar Harbor, ME)
were crossed to generate mice homozygous for both LysMcre and the floxed HIF-2 α allele.
LysMcre recombinase mice, which express no floxed alleles, were used as controls.
flox/flox
Deletion of HIF-2 α in HIF-2 α /LysMcre macrophages, but not the LysMcre control
macrophages, was confirmed at the transcript level by real-time PCR.
To generate bone marrow-derived macrophages (BDMs), femoral bone marrow was
isolated and progenitor cells were plated in RPMI-1640 supplemented with 10% FBS, 1%
PSA, 10 mg/mL of polymyxin B, and 20 ng/mL of recombinant murine M-CSF. Cells were
cultured for 5 days with the addition of fresh M-CSF every other day. Differentiated BDM
were serum-starved for 2 hours and then treated with 100 ng/mL of murine GM-CSF and/or
µM the disclosed HIF-2a stabilizer in RPMI-1640 containing 1% FBS and 10 mg/mL
polymixin B. Culture supernatants were collected after 72 hours and assayed for VEGF and
sVEGFR-1 content by ELISA (R&D Systems).
Real-time PCR.
Human monocytes were left untreated or were stimulated with 100 ng/mL GM-CSF
at normoxia or at 0.5% O . At various time-points, cells were harvested in Trizol reagent
(Invitrogen) and RNA was extracted in chloroform and then purified using the RNeasy
Minikit (Qiagen). In murine studies, organs harvested at the time of euthanasia were flash-
frozen in liquid nitrogen, pulverized in liquid nitrogen, and then dissolved in Trizol. cDNA
was generated from 1 µg of RNA using the Superscript First Strand Synthesis System
(Invitrogen) and used for real-time PCR using previously described primers and SYBR
Green PCR Master Mix (Applied Biosciences), according to the manufacturer’s
instructions. Data were analyzed according to the comparative threshold method and
normalized against the β-actin internal control transcript. Results are semi-quantitative and
represent the fold difference in transcript levels in a particular sample as compared with
levels in untreated cells from the same donor.
Murine melanoma tumor model.
6week-old C57BL/6 mice were injected with 1 x 10 B16F10 murine melanoma
cells murine subcutaneously on the left flank. Once tumors become palpable
(approximately 5 days), mice were randomly allocated to receive treatment with either:
% PEG-400 in 5% sucrose (vehicle for disclosed HIF-2a stabilizer) and PBS (vehicle for
GM-CSF), 20% PEG-400 and GM-CSF (100 ng per mouse in a 50 µL volume), disclosed
HIF-2a stabilizer (17.5 mg/kg mouse weight in a 100 µL volume) and PBS, or the disclosed
HIF-2a stabilizer and GM-CSF (same concentrations). The disclosed HIF-2a stabilizer (or
the vehicle control) was administered intraperitoneally, while GM-CSF (or the vehicle
control) was administered intratumorally. Mice were treated intratumorally 3 times per
week until tumors reached a size of 20 mm in any dimension (approximately 2.5 weeks), at
which point mice were be euthanized, in accordance with institutional policy. Tumor
diameters were measured 3 times per week with calipers, and tumor volumes will be
calculated as follows: Tumor volume = 0.5 x [(large diameter) x (small diameter) ]. For
experiments analyzing the effect of neutralizing sVEGFR-1 in combination with disclosed
HIF-2a stabilizer treatment, mice were treated intraperitoneally 3x/week with either
disclosed HIF-2a stabilizer or vehicle control, and intratumorally with either 4 µg anti-
VEGFR-1 neutralizing antibody (R&D Systems) or 4 µg polyclonal goat IgG isotype
control (Santa Cruz Biotechnology) in a 50 µL volume. All protocols were approved by the
Ohio State University Animal Care and Use Committee, and mice were treated in
accordance with institutional guidelines for animal care.
Evaluation of lung metastases.
Lung metastases were evaluated by detection of mRNA for melanocyte-specific
proteins within the lungs of tumor-bearing mice. B16F10 tumor-bearing mice were treated
with intratumoral GM-CSF and/or the disclosed HIF-2a stabilizer, as described above. At
the time of sacrifice, lungs were excised and flash-frozen in liquid nitrogen. Frozen lungs
were homogenized in liquid nitrogen and the pulverized material was dissolved in Trizol
reagent (Invitrogen). RNA was extracted in chloroform and purified using the RNeasy
Minikit (Qiagen). cDNA was generated from 1 µg of RNA using the Superscript First
Strand Synthesis System (Invitrogen) and used for real-time PCR using SYBR Green PCR
MasterMix (Applied Biosciences) according to the manufacturers’ instructions. The
melanocyte-specific mRNAs TRP2 and Pmel17 were detected by nested PCR using a
modification of the protocol described by Tsukamoto et al.. For the initial reaction, 30
cycles of PCR were carried out (95°C for 1 minute, 58 °C for 1 min, 72 °C for 1 min) in a
20 µl reaction volume containing 2 µl of cDNA. For reamplification with the nested
primers, 1 µL of the first reaction product was amplified in a 20 µl reaction volume for a
further 30 cycles. Data were analyzed according to the comparative threshold method and
normalized against the β-actin internal control transcript. Results are semi-quantitative and
represent the fold difference in transcript levels in the disclosed HIF-2a stabilizer and/or
GM-CSF-treated mice as compared with levels in vehicle control mice.
Statistical analyses.
The ANOVA test was used to compare independent measurements between multiple
treatment groups. The data was log-transformed to normalize the variance across groups.
P-values were adjusted using the Holm’s procedure to conserve the type I error at 0.05 due
to the multiple comparisons. For tumor growth data, changes in tumor volume over time
were assessed via a longitudinal model. Tumor values were log-transformed, and estimated
slopes (changes in tumor volume over time) were calculated with 95% confidence intervals.
Estimated differences in tumor volume were calculated by a random-effects regression of
the longitudinal data. For all analyses, p ≤ 0.05 was considered statistically significant.
Inhibition of PHD3 with the disclosed HIF-2a stabilizer enhances monocyte and
macrophage production of sVEGFR-1 but not VEGF.
Monocyte production of sVEGFR-1 in response to GM-CSF and hypoxia is
dependent on HIF-2 α, while HIF-1 α controlled monocyte production of VEGF under the
same conditions. While not wishing to be bound by theory, the inventors herein now
believe that selective stabilization of HIF-2 α would enhance sVEGFR-1 production from
GM-CSF-stimulated monocytes, without affecting VEGF production.
In order to confirm the selective upregulation of HIF-2 α by the disclosed HIF-2a
stabilizer, murine bone marrow-derived macrophages were treated with the disclosed HIF-
2a stabilizer for 18 hours, and cells were then lysed and immunoblotted for HIF-1 α and
HIF-2 α. The inventors observed an increase in HIF-2 α protein in cells treated with the
disclosed HIF-2a stabilizer, with no corresponding increase in HIF-1 α (Figure 11A).
In order to determine whether stabilization of HIF-2 α increased sVEGFR-1
production, human peripheral blood monocytes were stimulated with 100 ng/mL GM-CSF
in the presence or absence of 10 µM the disclosed HIF-2a stabilizer. sVEGFR-1 production
by GM-CSF-treated monocytes increased significantly when monocytes were also treated
with the disclosed HIF-2a stabilizer, at both the protein and the transcript level (p = 0.007
and p =0.033, respectively) (Figure 11B).
VEGF levels in the same supernatants were measured using an ELISA that detects
free (bioavailable) VEGF, but does not detect VEGF bound to sVEGFR-1. Treatment of
cells with the disclosed HIF-2a stabilizer did not significantly increase production of VEGF
(p = 0.133). VEGF protein was undetectable in the supernatants of GM-CSF-stimulated
monocytes, due to neutralization of VEGF by sVEGFR-1 (Figure 11C).
Evaluation of VEGF transcript levels by real-time PCR revealed that while GM-CSF
increased VEGF production, there was no difference in VEGF production between
monocytes stimulated with GM-CSF alone or with GM-CSF and the disclosed HIF-2a
stabilizer (p = 0.556) (Figure 11C).
These results demonstrate that selective stabilization of HIF-2 α enhances monocyte
production of sVEGFR-1 but not VEGF.
Since monocyte production of VEGF was dependent on HIF-1 α, the inventors
herein determined whether selective stabilization of HIF-1 α via inhibition of PHD2 would
increase monocyte production of VEGF but not sVEGFR-1. In order to make such
determination, human peripheral blood monocytes were stimulated with GM-CSF in the
presence of a selective inhibitor of PHD2 which results in the stabilization of HIF-1 α.
GM-CSF induced monocyte production of sVEGFR-1. However, there was no
difference in sVEGFR-1 production from monocytes stimulated with GM-CSF alone or
monocytes co-stimulated with the selective inhibitor of PHD2, at either the protein or
transcript level (p = 0.306 and p = 0.566, respectively) (Figure 11D).
However, the selective inhibitor of PHD3 increased monocyte production of VEGF
protein and mRNA (p = 0.011 and p = 0.007, respectively) (Figure 11E).
In order to confirm that sVEGFR-1 production was induced by stabilization of HIF-
2 α, bone marrow-derived macrophages from mice were utilized with a myeloid-specific
flox/flox
deletion of HIF-2 α (HIF-2 α /LysMcre).
The disclosed HIF-2a stabilizer induced sVEGFR-1 transcription from control
macrophages (p = 0.036), but not from HIF-2 α-deficient macrophages (p = 0.881) (Figure
11F).
These results show that sVEGFR-1 production is a HIF-2 α-dependent effect.
Furthermore, these results demonstrate that inhibition of PHD3 with the disclosed HIF-2a
stabilizer stabilizes HIF-2 α and selectively induces sVEGFR-1, but not VEGF, from GM-
CSF-stimulated monocytes.
Stabilization of HIF-2 α increases the anti-tumor effects of GM-CSF and enhances
survival in a murine melanoma model.
The anti-tumor effects of GM-CSF are dependent on HIF-2 α-mediated sVEGFR-1
production from tumor-associated macrophages in a murine melanoma model (Roda et al.,
J. Immunol, “Hypoxia-Inducible Factor-2 α Regulates GM-CSF–Derived Soluble Vascular
Endothelial Growth Factor Receptor 1 Production from Macrophages and Inhibits Tumor
Growth and Angiogenesis”, published on line before print July 15, 2011, doi: 10.4049/
jimmunol.1100841).
It was then determined whether the chemical stabilization of HIF-2 α might increase
sVEGFR-1 production from tumor-associated macrophages and therefore enhance the anti-
tumor effects of GM-CSF.
Mice bearing subcutaneous B16F10 melanomas were treated 3x/week with GM-
CSF (100 ng/mouse, intratumoral), the disclosed HIF-2a stabilizer (17.5 mg/kg,
intraperitoneal), or the combination (or the appropriate vehicle controls). Based on a
longitudinal model using log-transformed values, no significant differences in tumor
volume were found between the four groups at baseline. However, at day 16 of treatment,
the average tumor volumes for mice receiving either GM-CSF or the disclosed HIF-2a
stabilizer were significantly smaller than for mice treated with the vehicle controls (each p <
0.001). Furthermore, combined treatment with GM-CSF and the disclosed HIF-2a
stabilizer further decreased tumor growth compared to either treatment alone (Figure 12A)
(p < 0.001). These data demonstrate that the disclosed HIF-2a stabilizer can enhance the
anti-tumor effects of GM-CSF in a melanoma model. The disclosed HIF-2a stabilizer
alone also enhanced the survival of B16F10 melanoma-bearing mice. Figure 12B shows a
3-day increase in median survival (which was defined as the time to a tumor diameter of 20
mm ) in mice treated with the disclosed HIF-2a stabilizer (p = 0.023).
The disclosed HIF-2a stabilizer enhances sVEGFR-1 production and decreases tumor
angiogenesis in response to GM-CSF.
Again, while not wishing to be bound by theory, the inventors herein now believe
that chemical stabilization of HIF-2 α with the disclosed HIF-2a stabilizer would increase
sVEGFR-1 production in response to GM-CSF, thereby reducing tumor growth and
angiogenesis. Real-time PCR was used to evaluate the levels of sVEGFR-1 and VEGF
mRNA within tumors from mice treated with GM-CSF, the disclosed HIF-2a stabilizer, or
the combination.
Increased levels of sVEGFR-1 were detected within the tumors of mice treated with
both GM-CSF and the disclosed HIF-2a stabilizer (Figure 13A) (p = 0.031). Conversely,
GM-CSF (alone or in combination with the disclosed HIF-2a stabilizer) failed to increase
levels of intratumoral VEGF over the levels observed in vehicle control-treated mice
(Figure 13B) (p = 0.490). To confirm that the increased sVEGFR-1 production resulted in
decreased tumor angiogenesis, tumors from each of the mice were stained by
immunohistochemistry for the endothelial cell marker CD31. As shown in Figure 13C,
combination treatment with GM-CSF and the disclosed HIF-2a stabilizer significantly
reduced tumor vascularity in melanoma-bearing mice, possibly through the induction of
sVEGFR-1 (p < 0.001).
Because increased angiogenesis is associated with an increased risk of metastasis,
the inventors herein evaluated lung metastasis in mice treated with GM-CSF, the disclosed
HIF-2a stabilizer, or the combination. Significantly reduced levels of the melanoma-
specific gene Pmel17 were detected within the lungs of mice treated with GM-CSF and the
disclosed HIF-2a stabilizer, as compared to vehicle control-treated mice (Figure 13D).
These results demonstrate that the disclosed HIF-2a stabilizer enhances the anti-
angiogenic effects of GM-CSF, by increasing sVEGFR-1 production from tumor-associated
macrophages.
The anti-tumor effects of the disclosed HIF-2a stabilizer are dependent on sVEGFR-1
production.
Increased sVEGFR-1 levels in the tumors of mice treated with GM-CSF and the
disclosed HIF-2a stabilizer, correlating with decreased tumor growth and angiogenesis. To
confirm that the modulation of tumor growth and angiogenesis was due to sVEGFR-1
production in response to the disclosed HIF-2a stabilizer, mice were treated with the
disclosed HIF-2a stabilizer in the presence or absence of an sVEGFR-1 neutralizing Ab.
The disclosed HIF-2a stabilizer decreased tumor growth in mice treated with an
isotype control antibody (p < 0.001), but had no effect on tumor growth in mice also treated
with the anti-sVEGFR-1 neutralizing antibody (p = 0.245) (Figure 14A).
To confirm the role of sVEGFR-1 production in tumor angiogenesis, the inventors
herein immunostained the tumors for the endothelial cell marker CD31. As shown in
Figure 14B, the disclosed HIF-2a stabilizer decreased tumor vascularity in the mice treated
with the control antibody (p = 0.022) but not in the mice treated with the sVEGFR-1
neutralizing Ab.
These results demonstrate that the disclosed HIF-2a stabilizer decreases tumor
angiogenesis by inducing sVEGFR-1.
sVEGFR-1 production in response to the disclosed HIF-2a stabilizer is dependent on
macrophage production of HIF-2 α.
The disclosed HIF-2a stabilizer is not targeted specifically to macrophages, and will
stabilize HIF-2 α in all tissues, not only the tumor-associated macrophages. In order to
determine the role of macrophages in the anti-tumor response to the disclosed HIF-2a
flox/flox
stabilizer, mice with a myeloid-specific deletion of HIF-2 α (HIF-2 α /LysMcre mice)
were utilized.
The disclosed HIF-2a stabilizer inhibited tumor growth in LysMcre control mice
(which contain LysM-driven cre recombinase but no floxed alleles). Although the disclosed
HIF-2a stabilizer reduced tumor growth in mice with HIF-2 α-deficient macrophages, the
magnitude of the anti-tumor response was much less than in control mice (Figure 15).
These results demonstrate that the disclosed HIF-2a stabilizer inhibits tumor growth
and angiogenesis, at least in part, by stabilizing HIF-2 α in tumor-associated macrophages
and inducing sVEGFR-1 production.
Human Melanoma Cell Line (A375)
Immunodeficient mice with a human melanoma cell line (A375) and treated with
GM-CSF, the disclosed HIF-2a stabilizer, or the combination, as the inventor did for the
B16F10 murine melanoma model. The combination of GM-CSF and the disclosed HIF-2a
stabilizer significantly reduced tumor growth in this model (p = 0.05). This data confirms
the inventors’ finding of the efficacy of GM and the disclosed HIF-2a stabilizer in an
additional murine model, and is also highly biologically relevant to human cancer, at least
in part because a human cancer cell line grown in mice is tested. See Figure 15.
Murine melanoma tumor models.
6week-old C57BL/6 mice or SCID mice were injected with 1 x 10 B16F10
murine melanoma cells or 1 x 10 A375 human melanoma cells, respectively,
subcutaneously on the left flank. Once tumors become palpable (approximately 5 days),
mice were randomly allocated to receive treatment with either: 20% PEG-400 in 5%
sucrose (vehicle for the disclosed HIF-2a stabilizer) and PBS (vehicle for GM-CSF), 20%
PEG-400 and GM-CSF (100 ng per mouse in a 50 µL volume), the disclosed HIF-2a
stabilizer (17.5 mg/kg mouse weight in a 100 µL volume) and PBS, or the disclosed HIF-2a
stabilizer and GM-CSF (same concentrations). The disclosed HIF-2a stabilizer (or the
vehicle control) was administered intraperitoneally, while GM-CSF (or the vehicle control)
was administered intratumorally. Mice were treated intratumorally 3 times per week until
tumors reached a size of 20 mm in any dimension (approximately 2.5 weeks), at which
point mice were be euthanized, in accordance with institutional policy. Tumor diameters
were measured 3 times per week with calipers, and tumor volumes will be calculated as
follows: Tumor volume = 0.5 x [(large diameter) x (small diameter) ].
In the study, immunocompromised SCID mice were inoculated with A375 human
melanoma tumors subcutaneously. Starting when the tumors became palpable (7 days after
injection), mice were treated with either the cytotoxic chemotherapy docetaxel or with the
disclosed HIF-2a stabilizer. The disclosed HIF-2a stabilizer was given at a dose of 17
mg/kg, and the docetaxel was given at 1 mg/kg. Both drugs were given IP 3 times per week.
The combination of docetaxel and the disclosed HIF-2a stabilizer significantly inhibited
tumor growth compared to either drug alone. At the time of sacrifice, the tumors in the mice
that received only the disclosed HIF-2a stabilizer were approximately 78% of the size of
the control tumors, the tumors of the mice that received only chemotherapy were
approximately 50% of the size of the control tumors, and the tumors of the mice that
received both drugs were approximately 16% of the size of the control tumors.
While particular embodiments of the present disclosure have been illustrated and
described, it would be obvious to those skilled in the art that various other changes and
modifications can be made without departing from the spirit and scope of the disclosure. It
is therefore intended to cover in the appended claims all such changes and modifications
that are within the scope of this disclosure.
In this specification where reference has been made to patent specifications, other
external documents, or other sources of information, this is generally for the purpose of
providing a context for discussing the features of the invention. Unless specifically stated
otherwise, reference to such external documents is not to be construed as an admission that
such documents, or such sources of information, in any jurisdiction, are prior art, or form
part of the common general knowledge in the art.
Claims (14)
1. A use of a compound of the structure: or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer, wherein the cancer is selected from the group consisting of malignant melanoma, breast cancer and ovarian cancer.
2. A composition comprising: A) a compound of the structure: or a pharmaceutically acceptable salt thereof; and B) Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF).
3. The composition of claim 2 for treating cancer.
4. The composition of claim 3, wherein the cancer is selected from the group consisting of malignant melanoma, breast cancer and ovarian cancer.
5. A use of: A) a compound of the structure: or a pharmaceutically acceptable salt thereof; and B) Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), in the manufacture of a medicament for treating cancer.
6. The use of claim 5, wherein the cancer is selected from the group consisting of malignant melanoma, breast cancer and ovarian cancer.
7. A use of a compound of the structure: or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for increasing soluble vascular endothelial growth factor receptor-1 (sVEGF-1) secreted from a cell.
8. A use of a compound of the structure: or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for downregulating phosphoglycerate kinase (PGK) in a cell.
9. A use of a compound of the structure: or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for downregulating phosphoglycerate kinase (PGK) in a cell and increasing soluble vascular endothelial growth factor receptor-1 (sVEGF-1) secreted from a cell.
10. The use according to any one of Claims 7 to 9, wherein the cell is contacted with the medicament in vitro, in vivo or ex vivo.
11. The use according to any one of Claims 7 to 10, wherein the cell is a cancer cell.
12. The use according to any one of claims 7 to 11, wherein the medicament is for the treatment of cancer.
13. A composition according to any one of claims 2 to 4 substantially as herein described with reference to any example thereof.
14. A use according to any one of claims 1 and 5 to 12 substantially as herein described with reference to any example thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161493534P | 2011-06-06 | 2011-06-06 | |
US61/493,534 | 2011-06-06 | ||
PCT/US2012/040945 WO2012170442A1 (en) | 2011-06-06 | 2012-06-05 | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ619241A NZ619241A (en) | 2016-07-29 |
NZ619241B2 true NZ619241B2 (en) | 2016-11-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012268400B2 (en) | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer | |
US10167289B2 (en) | Pyrazolopyrimidine compounds | |
CN105412094A (en) | Compounds, Compositions, And Methods For Preventing Metastasis Of Cancer Cells | |
JP2018519357A (en) | K-RAS regulator | |
TWI721136B (en) | Use of benzofuran lignans to induce il-25 expression and suppress mammary tumor metastasis | |
EP3957304A1 (en) | Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer | |
US9387213B2 (en) | Small molecules inhibiting oncoprotein Myc | |
US20210008206A1 (en) | Adenosine pathway inhibitors for cancer treatment | |
US20210077535A1 (en) | Neural stem cell delivery of therapeutic agents | |
NZ619241B2 (en) | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer | |
US10646479B2 (en) | Use of N-(4-iodobenzoylamino)-5-ethyl-1,2,3,6-tetrahydropyridine as a treatment for cancer | |
US20200261462A1 (en) | Combination therapy for cancer treatment | |
WO2018156680A1 (en) | Treatment of refractory of relapsed hematological cancer with durvalumab |